id	sid	tid	token	lemma	pos
dpc-2120	1	1	dermatology	dermatology	NOUN
dpc-2120	1	2	:	:	PUNCT
dpc-2120	1	3	practical	practical	ADJ
dpc-2120	1	4	and	and	CCONJ
dpc-2120	1	5	conceptual	conceptual	ADJ
dpc-2120	1	6	dermatology	dermatology	NOUN
dpc-2120	1	7	practical	practical	ADJ
dpc-2120	1	8	&	&	CCONJ
dpc-2120	1	9	conceptual	conceptual	ADJ
dpc-2120	1	10	review	review	NOUN
dpc-2120	1	11	|	|	ADV
dpc-2120	1	12	dermatol	dermatol	ADJ
dpc-2120	1	13	pract	pract	NOUN
dpc-2120	1	14	concept	concept	NOUN
dpc-2120	1	15	.	.	PUNCT
dpc-2120	2	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	2	2	1	1	NUM
dpc-2120	2	3	the	the	DET
dpc-2120	2	4	new	new	ADJ
dpc-2120	2	5	era	era	NOUN
dpc-2120	2	6	of	of	ADP
dpc-2120	2	7	biologics	biologic	NOUN
dpc-2120	2	8	in	in	ADP
dpc-2120	2	9	atopic	atopic	NOUN
dpc-2120	2	10	dermatitis	dermatitis	NOUN
dpc-2120	2	11	:	:	PUNCT
dpc-2120	2	12	a	a	DET
dpc-2120	2	13	review	review	NOUN
dpc-2120	2	14	simon	simon	PROPN
dpc-2120	2	15	schneider1	schneider1	PROPN
dpc-2120	2	16	,	,	PUNCT
dpc-2120	2	17	linda	linda	PROPN
dpc-2120	2	18	li1	li1	NOUN
dpc-2120	2	19	,	,	PUNCT
dpc-2120	2	20	alexander	alexander	PROPN
dpc-2120	2	21	zink1,2	zink1,2	PROPN
dpc-2120	2	22	1	1	NUM
dpc-2120	2	23	technical	technical	PROPN
dpc-2120	2	24	university	university	PROPN
dpc-2120	2	25	of	of	ADP
dpc-2120	2	26	munich	munich	PROPN
dpc-2120	2	27	,	,	PUNCT
dpc-2120	2	28	school	school	NOUN
dpc-2120	2	29	of	of	ADP
dpc-2120	2	30	medicine	medicine	NOUN
dpc-2120	2	31	,	,	PUNCT
dpc-2120	2	32	department	department	NOUN
dpc-2120	2	33	of	of	ADP
dpc-2120	2	34	dermatology	dermatology	NOUN
dpc-2120	2	35	and	and	CCONJ
dpc-2120	2	36	allergy	allergy	NOUN
dpc-2120	2	37	,	,	PUNCT
dpc-2120	2	38	munich	munich	PROPN
dpc-2120	2	39	,	,	PUNCT
dpc-2120	2	40	germany	germany	PROPN
dpc-2120	2	41	2	2	NUM
dpc-2120	2	42	division	division	NOUN
dpc-2120	2	43	of	of	ADP
dpc-2120	2	44	dermatology	dermatology	NOUN
dpc-2120	2	45	and	and	CCONJ
dpc-2120	2	46	venereology	venereology	NOUN
dpc-2120	2	47	,	,	PUNCT
dpc-2120	2	48	department	department	NOUN
dpc-2120	2	49	of	of	ADP
dpc-2120	2	50	medicine	medicine	PROPN
dpc-2120	2	51	solna	solna	PROPN
dpc-2120	2	52	,	,	PUNCT
dpc-2120	2	53	karolinska	karolinska	PROPN
dpc-2120	2	54	institute	institute	PROPN
dpc-2120	2	55	,	,	PUNCT
dpc-2120	2	56	stockholm	stockholm	PROPN
dpc-2120	2	57	,	,	PUNCT
dpc-2120	2	58	sweden	sweden	PROPN
dpc-2120	2	59	key	key	ADJ
dpc-2120	2	60	words	word	NOUN
dpc-2120	2	61	:	:	PUNCT
dpc-2120	2	62	atopic	atopic	NOUN
dpc-2120	2	63	dermatitis	dermatitis	NOUN
dpc-2120	2	64	,	,	PUNCT
dpc-2120	2	65	therapy	therapy	NOUN
dpc-2120	2	66	,	,	PUNCT
dpc-2120	2	67	biological	biological	NOUN
dpc-2120	2	68	,	,	PUNCT
dpc-2120	2	69	dupilumab	dupilumab	NOUN
dpc-2120	2	70	citation	citation	NOUN
dpc-2120	2	71	:	:	PUNCT
dpc-2120	3	1	schneider	schneider	PROPN
dpc-2120	3	2	s	s	PROPN
dpc-2120	3	3	,	,	PUNCT
dpc-2120	3	4	li	li	PROPN
dpc-2120	3	5	l	l	PROPN
dpc-2120	3	6	,	,	PUNCT
dpc-2120	3	7	zink	zink	NOUN
dpc-2120	3	8	a.	a.	NOUN
dpc-2120	3	9	the	the	DET
dpc-2120	3	10	new	new	ADJ
dpc-2120	3	11	era	era	NOUN
dpc-2120	3	12	of	of	ADP
dpc-2120	3	13	biologics	biologic	NOUN
dpc-2120	3	14	in	in	ADP
dpc-2120	3	15	atopic	atopic	NOUN
dpc-2120	3	16	dermatitis	dermatitis	NOUN
dpc-2120	3	17	:	:	PUNCT
dpc-2120	3	18	a	a	DET
dpc-2120	3	19	review	review	NOUN
dpc-2120	3	20	.	.	PUNCT
dpc-2120	4	1	dermatol	dermatol	NOUN
dpc-2120	4	2	pract	pract	PROPN
dpc-2120	4	3	concept	concept	NOUN
dpc-2120	4	4	.	.	PUNCT
dpc-2120	5	1	2021;11(4):e2021144	2021;11(4):e2021144	X
dpc-2120	5	2	.	.	PUNCT
dpc-2120	6	1	doi	doi	NOUN
dpc-2120	6	2	:	:	PUNCT
dpc-2120	6	3	https://doi.org/10.5826/dpc.1104a144	https://doi.org/10.5826/dpc.1104a144	PROPN
dpc-2120	6	4	accepted	accept	VERB
dpc-2120	6	5	:	:	PUNCT
dpc-2120	6	6	october	october	PROPN
dpc-2120	6	7	19	19	NUM
dpc-2120	6	8	,	,	PUNCT
dpc-2120	6	9	2021	2021	NUM
dpc-2120	6	10	;	;	PUNCT
dpc-2120	6	11	published	publish	VERB
dpc-2120	6	12	:	:	PUNCT
dpc-2120	6	13	october	october	PROPN
dpc-2120	6	14	,	,	PUNCT
dpc-2120	6	15	2021	2021	NUM
dpc-2120	6	16	copyright	copyright	NOUN
dpc-2120	6	17	:	:	PUNCT
dpc-2120	6	18	©	©	PROPN
dpc-2120	6	19	2021	2021	NUM
dpc-2120	6	20	schneider	schneider	NOUN
dpc-2120	6	21	et	et	PROPN
dpc-2120	6	22	al	al	PROPN
dpc-2120	6	23	.	.	PUNCT
dpc-2120	7	1	this	this	PRON
dpc-2120	7	2	is	be	AUX
dpc-2120	7	3	an	an	DET
dpc-2120	7	4	open	open	ADJ
dpc-2120	7	5	-	-	PUNCT
dpc-2120	7	6	access	access	NOUN
dpc-2120	7	7	article	article	NOUN
dpc-2120	7	8	distributed	distribute	VERB
dpc-2120	7	9	under	under	ADP
dpc-2120	7	10	the	the	DET
dpc-2120	7	11	terms	term	NOUN
dpc-2120	7	12	of	of	ADP
dpc-2120	7	13	the	the	DET
dpc-2120	7	14	creative	creative	ADJ
dpc-2120	7	15	commons	common	NOUN
dpc-2120	7	16	attribution	attribution	NOUN
dpc-2120	7	17	license	license	NOUN
dpc-2120	7	18	by	by	ADP
dpc-2120	7	19	-	-	PUNCT
dpc-2120	7	20	nc-4.0	nc-4.0	NOUN
dpc-2120	7	21	,	,	PUNCT
dpc-2120	7	22	which	which	PRON
dpc-2120	7	23	permits	permit	VERB
dpc-2120	7	24	unrestricted	unrestricted	ADJ
dpc-2120	7	25	noncommercial	noncommercial	ADJ
dpc-2120	7	26	use	use	NOUN
dpc-2120	7	27	,	,	PUNCT
dpc-2120	7	28	distribution	distribution	NOUN
dpc-2120	7	29	,	,	PUNCT
dpc-2120	7	30	and	and	CCONJ
dpc-2120	7	31	reproduction	reproduction	NOUN
dpc-2120	7	32	in	in	ADP
dpc-2120	7	33	any	any	DET
dpc-2120	7	34	medium	medium	NOUN
dpc-2120	7	35	,	,	PUNCT
dpc-2120	7	36	provided	provide	VERB
dpc-2120	7	37	the	the	DET
dpc-2120	7	38	original	original	ADJ
dpc-2120	7	39	authors	author	NOUN
dpc-2120	7	40	and	and	CCONJ
dpc-2120	7	41	source	source	NOUN
dpc-2120	7	42	are	be	AUX
dpc-2120	7	43	credited	credit	VERB
dpc-2120	7	44	.	.	PUNCT
dpc-2120	8	1	funding	funding	NOUN
dpc-2120	8	2	:	:	PUNCT
dpc-2120	8	3	none	none	NOUN
dpc-2120	8	4	.	.	PUNCT
dpc-2120	9	1	competing	compete	VERB
dpc-2120	9	2	interests	interest	NOUN
dpc-2120	9	3	:	:	PUNCT
dpc-2120	9	4	none	none	NOUN
dpc-2120	9	5	.	.	PUNCT
dpc-2120	10	1	authorship	authorship	NOUN
dpc-2120	10	2	:	:	PUNCT
dpc-2120	10	3	ss	ss	NOUN
dpc-2120	11	1	and	and	CCONJ
dpc-2120	11	2	ll	ll	AUX
dpc-2120	11	3	have	have	AUX
dpc-2120	11	4	equally	equally	ADV
dpc-2120	11	5	contributed	contribute	VERB
dpc-2120	11	6	to	to	ADP
dpc-2120	11	7	this	this	DET
dpc-2120	11	8	publication	publication	NOUN
dpc-2120	11	9	.	.	PUNCT
dpc-2120	12	1	corresponding	correspond	VERB
dpc-2120	12	2	author	author	NOUN
dpc-2120	12	3	:	:	PUNCT
dpc-2120	12	4	simon	simon	PROPN
dpc-2120	12	5	schneider	schneider	PROPN
dpc-2120	12	6	,	,	PUNCT
dpc-2120	12	7	technical	technical	ADJ
dpc-2120	12	8	university	university	PROPN
dpc-2120	12	9	of	of	ADP
dpc-2120	12	10	munich	munich	PROPN
dpc-2120	12	11	,	,	PUNCT
dpc-2120	12	12	school	school	NOUN
dpc-2120	12	13	of	of	ADP
dpc-2120	12	14	medicine	medicine	PROPN
dpc-2120	12	15	department	department	PROPN
dpc-2120	12	16	of	of	ADP
dpc-2120	12	17	dermatology	dermatology	NOUN
dpc-2120	12	18	and	and	CCONJ
dpc-2120	12	19	allergy	allergy	NOUN
dpc-2120	12	20	,	,	PUNCT
dpc-2120	12	21	munich	munich	PROPN
dpc-2120	12	22	,	,	PUNCT
dpc-2120	12	23	germany	germany	PROPN
dpc-2120	12	24	.	.	PUNCT
dpc-2120	12	25	email	email	NOUN
dpc-2120	12	26	:	:	PUNCT
dpc-2120	12	27	simon.a.schneider@tum.de	simon.a.schneider@tum.de	ADJ
dpc-2120	12	28	atopic	atopic	NOUN
dpc-2120	12	29	dermatitis	dermatitis	NOUN
dpc-2120	12	30	(	(	PUNCT
dpc-2120	12	31	ad	ad	NOUN
dpc-2120	12	32	)	)	PUNCT
dpc-2120	12	33	is	be	AUX
dpc-2120	12	34	a	a	DET
dpc-2120	12	35	prevalent	prevalent	ADJ
dpc-2120	12	36	inflammatory	inflammatory	ADJ
dpc-2120	12	37	skin	skin	NOUN
dpc-2120	12	38	disorder	disorder	NOUN
dpc-2120	12	39	affecting	affect	VERB
dpc-2120	12	40	all	all	DET
dpc-2120	12	41	age	age	NOUN
dpc-2120	12	42	and	and	CCONJ
dpc-2120	12	43	ethnic	ethnic	ADJ
dpc-2120	12	44	groups	group	NOUN
dpc-2120	12	45	.	.	PUNCT
dpc-2120	13	1	the	the	DET
dpc-2120	13	2	age	age	NOUN
dpc-2120	13	3	-	-	PUNCT
dpc-2120	13	4	dependent	dependent	ADJ
dpc-2120	13	5	varying	varying	ADJ
dpc-2120	13	6	appearance	appearance	NOUN
dpc-2120	13	7	and	and	CCONJ
dpc-2120	13	8	extent	extent	NOUN
dpc-2120	13	9	of	of	ADP
dpc-2120	13	10	pruritic	pruritic	ADJ
dpc-2120	13	11	lesions	lesion	NOUN
dpc-2120	13	12	are	be	AUX
dpc-2120	13	13	accompanied	accompany	VERB
dpc-2120	13	14	by	by	ADP
dpc-2120	13	15	distinct	distinct	ADJ
dpc-2120	13	16	individual	individual	ADJ
dpc-2120	13	17	suffering	suffering	NOUN
dpc-2120	13	18	,	,	PUNCT
dpc-2120	13	19	highlighting	highlight	VERB
dpc-2120	13	20	the	the	DET
dpc-2120	13	21	importance	importance	NOUN
dpc-2120	13	22	of	of	ADP
dpc-2120	13	23	effective	effective	ADJ
dpc-2120	13	24	treatment	treatment	NOUN
dpc-2120	13	25	options	option	NOUN
dpc-2120	13	26	.	.	PUNCT
dpc-2120	14	1	over	over	ADP
dpc-2120	14	2	the	the	DET
dpc-2120	14	3	past	past	ADJ
dpc-2120	14	4	years	year	NOUN
dpc-2120	14	5	systemic	systemic	ADJ
dpc-2120	14	6	drugs	drug	NOUN
dpc-2120	14	7	have	have	AUX
dpc-2120	14	8	considerably	considerably	ADV
dpc-2120	14	9	extended	extend	VERB
dpc-2120	14	10	therapeutic	therapeutic	ADJ
dpc-2120	14	11	approaches	approach	NOUN
dpc-2120	14	12	of	of	ADP
dpc-2120	14	13	patients	patient	NOUN
dpc-2120	14	14	with	with	ADP
dpc-2120	14	15	moderate	moderate	ADJ
dpc-2120	14	16	to	to	ADP
dpc-2120	14	17	severe	severe	ADJ
dpc-2120	14	18	ad	ad	NOUN
dpc-2120	14	19	,	,	PUNCT
dpc-2120	14	20	in	in	ADP
dpc-2120	14	21	particular	particular	ADJ
dpc-2120	14	22	new	new	ADJ
dpc-2120	14	23	biologics	biologic	NOUN
dpc-2120	14	24	,	,	PUNCT
dpc-2120	14	25	most	most	ADV
dpc-2120	14	26	notably	notably	ADV
dpc-2120	14	27	dupilumab	dupilumab	NOUN
dpc-2120	14	28	has	have	AUX
dpc-2120	14	29	appeared	appear	VERB
dpc-2120	14	30	as	as	ADP
dpc-2120	14	31	major	major	ADJ
dpc-2120	14	32	breakthrough	breakthrough	NOUN
dpc-2120	14	33	.	.	PUNCT
dpc-2120	15	1	in	in	ADP
dpc-2120	15	2	addition	addition	NOUN
dpc-2120	15	3	to	to	ADP
dpc-2120	15	4	monoclonal	monoclonal	NOUN
dpc-2120	15	5	blockade	blockade	NOUN
dpc-2120	15	6	of	of	ADP
dpc-2120	15	7	il-4	il-4	NOUN
dpc-2120	15	8	and	and	CCONJ
dpc-2120	15	9	il-13	il-13	ADP
dpc-2120	15	10	pathway	pathway	NOUN
dpc-2120	15	11	,	,	PUNCT
dpc-2120	15	12	more	more	ADJ
dpc-2120	15	13	cytokines	cytokine	NOUN
dpc-2120	15	14	have	have	AUX
dpc-2120	15	15	been	be	AUX
dpc-2120	15	16	found	find	VERB
dpc-2120	15	17	to	to	PART
dpc-2120	15	18	play	play	VERB
dpc-2120	15	19	a	a	DET
dpc-2120	15	20	substantial	substantial	ADJ
dpc-2120	15	21	role	role	NOUN
dpc-2120	15	22	in	in	ADP
dpc-2120	15	23	ad	ad	NOUN
dpc-2120	15	24	pathogenesis	pathogenesis	NOUN
dpc-2120	15	25	,	,	PUNCT
dpc-2120	15	26	presenting	present	VERB
dpc-2120	15	27	potential	potential	ADJ
dpc-2120	15	28	targets	target	NOUN
dpc-2120	15	29	for	for	ADP
dpc-2120	15	30	new	new	ADJ
dpc-2120	15	31	therapy	therapy	NOUN
dpc-2120	15	32	options	option	NOUN
dpc-2120	15	33	.	.	PUNCT
dpc-2120	16	1	abstract	abstract	ADJ
dpc-2120	16	2	this	this	DET
dpc-2120	16	3	article	article	NOUN
dpc-2120	16	4	is	be	AUX
dpc-2120	16	5	part	part	NOUN
dpc-2120	16	6	of	of	ADP
dpc-2120	16	7	a	a	DET
dpc-2120	16	8	series	series	NOUN
dpc-2120	16	9	of	of	ADP
dpc-2120	16	10	reviews	review	NOUN
dpc-2120	16	11	dedicated	dedicate	VERB
dpc-2120	16	12	to	to	ADP
dpc-2120	16	13	atopic	atopic	NOUN
dpc-2120	16	14	dermatitis	dermatitis	NOUN
dpc-2120	16	15	,	,	PUNCT
dpc-2120	16	16	guest	guest	NOUN
dpc-2120	16	17	edited	edit	VERB
dpc-2120	16	18	by	by	ADP
dpc-2120	16	19	prof	prof	PROPN
dpc-2120	16	20	anna	anna	PROPN
dpc-2120	16	21	balato	balato	PROPN
dpc-2120	16	22	.	.	PUNCT
dpc-2120	17	1	guest	guest	PROPN
dpc-2120	17	2	editor	editor	PROPN
dpc-2120	17	3	prof	prof	PROPN
dpc-2120	17	4	.	.	PROPN
dpc-2120	18	1	anna	anna	PROPN
dpc-2120	18	2	balato	balato	PROPN
dpc-2120	18	3	,	,	PUNCT
dpc-2120	18	4	md	md	PROPN
dpc-2120	18	5	,	,	PUNCT
dpc-2120	18	6	phd	phd	NOUN
dpc-2120	18	7	associate	associate	NOUN
dpc-2120	18	8	professor	professor	NOUN
dpc-2120	18	9	of	of	ADP
dpc-2120	18	10	dermatology	dermatology	NOUN
dpc-2120	18	11	,	,	PUNCT
dpc-2120	18	12	dermatology	dermatology	NOUN
dpc-2120	18	13	unit	unit	NOUN
dpc-2120	18	14	,	,	PUNCT
dpc-2120	18	15	university	university	PROPN
dpc-2120	18	16	of	of	ADP
dpc-2120	18	17	campania	campania	PROPN
dpc-2120	18	18	,	,	PUNCT
dpc-2120	18	19	naples	naples	PROPN
dpc-2120	18	20	,	,	PUNCT
dpc-2120	18	21	italy	italy	PROPN
dpc-2120	18	22	2	2	NUM
dpc-2120	18	23	review	review	NOUN
dpc-2120	18	24	|	|	ADV
dpc-2120	18	25	dermatol	dermatol	ADJ
dpc-2120	18	26	pract	pract	NOUN
dpc-2120	18	27	concept	concept	NOUN
dpc-2120	18	28	.	.	PUNCT
dpc-2120	19	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	19	2	introduction	introduction	NOUN
dpc-2120	19	3	atopic	atopic	NOUN
dpc-2120	19	4	dermatitis	dermatitis	NOUN
dpc-2120	19	5	(	(	PUNCT
dpc-2120	19	6	ad	ad	NOUN
dpc-2120	19	7	)	)	PUNCT
dpc-2120	19	8	,	,	PUNCT
dpc-2120	19	9	one	one	NUM
dpc-2120	19	10	of	of	ADP
dpc-2120	19	11	the	the	DET
dpc-2120	19	12	most	most	ADV
dpc-2120	19	13	common	common	ADJ
dpc-2120	19	14	inflammatory	inflammatory	ADJ
dpc-2120	19	15	skin	skin	NOUN
dpc-2120	19	16	disorders	disorder	NOUN
dpc-2120	19	17	affecting	affect	VERB
dpc-2120	19	18	people	people	NOUN
dpc-2120	19	19	of	of	ADP
dpc-2120	19	20	all	all	DET
dpc-2120	19	21	ages	age	NOUN
dpc-2120	19	22	and	and	CCONJ
dpc-2120	19	23	ethnicities	ethnicity	NOUN
dpc-2120	19	24	,	,	PUNCT
dpc-2120	19	25	is	be	AUX
dpc-2120	19	26	characterized	characterize	VERB
dpc-2120	19	27	by	by	ADP
dpc-2120	19	28	typical	typical	ADJ
dpc-2120	19	29	age	age	NOUN
dpc-2120	19	30	-	-	PUNCT
dpc-2120	19	31	dependent	dependent	ADJ
dpc-2120	19	32	clinical	clinical	ADJ
dpc-2120	19	33	features	feature	NOUN
dpc-2120	19	34	and	and	CCONJ
dpc-2120	19	35	substantial	substantial	ADJ
dpc-2120	19	36	individual	individual	ADJ
dpc-2120	19	37	suffering	suffering	NOUN
dpc-2120	19	38	as	as	ADV
dpc-2120	19	39	well	well	ADV
dpc-2120	19	40	as	as	ADP
dpc-2120	19	41	extensive	extensive	ADJ
dpc-2120	19	42	economic	economic	ADJ
dpc-2120	19	43	impact	impact	NOUN
dpc-2120	19	44	[	[	X
dpc-2120	19	45	1	1	NUM
dpc-2120	19	46	,	,	PUNCT
dpc-2120	19	47	2	2	NUM
dpc-2120	19	48	]	]	PUNCT
dpc-2120	19	49	.	.	PUNCT
dpc-2120	20	1	whereas	whereas	SCONJ
dpc-2120	20	2	infants	infant	NOUN
dpc-2120	20	3	often	often	ADV
dpc-2120	20	4	present	present	VERB
dpc-2120	20	5	acute	acute	ADJ
dpc-2120	20	6	eczematous	eczematous	ADJ
dpc-2120	20	7	pruritic	pruritic	ADJ
dpc-2120	20	8	lesions	lesion	NOUN
dpc-2120	20	9	involving	involve	VERB
dpc-2120	20	10	the	the	DET
dpc-2120	20	11	face	face	NOUN
dpc-2120	20	12	,	,	PUNCT
dpc-2120	20	13	cheeks	cheek	NOUN
dpc-2120	20	14	,	,	PUNCT
dpc-2120	20	15	and	and	CCONJ
dpc-2120	20	16	trunk	trunk	NOUN
dpc-2120	20	17	,	,	PUNCT
dpc-2120	20	18	children	child	NOUN
dpc-2120	20	19	,	,	PUNCT
dpc-2120	20	20	adolescents	adolescent	NOUN
dpc-2120	20	21	,	,	PUNCT
dpc-2120	20	22	and	and	CCONJ
dpc-2120	20	23	adults	adult	NOUN
dpc-2120	20	24	develop	develop	VERB
dpc-2120	20	25	rather	rather	ADV
dpc-2120	20	26	diffuse	diffuse	VERB
dpc-2120	20	27	lesions	lesion	NOUN
dpc-2120	20	28	affecting	affect	VERB
dpc-2120	20	29	the	the	DET
dpc-2120	20	30	flexures	flexure	NOUN
dpc-2120	20	31	,	,	PUNCT
dpc-2120	20	32	alternating	alternate	VERB
dpc-2120	20	33	between	between	ADP
dpc-2120	20	34	acute	acute	ADJ
dpc-2120	20	35	and	and	CCONJ
dpc-2120	20	36	chronic	chronic	ADJ
dpc-2120	20	37	areas	area	NOUN
dpc-2120	20	38	[	[	X
dpc-2120	20	39	3	3	NUM
dpc-2120	20	40	]	]	PUNCT
dpc-2120	20	41	.	.	PUNCT
dpc-2120	21	1	with	with	ADP
dpc-2120	21	2	numerous	numerous	ADJ
dpc-2120	21	3	new	new	ADJ
dpc-2120	21	4	emerging	emerge	VERB
dpc-2120	21	5	drugs	drug	NOUN
dpc-2120	21	6	expanding	expand	VERB
dpc-2120	21	7	the	the	DET
dpc-2120	21	8	clinical	clinical	ADJ
dpc-2120	21	9	practice	practice	NOUN
dpc-2120	21	10	of	of	ADP
dpc-2120	21	11	ad	ad	NOUN
dpc-2120	21	12	healthcare	healthcare	NOUN
dpc-2120	21	13	in	in	ADP
dpc-2120	21	14	recent	recent	ADJ
dpc-2120	21	15	years	year	NOUN
dpc-2120	21	16	,	,	PUNCT
dpc-2120	21	17	the	the	DET
dpc-2120	21	18	approval	approval	NOUN
dpc-2120	21	19	of	of	ADP
dpc-2120	21	20	dupilumab	dupilumab	NOUN
dpc-2120	21	21	,	,	PUNCT
dpc-2120	21	22	represented	represent	VERB
dpc-2120	21	23	a	a	DET
dpc-2120	21	24	major	major	ADJ
dpc-2120	21	25	breakthrough	breakthrough	NOUN
dpc-2120	21	26	in	in	ADP
dpc-2120	21	27	the	the	DET
dpc-2120	21	28	therapy	therapy	NOUN
dpc-2120	21	29	of	of	ADP
dpc-2120	21	30	patients	patient	NOUN
dpc-2120	21	31	with	with	ADP
dpc-2120	21	32	moderate	moderate	ADJ
dpc-2120	21	33	to	to	ADP
dpc-2120	21	34	severe	severe	ADJ
dpc-2120	21	35	ad	ad	NOUN
dpc-2120	21	36	.	.	PUNCT
dpc-2120	22	1	this	this	DET
dpc-2120	22	2	review	review	NOUN
dpc-2120	22	3	aims	aim	VERB
dpc-2120	22	4	to	to	PART
dpc-2120	22	5	describe	describe	VERB
dpc-2120	22	6	currently	currently	ADV
dpc-2120	22	7	available	available	ADJ
dpc-2120	22	8	biological	biological	ADJ
dpc-2120	22	9	treatment	treatment	NOUN
dpc-2120	22	10	options	option	NOUN
dpc-2120	22	11	and	and	CCONJ
dpc-2120	22	12	potential	potential	ADJ
dpc-2120	22	13	future	future	ADJ
dpc-2120	22	14	developments	development	NOUN
dpc-2120	22	15	.	.	PUNCT
dpc-2120	23	1	dupilumab	dupilumab	NOUN
dpc-2120	23	2	the	the	DET
dpc-2120	23	3	pathophysiology	pathophysiology	NOUN
dpc-2120	23	4	of	of	ADP
dpc-2120	23	5	ad	ad	NOUN
dpc-2120	23	6	is	be	AUX
dpc-2120	23	7	multifactorial	multifactorial	ADJ
dpc-2120	23	8	,	,	PUNCT
dpc-2120	23	9	involving	involve	VERB
dpc-2120	23	10	a	a	DET
dpc-2120	23	11	genetic	genetic	ADJ
dpc-2120	23	12	predisposition	predisposition	NOUN
dpc-2120	23	13	,	,	PUNCT
dpc-2120	23	14	epidermal	epidermal	ADJ
dpc-2120	23	15	barrier	barrier	NOUN
dpc-2120	23	16	dysfunction	dysfunction	NOUN
dpc-2120	23	17	,	,	PUNCT
dpc-2120	23	18	the	the	DET
dpc-2120	23	19	skin	skin	NOUN
dpc-2120	23	20	microbiome	microbiome	NOUN
dpc-2120	23	21	,	,	PUNCT
dpc-2120	23	22	and	and	CCONJ
dpc-2120	23	23	type-2	type-2	NUM
dpc-2120	23	24	-	-	PUNCT
dpc-2120	23	25	t	t	NOUN
dpc-2120	23	26	-	-	PUNCT
dpc-2120	23	27	helper	helper	NOUN
dpc-2120	23	28	-	-	PUNCT
dpc-2120	23	29	cells	cell	NOUN
dpc-2120	23	30	(	(	PUNCT
dpc-2120	23	31	th2)-predominant	th2)-predominant	NUM
dpc-2120	23	32	inflammation	inflammation	NOUN
dpc-2120	23	33	[	[	X
dpc-2120	23	34	4	4	NUM
dpc-2120	23	35	-	-	SYM
dpc-2120	23	36	6	6	NUM
dpc-2120	23	37	]	]	PUNCT
dpc-2120	23	38	.	.	PUNCT
dpc-2120	24	1	the	the	DET
dpc-2120	24	2	latter	latter	ADJ
dpc-2120	24	3	is	be	AUX
dpc-2120	24	4	mediated	mediate	VERB
dpc-2120	24	5	by	by	ADP
dpc-2120	24	6	various	various	ADJ
dpc-2120	24	7	type-2	type-2	NUM
dpc-2120	24	8	cytokines	cytokine	NOUN
dpc-2120	24	9	,	,	PUNCT
dpc-2120	24	10	among	among	ADP
dpc-2120	24	11	others	other	NOUN
dpc-2120	24	12	interleukin-4	interleukin-4	NUM
dpc-2120	24	13	(	(	PUNCT
dpc-2120	24	14	il-4	il-4	NUM
dpc-2120	24	15	)	)	PUNCT
dpc-2120	24	16	,	,	PUNCT
dpc-2120	24	17	and	and	CCONJ
dpc-2120	24	18	il-13	il-13	NUM
dpc-2120	24	19	.	.	PUNCT
dpc-2120	25	1	moreover	moreover	ADV
dpc-2120	25	2	,	,	PUNCT
dpc-2120	25	3	il-4	il-4	PRON
dpc-2120	25	4	induces	induce	VERB
dpc-2120	25	5	differentiation	differentiation	NOUN
dpc-2120	25	6	of	of	ADP
dpc-2120	25	7	th	th	NOUN
dpc-2120	25	8	-	-	PUNCT
dpc-2120	25	9	cells	cell	NOUN
dpc-2120	25	10	into	into	ADP
dpc-2120	25	11	th2	th2	PROPN
dpc-2120	25	12	-	-	PUNCT
dpc-2120	25	13	cells	cell	NOUN
dpc-2120	25	14	,	,	PUNCT
dpc-2120	25	15	thus	thus	ADV
dpc-2120	25	16	promoting	promote	VERB
dpc-2120	25	17	further	further	ADJ
dpc-2120	25	18	production	production	NOUN
dpc-2120	25	19	of	of	ADP
dpc-2120	25	20	il-4	il-4	NOUN
dpc-2120	25	21	and	and	CCONJ
dpc-2120	25	22	il-13	il-13	X
dpc-2120	26	1	[	[	X
dpc-2120	26	2	7	7	NUM
dpc-2120	26	3	]	]	PUNCT
dpc-2120	26	4	.	.	PUNCT
dpc-2120	27	1	both	both	PRON
dpc-2120	27	2	using	use	VERB
dpc-2120	27	3	the	the	DET
dpc-2120	27	4	same	same	ADJ
dpc-2120	27	5	il-4	il-4	NOUN
dpc-2120	27	6	receptor	receptor	NOUN
dpc-2120	27	7	subunit	subunit	NOUN
dpc-2120	27	8	alpha	alpha	NOUN
dpc-2120	27	9	(	(	PUNCT
dpc-2120	27	10	il-4rα	il-4rα	NOUN
dpc-2120	27	11	)	)	PUNCT
dpc-2120	27	12	,	,	PUNCT
dpc-2120	27	13	these	these	DET
dpc-2120	27	14	cytokines	cytokine	NOUN
dpc-2120	27	15	are	be	AUX
dpc-2120	27	16	responsible	responsible	ADJ
dpc-2120	27	17	for	for	ADP
dpc-2120	27	18	ige	ige	PROPN
dpc-2120	27	19	class	class	NOUN
dpc-2120	27	20	switching	switch	VERB
dpc-2120	27	21	in	in	ADP
dpc-2120	27	22	b	b	NOUN
dpc-2120	27	23	-	-	PUNCT
dpc-2120	27	24	cells	cell	NOUN
dpc-2120	27	25	[	[	X
dpc-2120	27	26	8	8	NUM
dpc-2120	27	27	]	]	PUNCT
dpc-2120	27	28	.	.	PUNCT
dpc-2120	28	1	given	give	VERB
dpc-2120	28	2	its	its	PRON
dpc-2120	28	3	key	key	ADJ
dpc-2120	28	4	role	role	NOUN
dpc-2120	28	5	in	in	ADP
dpc-2120	28	6	the	the	DET
dpc-2120	28	7	pathway	pathway	NOUN
dpc-2120	28	8	of	of	ADP
dpc-2120	28	9	type-2	type-2	NUM
dpc-2120	28	10	mediated	mediate	VERB
dpc-2120	28	11	immune	immune	ADJ
dpc-2120	28	12	response	response	NOUN
dpc-2120	28	13	,	,	PUNCT
dpc-2120	28	14	il-4rα	il-4rα	ADJ
dpc-2120	28	15	blockade	blockade	NOUN
dpc-2120	28	16	was	be	AUX
dpc-2120	28	17	anticipated	anticipate	VERB
dpc-2120	28	18	to	to	PART
dpc-2120	28	19	represent	represent	VERB
dpc-2120	28	20	a	a	DET
dpc-2120	28	21	therapeutic	therapeutic	ADJ
dpc-2120	28	22	approach	approach	NOUN
dpc-2120	28	23	to	to	ADP
dpc-2120	28	24	treating	treat	VERB
dpc-2120	28	25	allergic	allergic	ADJ
dpc-2120	28	26	diseases	disease	NOUN
dpc-2120	28	27	.	.	PUNCT
dpc-2120	29	1	indeed	indeed	ADV
dpc-2120	29	2	,	,	PUNCT
dpc-2120	29	3	dupilumab	dupilumab	NOUN
dpc-2120	29	4	,	,	PUNCT
dpc-2120	29	5	a	a	DET
dpc-2120	29	6	human	human	ADJ
dpc-2120	29	7	monoclonal	monoclonal	NOUN
dpc-2120	29	8	antibody	antibody	NOUN
dpc-2120	29	9	blocking	block	VERB
dpc-2120	29	10	il-4rα	il-4rα	NOUN
dpc-2120	29	11	,	,	PUNCT
dpc-2120	29	12	was	be	AUX
dpc-2120	29	13	first	first	ADV
dpc-2120	29	14	shown	show	VERB
dpc-2120	29	15	to	to	PART
dpc-2120	29	16	be	be	AUX
dpc-2120	29	17	effective	effective	ADJ
dpc-2120	29	18	in	in	ADP
dpc-2120	29	19	the	the	DET
dpc-2120	29	20	treatment	treatment	NOUN
dpc-2120	29	21	of	of	ADP
dpc-2120	29	22	ad	ad	NOUN
dpc-2120	29	23	in	in	ADP
dpc-2120	29	24	an	an	DET
dpc-2120	29	25	early	early	ADJ
dpc-2120	29	26	-	-	PUNCT
dpc-2120	29	27	phase	phase	NOUN
dpc-2120	29	28	randomized	randomize	VERB
dpc-2120	29	29	,	,	PUNCT
dpc-2120	29	30	double	double	ADJ
dpc-2120	29	31	-	-	PUNCT
dpc-2120	29	32	blind	blind	ADJ
dpc-2120	29	33	,	,	PUNCT
dpc-2120	29	34	placebo	placebo	NOUN
dpc-2120	29	35	-	-	PUNCT
dpc-2120	29	36	controlled	control	VERB
dpc-2120	29	37	trial	trial	NOUN
dpc-2120	29	38	in	in	ADP
dpc-2120	29	39	adults	adult	NOUN
dpc-2120	29	40	in	in	ADP
dpc-2120	29	41	2014	2014	NUM
dpc-2120	30	1	[	[	X
dpc-2120	30	2	9	9	NUM
dpc-2120	30	3	]	]	PUNCT
dpc-2120	30	4	.	.	PUNCT
dpc-2120	31	1	monotherapy	monotherapy	NOUN
dpc-2120	31	2	of	of	ADP
dpc-2120	31	3	dupilumab	dupilumab	NOUN
dpc-2120	31	4	at	at	ADP
dpc-2120	31	5	4	4	NUM
dpc-2120	31	6	weeks	week	NOUN
dpc-2120	31	7	compared	compare	VERB
dpc-2120	31	8	to	to	ADP
dpc-2120	31	9	placebo	placebo	NOUN
dpc-2120	31	10	showed	show	VERB
dpc-2120	31	11	a	a	DET
dpc-2120	31	12	rapid	rapid	ADJ
dpc-2120	31	13	and	and	CCONJ
dpc-2120	31	14	dose	dose	NOUN
dpc-2120	31	15	-	-	PUNCT
dpc-2120	31	16	dependent	dependent	ADJ
dpc-2120	31	17	50	50	NUM
dpc-2120	31	18	%	%	NOUN
dpc-2120	31	19	improvement	improvement	NOUN
dpc-2120	31	20	in	in	ADP
dpc-2120	31	21	the	the	DET
dpc-2120	31	22	eczema	eczema	NOUN
dpc-2120	31	23	area	area	NOUN
dpc-2120	31	24	and	and	CCONJ
dpc-2120	31	25	severity	severity	NOUN
dpc-2120	31	26	index	index	NOUN
dpc-2120	31	27	score	score	NOUN
dpc-2120	31	28	(	(	PUNCT
dpc-2120	31	29	easi-50	easi-50	ADJ
dpc-2120	31	30	)	)	PUNCT
dpc-2120	31	31	and	and	CCONJ
dpc-2120	31	32	decline	decline	VERB
dpc-2120	31	33	in	in	ADP
dpc-2120	31	34	the	the	DET
dpc-2120	31	35	pruritus	pruritus	NOUN
dpc-2120	31	36	numerical	numerical	ADJ
dpc-2120	31	37	-	-	PUNCT
dpc-2120	31	38	rating	rating	NOUN
dpc-2120	31	39	scale	scale	NOUN
dpc-2120	31	40	.	.	PUNCT
dpc-2120	32	1	this	this	DET
dpc-2120	32	2	effect	effect	NOUN
dpc-2120	32	3	was	be	AUX
dpc-2120	32	4	further	far	ADV
dpc-2120	32	5	intensified	intensify	VERB
dpc-2120	32	6	at	at	ADP
dpc-2120	32	7	12	12	NUM
dpc-2120	32	8	weeks	week	NOUN
dpc-2120	33	1	[	[	X
dpc-2120	33	2	9	9	NUM
dpc-2120	33	3	]	]	PUNCT
dpc-2120	33	4	.	.	PUNCT
dpc-2120	34	1	dupilumab	dupilumab	NOUN
dpc-2120	34	2	was	be	AUX
dpc-2120	34	3	previously	previously	ADV
dpc-2120	34	4	shown	show	VERB
dpc-2120	34	5	to	to	PART
dpc-2120	34	6	be	be	AUX
dpc-2120	34	7	efficient	efficient	ADJ
dpc-2120	34	8	in	in	ADP
dpc-2120	34	9	treating	treat	VERB
dpc-2120	34	10	persistent	persistent	ADJ
dpc-2120	34	11	,	,	PUNCT
dpc-2120	34	12	moderate	moderate	ADJ
dpc-2120	34	13	-	-	PUNCT
dpc-2120	34	14	to	to	ADP
dpc-2120	34	15	-	-	PUNCT
dpc-2120	34	16	severe	severe	ADJ
dpc-2120	34	17	asthma	asthma	NOUN
dpc-2120	34	18	with	with	ADP
dpc-2120	34	19	elevated	elevated	ADJ
dpc-2120	34	20	eosinophil	eosinophil	ADJ
dpc-2120	34	21	levels	level	NOUN
dpc-2120	34	22	[	[	X
dpc-2120	34	23	10	10	NUM
dpc-2120	34	24	]	]	PUNCT
dpc-2120	34	25	.	.	PUNCT
dpc-2120	35	1	simpson	simpson	PROPN
dpc-2120	35	2	et	et	PROPN
dpc-2120	35	3	al	al	PROPN
dpc-2120	35	4	reported	report	VERB
dpc-2120	35	5	in	in	ADP
dpc-2120	35	6	2016	2016	NUM
dpc-2120	35	7	an	an	DET
dpc-2120	35	8	improvement	improvement	NOUN
dpc-2120	35	9	of	of	ADP
dpc-2120	35	10	75	75	NUM
dpc-2120	35	11	%	%	NOUN
dpc-2120	35	12	in	in	ADP
dpc-2120	35	13	the	the	DET
dpc-2120	35	14	easi	easi	NOUN
dpc-2120	35	15	,	,	PUNCT
dpc-2120	35	16	a	a	DET
dpc-2120	35	17	reduction	reduction	NOUN
dpc-2120	35	18	of	of	ADP
dpc-2120	35	19	pruritus	pruritus	NOUN
dpc-2120	35	20	and	and	CCONJ
dpc-2120	35	21	improvement	improvement	NOUN
dpc-2120	35	22	in	in	ADP
dpc-2120	35	23	quality	quality	NOUN
dpc-2120	35	24	of	of	ADP
dpc-2120	35	25	life	life	NOUN
dpc-2120	35	26	in	in	ADP
dpc-2120	35	27	two	two	NUM
dpc-2120	35	28	phase-3	phase-3	NUM
dpc-2120	35	29	trials	trial	NOUN
dpc-2120	35	30	of	of	ADP
dpc-2120	35	31	dupilumab	dupilumab	NOUN
dpc-2120	35	32	versus	versus	ADP
dpc-2120	35	33	placebo	placebo	NOUN
dpc-2120	35	34	in	in	ADP
dpc-2120	35	35	ad	ad	NOUN
dpc-2120	35	36	,	,	PUNCT
dpc-2120	35	37	comprising	comprise	VERB
dpc-2120	35	38	almost	almost	ADV
dpc-2120	35	39	1,400	1,400	NUM
dpc-2120	35	40	patients	patient	NOUN
dpc-2120	35	41	aged	age	VERB
dpc-2120	35	42	18	18	NUM
dpc-2120	35	43	years	year	NOUN
dpc-2120	35	44	and	and	CCONJ
dpc-2120	35	45	older	old	ADJ
dpc-2120	35	46	in	in	ADP
dpc-2120	35	47	north	north	PROPN
dpc-2120	35	48	america	america	PROPN
dpc-2120	35	49	,	,	PUNCT
dpc-2120	35	50	europe	europe	PROPN
dpc-2120	35	51	,	,	PUNCT
dpc-2120	35	52	and	and	CCONJ
dpc-2120	35	53	asia	asia	PROPN
dpc-2120	35	54	.	.	PUNCT
dpc-2120	36	1	adverse	adverse	ADJ
dpc-2120	36	2	effects	effect	NOUN
dpc-2120	36	3	were	be	AUX
dpc-2120	36	4	mild	mild	ADJ
dpc-2120	36	5	to	to	AUX
dpc-2120	36	6	moderate	moderate	ADJ
dpc-2120	36	7	and	and	CCONJ
dpc-2120	36	8	comprised	comprise	VERB
dpc-2120	36	9	nasopharyngitis	nasopharyngitis	ADJ
dpc-2120	36	10	,	,	PUNCT
dpc-2120	36	11	upper	upper	ADJ
dpc-2120	36	12	respiratory	respiratory	ADJ
dpc-2120	36	13	tract	tract	NOUN
dpc-2120	36	14	infections	infection	NOUN
dpc-2120	36	15	,	,	PUNCT
dpc-2120	36	16	conjunctivitis	conjunctivitis	NOUN
dpc-2120	36	17	,	,	PUNCT
dpc-2120	36	18	injection	injection	NOUN
dpc-2120	36	19	-	-	PUNCT
dpc-2120	36	20	site	site	NOUN
dpc-2120	36	21	reactions	reaction	NOUN
dpc-2120	36	22	,	,	PUNCT
dpc-2120	36	23	and	and	CCONJ
dpc-2120	36	24	exacerbation	exacerbation	NOUN
dpc-2120	36	25	of	of	ADP
dpc-2120	36	26	ad	ad	NOUN
dpc-2120	36	27	[	[	X
dpc-2120	36	28	11	11	NUM
dpc-2120	36	29	]	]	PUNCT
dpc-2120	36	30	.	.	PUNCT
dpc-2120	37	1	in	in	ADP
dpc-2120	37	2	2017	2017	NUM
dpc-2120	37	3	,	,	PUNCT
dpc-2120	37	4	dupilumab	dupilumab	NOUN
dpc-2120	37	5	was	be	AUX
dpc-2120	37	6	authorized	authorize	VERB
dpc-2120	37	7	for	for	ADP
dpc-2120	37	8	the	the	DET
dpc-2120	37	9	treatment	treatment	NOUN
dpc-2120	37	10	of	of	ADP
dpc-2120	37	11	ad	ad	NOUN
dpc-2120	37	12	in	in	ADP
dpc-2120	37	13	the	the	DET
dpc-2120	37	14	european	european	PROPN
dpc-2120	37	15	union	union	PROPN
dpc-2120	37	16	by	by	ADP
dpc-2120	37	17	the	the	DET
dpc-2120	37	18	european	european	PROPN
dpc-2120	37	19	medicines	medicines	PROPN
dpc-2120	37	20	agency	agency	NOUN
dpc-2120	37	21	(	(	PUNCT
dpc-2120	37	22	ema	ema	PROPN
dpc-2120	37	23	)	)	PUNCT
dpc-2120	37	24	.	.	PUNCT
dpc-2120	38	1	shortly	shortly	ADV
dpc-2120	38	2	after	after	SCONJ
dpc-2120	38	3	,	,	PUNCT
dpc-2120	38	4	phase-3	phase-3	NUM
dpc-2120	38	5	trials	trial	NOUN
dpc-2120	38	6	for	for	ADP
dpc-2120	38	7	adolescents	adolescent	NOUN
dpc-2120	38	8	[	[	X
dpc-2120	38	9	12	12	NUM
dpc-2120	38	10	]	]	PUNCT
dpc-2120	38	11	and	and	CCONJ
dpc-2120	38	12	children	child	NOUN
dpc-2120	38	13	aged	age	VERB
dpc-2120	38	14	6	6	NUM
dpc-2120	38	15	years	year	NOUN
dpc-2120	38	16	and	and	CCONJ
dpc-2120	38	17	older	old	ADJ
dpc-2120	38	18	[	[	X
dpc-2120	38	19	13	13	NUM
dpc-2120	38	20	]	]	PUNCT
dpc-2120	38	21	were	be	AUX
dpc-2120	38	22	conducted	conduct	VERB
dpc-2120	38	23	,	,	PUNCT
dpc-2120	38	24	which	which	PRON
dpc-2120	38	25	showed	show	VERB
dpc-2120	38	26	an	an	DET
dpc-2120	38	27	improvement	improvement	NOUN
dpc-2120	38	28	in	in	ADP
dpc-2120	38	29	easi	easi	NOUN
dpc-2120	38	30	,	,	PUNCT
dpc-2120	38	31	investigator	investigator	NOUN
dpc-2120	38	32	’s	’s	PART
dpc-2120	38	33	global	global	ADJ
dpc-2120	38	34	assessment	assessment	NOUN
dpc-2120	38	35	(	(	PUNCT
dpc-2120	38	36	iga	iga	PROPN
dpc-2120	38	37	)	)	PUNCT
dpc-2120	38	38	score	score	NOUN
dpc-2120	38	39	,	,	PUNCT
dpc-2120	38	40	and	and	CCONJ
dpc-2120	38	41	quality	quality	NOUN
dpc-2120	38	42	of	of	ADP
dpc-2120	38	43	life	life	NOUN
dpc-2120	38	44	compared	compare	VERB
dpc-2120	38	45	to	to	ADP
dpc-2120	38	46	placebo	placebo	NOUN
dpc-2120	38	47	with	with	ADP
dpc-2120	38	48	similar	similar	ADJ
dpc-2120	38	49	adverse	adverse	ADJ
dpc-2120	38	50	effects	effect	NOUN
dpc-2120	38	51	in	in	ADP
dpc-2120	38	52	these	these	DET
dpc-2120	38	53	age	age	NOUN
dpc-2120	38	54	groups	group	NOUN
dpc-2120	38	55	as	as	ADV
dpc-2120	38	56	well	well	ADV
dpc-2120	38	57	.	.	PUNCT
dpc-2120	39	1	currently	currently	ADV
dpc-2120	39	2	,	,	PUNCT
dpc-2120	39	3	the	the	DET
dpc-2120	39	4	treatment	treatment	NOUN
dpc-2120	39	5	of	of	ADP
dpc-2120	39	6	ad	ad	NOUN
dpc-2120	39	7	with	with	ADP
dpc-2120	39	8	dupilumab	dupilumab	NOUN
dpc-2120	39	9	is	be	AUX
dpc-2120	39	10	authorized	authorize	VERB
dpc-2120	39	11	by	by	ADP
dpc-2120	39	12	ema	ema	PROPN
dpc-2120	39	13	for	for	ADP
dpc-2120	39	14	patients	patient	NOUN
dpc-2120	39	15	aged	age	VERB
dpc-2120	39	16	6	6	NUM
dpc-2120	39	17	years	year	NOUN
dpc-2120	39	18	and	and	CCONJ
dpc-2120	39	19	older	old	ADJ
dpc-2120	39	20	.	.	PUNCT
dpc-2120	40	1	recently	recently	ADV
dpc-2120	40	2	,	,	PUNCT
dpc-2120	40	3	a	a	DET
dpc-2120	40	4	promising	promising	ADJ
dpc-2120	40	5	phase-2	phase-2	PROPN
dpc-2120	40	6	,	,	PUNCT
dpc-2120	40	7	two	two	NUM
dpc-2120	40	8	-	-	PUNCT
dpc-2120	40	9	age	age	NOUN
dpc-2120	40	10	cohort	cohort	NOUN
dpc-2120	40	11	,	,	PUNCT
dpc-2120	40	12	two	two	NUM
dpc-2120	40	13	-	-	PUNCT
dpc-2120	40	14	dose	dose	NOUN
dpc-2120	40	15	level	level	NOUN
dpc-2120	40	16	,	,	PUNCT
dpc-2120	40	17	multicenter	multicenter	ADJ
dpc-2120	40	18	study	study	NOUN
dpc-2120	40	19	of	of	ADP
dpc-2120	40	20	dupilumab	dupilumab	NOUN
dpc-2120	40	21	in	in	ADP
dpc-2120	40	22	the	the	DET
dpc-2120	40	23	treatment	treatment	NOUN
dpc-2120	40	24	of	of	ADP
dpc-2120	40	25	severe	severe	ADJ
dpc-2120	40	26	uncontrolled	uncontrolled	ADJ
dpc-2120	40	27	ad	ad	NOUN
dpc-2120	40	28	in	in	ADP
dpc-2120	40	29	children	child	NOUN
dpc-2120	40	30	aged	age	VERB
dpc-2120	40	31	6	6	NUM
dpc-2120	40	32	months	month	NOUN
dpc-2120	40	33	to	to	ADP
dpc-2120	40	34	<	<	X
dpc-2120	40	35	6	6	NUM
dpc-2120	40	36	years	year	NOUN
dpc-2120	40	37	has	have	AUX
dpc-2120	40	38	showed	show	VERB
dpc-2120	40	39	efficacy	efficacy	NOUN
dpc-2120	40	40	and	and	CCONJ
dpc-2120	40	41	a	a	DET
dpc-2120	40	42	similar	similar	ADJ
dpc-2120	40	43	safety	safety	NOUN
dpc-2120	40	44	-	-	PUNCT
dpc-2120	40	45	profile	profile	NOUN
dpc-2120	40	46	as	as	SCONJ
dpc-2120	40	47	seen	see	VERB
dpc-2120	40	48	in	in	ADP
dpc-2120	40	49	older	old	ADJ
dpc-2120	40	50	age	age	NOUN
dpc-2120	40	51	groups	group	NOUN
dpc-2120	40	52	[	[	X
dpc-2120	40	53	14	14	NUM
dpc-2120	40	54	]	]	PUNCT
dpc-2120	40	55	.	.	PUNCT
dpc-2120	41	1	these	these	DET
dpc-2120	41	2	data	datum	NOUN
dpc-2120	41	3	could	could	AUX
dpc-2120	41	4	support	support	VERB
dpc-2120	41	5	a	a	DET
dpc-2120	41	6	phase-3	phase-3	NUM
dpc-2120	41	7	trial	trial	NOUN
dpc-2120	41	8	of	of	ADP
dpc-2120	41	9	dupilumab	dupilumab	NOUN
dpc-2120	41	10	in	in	ADP
dpc-2120	41	11	this	this	DET
dpc-2120	41	12	patient	patient	ADJ
dpc-2120	41	13	population	population	NOUN
dpc-2120	41	14	to	to	PART
dpc-2120	41	15	further	far	ADV
dpc-2120	41	16	offer	offer	VERB
dpc-2120	41	17	therapeutic	therapeutic	ADJ
dpc-2120	41	18	approaches	approach	NOUN
dpc-2120	41	19	for	for	ADP
dpc-2120	41	20	topical	topical	ADJ
dpc-2120	41	21	corticosteroid	corticosteroid	ADJ
dpc-2120	41	22	-	-	PUNCT
dpc-2120	41	23	refractory	refractory	NOUN
dpc-2120	41	24	ad	ad	NOUN
dpc-2120	41	25	in	in	ADP
dpc-2120	41	26	this	this	DET
dpc-2120	41	27	age	age	NOUN
dpc-2120	41	28	group	group	NOUN
dpc-2120	41	29	.	.	PUNCT
dpc-2120	42	1	further	further	ADJ
dpc-2120	42	2	biologics	biologic	NOUN
dpc-2120	42	3	in	in	ADP
dpc-2120	42	4	atopic	atopic	NOUN
dpc-2120	42	5	dermatitis	dermatitis	NOUN
dpc-2120	42	6	’	'	PUNCT
dpc-2120	42	7	treatment	treatment	NOUN
dpc-2120	42	8	in	in	ADP
dpc-2120	42	9	addition	addition	NOUN
dpc-2120	42	10	to	to	ADP
dpc-2120	42	11	il-4	il-4	X
dpc-2120	42	12	and	and	CCONJ
dpc-2120	42	13	il-13	il-13	CCONJ
dpc-2120	42	14	,	,	PUNCT
dpc-2120	42	15	other	other	ADJ
dpc-2120	42	16	cytokines	cytokine	NOUN
dpc-2120	42	17	have	have	AUX
dpc-2120	42	18	been	be	AUX
dpc-2120	42	19	identified	identify	VERB
dpc-2120	42	20	to	to	PART
dpc-2120	42	21	play	play	VERB
dpc-2120	42	22	an	an	DET
dpc-2120	42	23	important	important	ADJ
dpc-2120	42	24	role	role	NOUN
dpc-2120	42	25	in	in	ADP
dpc-2120	42	26	the	the	DET
dpc-2120	42	27	pathophysiology	pathophysiology	NOUN
dpc-2120	42	28	of	of	ADP
dpc-2120	42	29	chronic	chronic	ADJ
dpc-2120	42	30	inflammatory	inflammatory	ADJ
dpc-2120	42	31	skin	skin	NOUN
dpc-2120	42	32	disease	disease	NOUN
dpc-2120	42	33	.	.	PUNCT
dpc-2120	43	1	these	these	PRON
dpc-2120	43	2	are	be	AUX
dpc-2120	43	3	il-31	il-31	PRON
dpc-2120	43	4	,	,	PUNCT
dpc-2120	43	5	thymic	thymic	ADJ
dpc-2120	43	6	stromal	stromal	ADJ
dpc-2120	43	7	lymphopoietin	lymphopoietin	NOUN
dpc-2120	43	8	(	(	PUNCT
dpc-2120	43	9	tslp	tslp	PROPN
dpc-2120	43	10	)	)	PUNCT
dpc-2120	43	11	,	,	PUNCT
dpc-2120	43	12	il-17	il-17	X
dpc-2120	43	13	,	,	PUNCT
dpc-2120	43	14	and	and	CCONJ
dpc-2120	43	15	il-22	il-22	ADJ
dpc-2120	43	16	cytokines	cytokine	NOUN
dpc-2120	43	17	,	,	PUNCT
dpc-2120	43	18	which	which	PRON
dpc-2120	43	19	can	can	AUX
dpc-2120	43	20	also	also	ADV
dpc-2120	43	21	negatively	negatively	ADV
dpc-2120	43	22	affect	affect	VERB
dpc-2120	43	23	the	the	DET
dpc-2120	43	24	expression	expression	NOUN
dpc-2120	43	25	of	of	ADP
dpc-2120	43	26	barrier	barrier	NOUN
dpc-2120	43	27	proteins	protein	NOUN
dpc-2120	43	28	.	.	PUNCT
dpc-2120	44	1	il-13	il-13	ADP
dpc-2120	44	2	a	a	DET
dpc-2120	44	3	th-2	th-2	ADV
dpc-2120	44	4	mediated	mediate	VERB
dpc-2120	44	5	exuberant	exuberant	ADJ
dpc-2120	44	6	immune	immune	ADJ
dpc-2120	44	7	response	response	NOUN
dpc-2120	44	8	is	be	AUX
dpc-2120	44	9	stated	state	VERB
dpc-2120	44	10	to	to	PART
dpc-2120	44	11	be	be	AUX
dpc-2120	44	12	the	the	DET
dpc-2120	44	13	key	key	ADJ
dpc-2120	44	14	mechanism	mechanism	NOUN
dpc-2120	44	15	in	in	ADP
dpc-2120	44	16	the	the	DET
dpc-2120	44	17	pathogenesis	pathogenesis	NOUN
dpc-2120	44	18	of	of	ADP
dpc-2120	44	19	ad	ad	NOUN
dpc-2120	44	20	.	.	PUNCT
dpc-2120	45	1	zheng	zheng	PROPN
dpc-2120	45	2	et	et	PROPN
dpc-2120	45	3	al	al	PROPN
dpc-2120	45	4	induced	induce	VERB
dpc-2120	45	5	pruritic	pruritic	ADJ
dpc-2120	45	6	dermatitis	dermatitis	NOUN
dpc-2120	45	7	and	and	CCONJ
dpc-2120	45	8	skin	skin	NOUN
dpc-2120	45	9	remodeling	remodeling	NOUN
dpc-2120	45	10	in	in	ADP
dpc-2120	45	11	an	an	DET
dpc-2120	45	12	il-13	il-13	VERB
dpc-2120	45	13	overexpressing	overexpresse	VERB
dpc-2120	45	14	mouse	mouse	NOUN
dpc-2120	45	15	model	model	NOUN
dpc-2120	45	16	.	.	PUNCT
dpc-2120	46	1	they	they	PRON
dpc-2120	46	2	showed	show	VERB
dpc-2120	46	3	that	that	SCONJ
dpc-2120	46	4	il-13	il-13	PUNCT
dpc-2120	46	5	was	be	AUX
dpc-2120	46	6	mainly	mainly	ADV
dpc-2120	46	7	produced	produce	VERB
dpc-2120	46	8	in	in	ADP
dpc-2120	46	9	the	the	DET
dpc-2120	46	10	skin	skin	NOUN
dpc-2120	46	11	and	and	CCONJ
dpc-2120	46	12	caused	cause	VERB
dpc-2120	46	13	xerosis	xerosis	NOUN
dpc-2120	46	14	,	,	PUNCT
dpc-2120	46	15	itching	itching	NOUN
dpc-2120	46	16	lesions	lesion	NOUN
dpc-2120	46	17	,	,	PUNCT
dpc-2120	46	18	chronic	chronic	ADJ
dpc-2120	46	19	inflammation	inflammation	NOUN
dpc-2120	46	20	of	of	ADP
dpc-2120	46	21	the	the	DET
dpc-2120	46	22	skin	skin	NOUN
dpc-2120	46	23	,	,	PUNCT
dpc-2120	46	24	and	and	CCONJ
dpc-2120	46	25	dermal	dermal	ADJ
dpc-2120	46	26	infiltration	infiltration	NOUN
dpc-2120	46	27	of	of	ADP
dpc-2120	46	28	cd4	cd4	PROPN
dpc-2120	46	29	+	+	PROPN
dpc-2120	46	30	-cells	-cell	NOUN
dpc-2120	46	31	,	,	PUNCT
dpc-2120	46	32	mast	mast	NOUN
dpc-2120	46	33	cells	cell	NOUN
dpc-2120	46	34	,	,	PUNCT
dpc-2120	46	35	and	and	CCONJ
dpc-2120	46	36	eosinophils	eosinophil	VERB
dpc-2120	46	37	.	.	PUNCT
dpc-2120	47	1	mice	mouse	NOUN
dpc-2120	47	2	models	model	NOUN
dpc-2120	47	3	’	'	PUNCT
dpc-2120	47	4	skin	skin	NOUN
dpc-2120	47	5	also	also	ADV
dpc-2120	47	6	showed	show	VERB
dpc-2120	47	7	increased	increase	VERB
dpc-2120	47	8	fibrosis	fibrosis	NOUN
dpc-2120	47	9	and	and	CCONJ
dpc-2120	47	10	vascularization	vascularization	NOUN
dpc-2120	47	11	[	[	X
dpc-2120	47	12	15	15	NUM
dpc-2120	47	13	]	]	PUNCT
dpc-2120	47	14	.	.	PUNCT
dpc-2120	48	1	another	another	DET
dpc-2120	48	2	study	study	NOUN
dpc-2120	48	3	was	be	AUX
dpc-2120	48	4	able	able	ADJ
dpc-2120	48	5	to	to	PART
dpc-2120	48	6	show	show	VERB
dpc-2120	48	7	a	a	DET
dpc-2120	48	8	relative	relative	ADJ
dpc-2120	48	9	upregulation	upregulation	NOUN
dpc-2120	48	10	of	of	ADP
dpc-2120	48	11	il-13	il-13	PUNCT
dpc-2120	48	12	mrna	mrna	PROPN
dpc-2120	48	13	compared	compare	VERB
dpc-2120	48	14	to	to	ADP
dpc-2120	48	15	il-4	il-4	PRON
dpc-2120	48	16	mrna	mrna	PROPN
dpc-2120	48	17	in	in	ADP
dpc-2120	48	18	lesional	lesional	ADJ
dpc-2120	48	19	skin	skin	NOUN
dpc-2120	48	20	of	of	ADP
dpc-2120	48	21	ad	ad	NOUN
dpc-2120	48	22	patients	patient	NOUN
dpc-2120	48	23	,	,	PUNCT
dpc-2120	48	24	thus	thus	ADV
dpc-2120	48	25	providing	provide	VERB
dpc-2120	48	26	first	first	ADJ
dpc-2120	48	27	evidence	evidence	NOUN
dpc-2120	48	28	that	that	SCONJ
dpc-2120	48	29	il-13	il-13	PRON
dpc-2120	48	30	may	may	AUX
dpc-2120	48	31	be	be	AUX
dpc-2120	48	32	the	the	DET
dpc-2120	48	33	crucial	crucial	ADJ
dpc-2120	48	34	cytokine	cytokine	NOUN
dpc-2120	48	35	in	in	ADP
dpc-2120	48	36	the	the	DET
dpc-2120	48	37	il-4	il-4	NOUN
dpc-2120	48	38	/	/	SYM
dpc-2120	48	39	il-13	il-13	NOUN
dpc-2120	48	40	axis	axis	NOUN
dpc-2120	49	1	[	[	X
dpc-2120	49	2	16	16	NUM
dpc-2120	49	3	]	]	PUNCT
dpc-2120	49	4	.	.	PUNCT
dpc-2120	50	1	il-13	il-13	X
dpc-2120	50	2	as	as	ADP
dpc-2120	50	3	a	a	DET
dpc-2120	50	4	potent	potent	ADJ
dpc-2120	50	5	stimulator	stimulator	NOUN
dpc-2120	50	6	of	of	ADP
dpc-2120	50	7	dermal	dermal	ADJ
dpc-2120	50	8	inflammation	inflammation	NOUN
dpc-2120	50	9	and	and	CCONJ
dpc-2120	50	10	remodeling	remodeling	NOUN
dpc-2120	50	11	is	be	AUX
dpc-2120	50	12	another	another	DET
dpc-2120	50	13	hypothesis	hypothesis	NOUN
dpc-2120	50	14	for	for	ADP
dpc-2120	50	15	the	the	DET
dpc-2120	50	16	pathogenesis	pathogenesis	NOUN
dpc-2120	50	17	of	of	ADP
dpc-2120	50	18	ad	ad	NOUN
dpc-2120	50	19	[	[	X
dpc-2120	50	20	17	17	NUM
dpc-2120	50	21	,	,	PUNCT
dpc-2120	50	22	18	18	NUM
dpc-2120	50	23	]	]	PUNCT
dpc-2120	50	24	.	.	PUNCT
dpc-2120	51	1	both	both	PRON
dpc-2120	51	2	lebrikizumab	lebrikizumab	NOUN
dpc-2120	51	3	and	and	CCONJ
dpc-2120	51	4	tralokinumab	tralokinumab	NOUN
dpc-2120	51	5	,	,	PUNCT
dpc-2120	51	6	monoclonal	monoclonal	NOUN
dpc-2120	51	7	antibodies	antibodie	VERB
dpc-2120	51	8	that	that	DET
dpc-2120	51	9	target	target	VERB
dpc-2120	51	10	il-13	il-13	ADP
dpc-2120	51	11	,	,	PUNCT
dpc-2120	51	12	have	have	AUX
dpc-2120	51	13	been	be	AUX
dpc-2120	51	14	recently	recently	ADV
dpc-2120	51	15	investigated	investigate	VERB
dpc-2120	51	16	for	for	ADP
dpc-2120	51	17	ad	ad	NOUN
dpc-2120	51	18	treatment	treatment	NOUN
dpc-2120	51	19	.	.	PUNCT
dpc-2120	52	1	the	the	DET
dpc-2120	52	2	effectiveness	effectiveness	NOUN
dpc-2120	52	3	of	of	ADP
dpc-2120	52	4	a	a	DET
dpc-2120	52	5	therapy	therapy	NOUN
dpc-2120	52	6	with	with	ADP
dpc-2120	52	7	tralokinumab	tralokinumab	NOUN
dpc-2120	52	8	was	be	AUX
dpc-2120	52	9	analyzed	analyze	VERB
dpc-2120	52	10	in	in	ADP
dpc-2120	52	11	two	two	NUM
dpc-2120	52	12	52	52	NUM
dpc-2120	52	13	-	-	PUNCT
dpc-2120	52	14	week	week	NOUN
dpc-2120	52	15	,	,	PUNCT
dpc-2120	52	16	randomized	randomize	VERB
dpc-2120	52	17	,	,	PUNCT
dpc-2120	52	18	double	double	ADJ
dpc-2120	52	19	-	-	PUNCT
dpc-2120	52	20	blind	blind	ADJ
dpc-2120	52	21	,	,	PUNCT
dpc-2120	52	22	multicenter	multicenter	NOUN
dpc-2120	52	23	,	,	PUNCT
dpc-2120	52	24	placebo	placebo	NOUN
dpc-2120	52	25	-	-	PUNCT
dpc-2120	52	26	controlled	control	VERB
dpc-2120	52	27	phase-3	phase-3	PROPN
dpc-2120	52	28	-	-	PUNCT
dpc-2120	52	29	trials	trial	NOUN
dpc-2120	52	30	among	among	ADP
dpc-2120	52	31	more	more	ADJ
dpc-2120	52	32	than	than	ADP
dpc-2120	52	33	1,500	1,500	NUM
dpc-2120	52	34	participants	participant	NOUN
dpc-2120	52	35	.	.	PUNCT
dpc-2120	53	1	tralokinumab	tralokinumab	NOUN
dpc-2120	53	2	showed	show	VERB
dpc-2120	53	3	significant	significant	ADJ
dpc-2120	53	4	reduction	reduction	NOUN
dpc-2120	53	5	in	in	ADP
dpc-2120	53	6	easi	easi	NOUN
dpc-2120	53	7	and	and	CCONJ
dpc-2120	53	8	iga	iga	PROPN
dpc-2120	53	9	scores	score	NOUN
dpc-2120	53	10	in	in	ADP
dpc-2120	53	11	a	a	DET
dpc-2120	53	12	dose	dose	NOUN
dpc-2120	53	13	-	-	PUNCT
dpc-2120	53	14	dependent	dependent	ADJ
dpc-2120	53	15	manner	manner	NOUN
dpc-2120	53	16	compared	compare	VERB
dpc-2120	53	17	to	to	ADP
dpc-2120	53	18	placebo	placebo	NOUN
dpc-2120	53	19	.	.	PUNCT
dpc-2120	54	1	participants	participant	NOUN
dpc-2120	54	2	receiving	receive	VERB
dpc-2120	54	3	tralokinumab	tralokinumab	NOUN
dpc-2120	54	4	had	have	VERB
dpc-2120	54	5	a	a	DET
dpc-2120	54	6	response	response	NOUN
dpc-2120	54	7	rate	rate	NOUN
dpc-2120	54	8	of	of	ADP
dpc-2120	54	9	up	up	ADP
dpc-2120	54	10	to	to	PART
dpc-2120	54	11	70	70	NUM
dpc-2120	54	12	%	%	NOUN
dpc-2120	54	13	for	for	ADP
dpc-2120	54	14	easi-50	easi-50	PROPN
dpc-2120	54	15	and	and	CCONJ
dpc-2120	54	16	up	up	ADP
dpc-2120	54	17	to	to	PART
dpc-2120	54	18	40	40	NUM
dpc-2120	54	19	%	%	NOUN
dpc-2120	54	20	for	for	ADP
dpc-2120	54	21	easi-75	easi-75	PROPN
dpc-2120	54	22	.	.	PUNCT
dpc-2120	55	1	in	in	ADP
dpc-2120	55	2	addition	addition	NOUN
dpc-2120	55	3	,	,	PUNCT
dpc-2120	55	4	early	early	ADJ
dpc-2120	55	5	improvements	improvement	NOUN
dpc-2120	55	6	were	be	AUX
dpc-2120	55	7	observed	observe	VERB
dpc-2120	55	8	in	in	ADP
dpc-2120	55	9	pruritus	pruritus	PROPN
dpc-2120	55	10	,	,	PUNCT
dpc-2120	55	11	sleep	sleep	NOUN
dpc-2120	55	12	disturbances	disturbance	NOUN
dpc-2120	55	13	,	,	PUNCT
dpc-2120	55	14	dermatology	dermatology	NOUN
dpc-2120	55	15	life	life	NOUN
dpc-2120	55	16	quality	quality	NOUN
dpc-2120	55	17	index	index	NOUN
dpc-2120	55	18	(	(	PUNCT
dpc-2120	55	19	dlqi	dlqi	PROPN
dpc-2120	55	20	)	)	PUNCT
dpc-2120	55	21	,	,	PUNCT
dpc-2120	55	22	and	and	CCONJ
dpc-2120	55	23	the	the	DET
dpc-2120	55	24	severity	severity	NOUN
dpc-2120	55	25	scoring	scoring	NOUN
dpc-2120	55	26	of	of	ADP
dpc-2120	55	27	atopic	atopic	NOUN
dpc-2120	55	28	dermatitis	dermatitis	NOUN
dpc-2120	55	29	(	(	PUNCT
dpc-2120	55	30	scorad	scorad	NOUN
dpc-2120	55	31	)	)	PUNCT
dpc-2120	55	32	.	.	PUNCT
dpc-2120	56	1	those	those	DET
dpc-2120	56	2	effects	effect	NOUN
dpc-2120	56	3	were	be	AUX
dpc-2120	56	4	demonstrated	demonstrate	VERB
dpc-2120	56	5	in	in	ADP
dpc-2120	56	6	most	most	ADJ
dpc-2120	56	7	participants	participant	NOUN
dpc-2120	56	8	at	at	ADP
dpc-2120	56	9	week	week	NOUN
dpc-2120	56	10	16	16	NUM
dpc-2120	56	11	,	,	PUNCT
dpc-2120	56	12	and	and	CCONJ
dpc-2120	56	13	after	after	ADP
dpc-2120	56	14	extended	extended	ADJ
dpc-2120	56	15	use	use	NOUN
dpc-2120	56	16	,	,	PUNCT
dpc-2120	56	17	at	at	ADP
dpc-2120	56	18	week	week	NOUN
dpc-2120	56	19	review	review	NOUN
dpc-2120	56	20	|	|	ADV
dpc-2120	56	21	dermatol	dermatol	ADJ
dpc-2120	56	22	pract	pract	NOUN
dpc-2120	56	23	concept	concept	NOUN
dpc-2120	56	24	.	.	PUNCT
dpc-2120	57	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	57	2	3	3	NUM
dpc-2120	57	3	52	52	NUM
dpc-2120	57	4	.	.	PUNCT
dpc-2120	58	1	the	the	DET
dpc-2120	58	2	most	most	ADV
dpc-2120	58	3	common	common	ADJ
dpc-2120	58	4	adverse	adverse	ADJ
dpc-2120	58	5	reactions	reaction	NOUN
dpc-2120	58	6	due	due	ADP
dpc-2120	58	7	to	to	ADP
dpc-2120	58	8	tralokinumab	tralokinumab	NOUN
dpc-2120	58	9	use	use	NOUN
dpc-2120	58	10	were	be	AUX
dpc-2120	58	11	upper	upper	ADJ
dpc-2120	58	12	respiratory	respiratory	ADJ
dpc-2120	58	13	tract	tract	NOUN
dpc-2120	58	14	infections	infection	NOUN
dpc-2120	58	15	,	,	PUNCT
dpc-2120	58	16	conjunctivitis	conjunctivitis	NOUN
dpc-2120	58	17	,	,	PUNCT
dpc-2120	58	18	and	and	CCONJ
dpc-2120	58	19	injection	injection	NOUN
dpc-2120	58	20	site	site	NOUN
dpc-2120	58	21	reactions	reaction	NOUN
dpc-2120	58	22	[	[	X
dpc-2120	58	23	19	19	NUM
dpc-2120	58	24	]	]	PUNCT
dpc-2120	58	25	.	.	PUNCT
dpc-2120	59	1	based	base	VERB
dpc-2120	59	2	on	on	ADP
dpc-2120	59	3	these	these	DET
dpc-2120	59	4	study	study	NOUN
dpc-2120	59	5	results	result	NOUN
dpc-2120	59	6	,	,	PUNCT
dpc-2120	59	7	the	the	DET
dpc-2120	59	8	ema	ema	PROPN
dpc-2120	59	9	recommended	recommend	VERB
dpc-2120	59	10	tralokinumab	tralokinumab	NOUN
dpc-2120	59	11	approval	approval	NOUN
dpc-2120	59	12	for	for	ADP
dpc-2120	59	13	the	the	DET
dpc-2120	59	14	treatment	treatment	NOUN
dpc-2120	59	15	of	of	ADP
dpc-2120	59	16	moderate	moderate	ADJ
dpc-2120	59	17	to	to	ADP
dpc-2120	59	18	severe	severe	ADJ
dpc-2120	59	19	ad	ad	NOUN
dpc-2120	59	20	,	,	PUNCT
dpc-2120	59	21	in	in	ADP
dpc-2120	59	22	june	june	PROPN
dpc-2120	59	23	2021	2021	NUM
dpc-2120	59	24	.	.	PUNCT
dpc-2120	60	1	like	like	ADP
dpc-2120	60	2	tralokinumab	tralokinumab	NOUN
dpc-2120	60	3	,	,	PUNCT
dpc-2120	60	4	lebrikizumab	lebrikizumab	NOUN
dpc-2120	60	5	is	be	AUX
dpc-2120	60	6	an	an	DET
dpc-2120	60	7	il-13	il-13	ADV
dpc-2120	60	8	antibody	antibody	NOUN
dpc-2120	60	9	.	.	PUNCT
dpc-2120	61	1	guttman	guttman	ADJ
dpc-2120	61	2	-	-	PUNCT
dpc-2120	61	3	yasky	yasky	NOUN
dpc-2120	61	4	et	et	NOUN
dpc-2120	61	5	al	al	PROPN
dpc-2120	61	6	examined	examine	VERB
dpc-2120	61	7	the	the	DET
dpc-2120	61	8	effects	effect	NOUN
dpc-2120	61	9	of	of	ADP
dpc-2120	61	10	the	the	DET
dpc-2120	61	11	biological	biological	ADJ
dpc-2120	61	12	lebrikizumab	lebrikizumab	NOUN
dpc-2120	61	13	in	in	ADP
dpc-2120	61	14	a	a	DET
dpc-2120	61	15	double	double	ADJ
dpc-2120	61	16	-	-	PUNCT
dpc-2120	61	17	blind	blind	ADJ
dpc-2120	61	18	,	,	PUNCT
dpc-2120	61	19	placebo	placebo	NOUN
dpc-2120	61	20	-	-	PUNCT
dpc-2120	61	21	controlled	control	VERB
dpc-2120	61	22	,	,	PUNCT
dpc-2120	61	23	16	16	NUM
dpc-2120	61	24	-	-	PUNCT
dpc-2120	61	25	week	week	NOUN
dpc-2120	61	26	,	,	PUNCT
dpc-2120	61	27	phase-2b	phase-2b	PUNCT
dpc-2120	61	28	study	study	NOUN
dpc-2120	61	29	among	among	ADP
dpc-2120	61	30	280	280	NUM
dpc-2120	61	31	individuals	individual	NOUN
dpc-2120	61	32	who	who	PRON
dpc-2120	61	33	were	be	AUX
dpc-2120	61	34	randomly	randomly	ADV
dpc-2120	61	35	assigned	assign	VERB
dpc-2120	61	36	to	to	ADP
dpc-2120	61	37	a	a	DET
dpc-2120	61	38	placebo	placebo	NOUN
dpc-2120	61	39	group	group	NOUN
dpc-2120	61	40	or	or	CCONJ
dpc-2120	61	41	to	to	ADP
dpc-2120	61	42	groups	group	NOUN
dpc-2120	61	43	receiving	receive	VERB
dpc-2120	61	44	lebrikizumab	lebrikizumab	NOUN
dpc-2120	61	45	in	in	ADP
dpc-2120	61	46	different	different	ADJ
dpc-2120	61	47	doses	dose	NOUN
dpc-2120	61	48	.	.	PUNCT
dpc-2120	62	1	a	a	DET
dpc-2120	62	2	rapid	rapid	ADJ
dpc-2120	62	3	dose	dose	NOUN
dpc-2120	62	4	-	-	PUNCT
dpc-2120	62	5	dependent	dependent	ADJ
dpc-2120	62	6	effect	effect	NOUN
dpc-2120	62	7	of	of	ADP
dpc-2120	62	8	lebrikizumab	lebrikizumab	NOUN
dpc-2120	62	9	was	be	AUX
dpc-2120	62	10	described	describe	VERB
dpc-2120	62	11	in	in	ADP
dpc-2120	62	12	clinical	clinical	ADJ
dpc-2120	62	13	scores	score	NOUN
dpc-2120	62	14	and	and	CCONJ
dpc-2120	62	15	symptoms	symptom	NOUN
dpc-2120	62	16	when	when	SCONJ
dpc-2120	62	17	compared	compare	VERB
dpc-2120	62	18	to	to	ADP
dpc-2120	62	19	placebo	placebo	NOUN
dpc-2120	62	20	.	.	PUNCT
dpc-2120	63	1	for	for	ADP
dpc-2120	63	2	instance	instance	NOUN
dpc-2120	63	3	,	,	PUNCT
dpc-2120	63	4	after	after	ADP
dpc-2120	63	5	16	16	NUM
dpc-2120	63	6	weeks	week	NOUN
dpc-2120	63	7	,	,	PUNCT
dpc-2120	63	8	an	an	DET
dpc-2120	63	9	easi	easi	NOUN
dpc-2120	63	10	improvement	improvement	NOUN
dpc-2120	63	11	of	of	ADP
dpc-2120	63	12	up	up	ADP
dpc-2120	63	13	to	to	PART
dpc-2120	63	14	72.1	72.1	NUM
dpc-2120	63	15	%	%	NOUN
dpc-2120	63	16	was	be	AUX
dpc-2120	63	17	shown	show	VERB
dpc-2120	63	18	in	in	ADP
dpc-2120	63	19	the	the	DET
dpc-2120	63	20	group	group	NOUN
dpc-2120	63	21	receiving	receive	VERB
dpc-2120	63	22	250	250	NUM
dpc-2120	63	23	mg	mg	PROPN
dpc-2120	63	24	lebrikizumab	lebrikizumab	NOUN
dpc-2120	63	25	every	every	DET
dpc-2120	63	26	2	2	NUM
dpc-2120	63	27	weeks	week	NOUN
dpc-2120	63	28	compared	compare	VERB
dpc-2120	63	29	to	to	ADP
dpc-2120	63	30	placebo	placebo	NOUN
dpc-2120	63	31	(	(	PUNCT
dpc-2120	63	32	p	p	X
dpc-2120	63	33	<	<	X
dpc-2120	63	34	0.001	0.001	NUM
dpc-2120	63	35	)	)	PUNCT
dpc-2120	63	36	.	.	PUNCT
dpc-2120	64	1	adverse	adverse	ADJ
dpc-2120	64	2	events	event	NOUN
dpc-2120	64	3	were	be	AUX
dpc-2120	64	4	mainly	mainly	ADV
dpc-2120	64	5	injection	injection	NOUN
dpc-2120	64	6	site	site	NOUN
dpc-2120	64	7	reactions	reaction	NOUN
dpc-2120	64	8	,	,	PUNCT
dpc-2120	64	9	herpes	herpe	NOUN
dpc-2120	64	10	virus	virus	NOUN
dpc-2120	64	11	infections	infection	NOUN
dpc-2120	64	12	,	,	PUNCT
dpc-2120	64	13	and	and	CCONJ
dpc-2120	64	14	conjunctivitis	conjunctivitis	NOUN
dpc-2120	64	15	.	.	PUNCT
dpc-2120	65	1	no	no	DET
dpc-2120	65	2	adverse	adverse	ADJ
dpc-2120	65	3	events	event	NOUN
dpc-2120	65	4	led	lead	VERB
dpc-2120	65	5	to	to	AUX
dpc-2120	65	6	premature	premature	VERB
dpc-2120	65	7	patient	patient	ADJ
dpc-2120	65	8	discontinuation	discontinuation	NOUN
dpc-2120	65	9	.	.	PUNCT
dpc-2120	66	1	if	if	SCONJ
dpc-2120	66	2	the	the	DET
dpc-2120	66	3	positive	positive	ADJ
dpc-2120	66	4	effect	effect	NOUN
dpc-2120	66	5	of	of	ADP
dpc-2120	66	6	this	this	DET
dpc-2120	66	7	biological	biological	NOUN
dpc-2120	66	8	can	can	AUX
dpc-2120	66	9	be	be	AUX
dpc-2120	66	10	reproduced	reproduce	VERB
dpc-2120	66	11	in	in	ADP
dpc-2120	66	12	currently	currently	ADV
dpc-2120	66	13	underway	underway	ADJ
dpc-2120	66	14	phase-3	phase-3	NUM
dpc-2120	66	15	studies	study	NOUN
dpc-2120	66	16	,	,	PUNCT
dpc-2120	66	17	lebrikizumab	lebrikizumab	NOUN
dpc-2120	66	18	can	can	AUX
dpc-2120	66	19	be	be	AUX
dpc-2120	66	20	considered	consider	VERB
dpc-2120	66	21	a	a	DET
dpc-2120	66	22	highly	highly	ADV
dpc-2120	66	23	effective	effective	ADJ
dpc-2120	66	24	therapy	therapy	NOUN
dpc-2120	66	25	modality	modality	NOUN
dpc-2120	66	26	in	in	ADP
dpc-2120	66	27	the	the	DET
dpc-2120	66	28	treatment	treatment	NOUN
dpc-2120	66	29	of	of	ADP
dpc-2120	66	30	moderate	moderate	ADJ
dpc-2120	66	31	to	to	ADP
dpc-2120	66	32	severe	severe	ADJ
dpc-2120	66	33	ad	ad	NOUN
dpc-2120	66	34	[	[	X
dpc-2120	66	35	20	20	NUM
dpc-2120	66	36	]	]	PUNCT
dpc-2120	66	37	.	.	PUNCT
dpc-2120	67	1	il-31	il-31	X
dpc-2120	67	2	intense	intense	ADJ
dpc-2120	67	3	itching	itching	NOUN
dpc-2120	67	4	is	be	AUX
dpc-2120	67	5	one	one	NUM
dpc-2120	67	6	of	of	ADP
dpc-2120	67	7	the	the	DET
dpc-2120	67	8	greatest	great	ADJ
dpc-2120	67	9	burdens	burden	NOUN
dpc-2120	67	10	of	of	ADP
dpc-2120	67	11	ad	ad	NOUN
dpc-2120	67	12	patients	patient	NOUN
dpc-2120	67	13	.	.	PUNCT
dpc-2120	68	1	il-31	il-31	PRON
dpc-2120	68	2	,	,	PUNCT
dpc-2120	68	3	a	a	DET
dpc-2120	68	4	cytokine	cytokine	NOUN
dpc-2120	68	5	primarily	primarily	ADV
dpc-2120	68	6	produced	produce	VERB
dpc-2120	68	7	by	by	ADP
dpc-2120	68	8	cd4	cd4	PROPN
dpc-2120	68	9	+	+	PROPN
dpc-2120	68	10	t	t	PROPN
dpc-2120	68	11	-	-	PUNCT
dpc-2120	68	12	cells	cell	NOUN
dpc-2120	68	13	,	,	PUNCT
dpc-2120	68	14	has	have	AUX
dpc-2120	68	15	been	be	AUX
dpc-2120	68	16	found	find	VERB
dpc-2120	68	17	to	to	PART
dpc-2120	68	18	be	be	AUX
dpc-2120	68	19	increased	increase	VERB
dpc-2120	68	20	in	in	ADP
dpc-2120	68	21	skin	skin	NOUN
dpc-2120	68	22	samples	sample	NOUN
dpc-2120	68	23	of	of	ADP
dpc-2120	68	24	ad	ad	NOUN
dpc-2120	68	25	patients	patient	NOUN
dpc-2120	68	26	compared	compare	VERB
dpc-2120	68	27	to	to	ADP
dpc-2120	68	28	healthy	healthy	ADJ
dpc-2120	68	29	subjects	subject	NOUN
dpc-2120	68	30	[	[	X
dpc-2120	68	31	21	21	NUM
dpc-2120	68	32	]	]	PUNCT
dpc-2120	68	33	.	.	PUNCT
dpc-2120	69	1	takamori	takamori	PROPN
dpc-2120	69	2	et	et	PROPN
dpc-2120	69	3	al	al	PROPN
dpc-2120	69	4	studied	study	VERB
dpc-2120	69	5	il-31	il-31	ADV
dpc-2120	69	6	-	-	PUNCT
dpc-2120	69	7	deficient	deficient	ADJ
dpc-2120	69	8	mice	mouse	NOUN
dpc-2120	69	9	models	model	NOUN
dpc-2120	69	10	.	.	PUNCT
dpc-2120	70	1	interestingly	interestingly	ADV
dpc-2120	70	2	these	these	PRON
dpc-2120	70	3	showed	show	VERB
dpc-2120	70	4	decreased	decrease	VERB
dpc-2120	70	5	scratch	scratch	NOUN
dpc-2120	70	6	frequency	frequency	NOUN
dpc-2120	70	7	and	and	CCONJ
dpc-2120	70	8	duration	duration	NOUN
dpc-2120	70	9	,	,	PUNCT
dpc-2120	70	10	during	during	ADP
dpc-2120	70	11	induced	induce	VERB
dpc-2120	70	12	contact	contact	NOUN
dpc-2120	70	13	dermatitis	dermatitis	NOUN
dpc-2120	70	14	[	[	X
dpc-2120	70	15	22	22	NUM
dpc-2120	70	16	]	]	PUNCT
dpc-2120	70	17	.	.	PUNCT
dpc-2120	71	1	treatment	treatment	NOUN
dpc-2120	71	2	with	with	ADP
dpc-2120	71	3	il-31	il-31	NOUN
dpc-2120	71	4	-	-	PUNCT
dpc-2120	71	5	antibodies	antibody	NOUN
dpc-2120	71	6	also	also	ADV
dpc-2120	71	7	showed	show	VERB
dpc-2120	71	8	reduced	reduced	ADJ
dpc-2120	71	9	scratching	scratching	NOUN
dpc-2120	71	10	behavior	behavior	NOUN
dpc-2120	71	11	in	in	ADP
dpc-2120	71	12	ad	ad	NOUN
dpc-2120	71	13	-	-	PUNCT
dpc-2120	71	14	induced	induce	VERB
dpc-2120	71	15	nc	nc	PROPN
dpc-2120	71	16	/	/	SYM
dpc-2120	71	17	nga	nga	ADJ
dpc-2120	71	18	mice	mouse	NOUN
dpc-2120	71	19	[	[	X
dpc-2120	71	20	17	17	NUM
dpc-2120	71	21	,	,	PUNCT
dpc-2120	71	22	18	18	NUM
dpc-2120	71	23	,	,	PUNCT
dpc-2120	71	24	23	23	NUM
dpc-2120	71	25	,	,	PUNCT
dpc-2120	71	26	24	24	NUM
dpc-2120	71	27	]	]	PUNCT
dpc-2120	71	28	.	.	PUNCT
dpc-2120	72	1	in	in	ADP
dpc-2120	72	2	a	a	DET
dpc-2120	72	3	randomized	randomized	ADJ
dpc-2120	72	4	,	,	PUNCT
dpc-2120	72	5	double	double	ADJ
dpc-2120	72	6	-	-	PUNCT
dpc-2120	72	7	blind	blind	ADJ
dpc-2120	72	8	,	,	PUNCT
dpc-2120	72	9	placebo	placebo	NOUN
dpc-2120	72	10	-	-	PUNCT
dpc-2120	72	11	controlled	control	VERB
dpc-2120	72	12	study	study	NOUN
dpc-2120	72	13	,	,	PUNCT
dpc-2120	72	14	ruzicka	ruzicka	PROPN
dpc-2120	72	15	et	et	NOUN
dpc-2120	72	16	al	al	PROPN
dpc-2120	72	17	investigated	investigate	VERB
dpc-2120	72	18	the	the	DET
dpc-2120	72	19	safety	safety	NOUN
dpc-2120	72	20	and	and	CCONJ
dpc-2120	72	21	efficacy	efficacy	NOUN
dpc-2120	72	22	of	of	ADP
dpc-2120	72	23	nemolizumab	nemolizumab	NOUN
dpc-2120	72	24	,	,	PUNCT
dpc-2120	72	25	a	a	DET
dpc-2120	72	26	humanized	humanize	VERB
dpc-2120	72	27	antihuman	antihuman	NOUN
dpc-2120	72	28	il-31a	il-31a	NOUN
dpc-2120	72	29	receptor	receptor	NOUN
dpc-2120	72	30	antibody	antibody	NOUN
dpc-2120	72	31	,	,	PUNCT
dpc-2120	72	32	in	in	ADP
dpc-2120	72	33	combination	combination	NOUN
dpc-2120	72	34	with	with	ADP
dpc-2120	72	35	topical	topical	ADJ
dpc-2120	72	36	steroids	steroid	NOUN
dpc-2120	72	37	in	in	ADP
dpc-2120	72	38	patients	patient	NOUN
dpc-2120	72	39	with	with	ADP
dpc-2120	72	40	ad	ad	NOUN
dpc-2120	72	41	.	.	PUNCT
dpc-2120	73	1	the	the	DET
dpc-2120	73	2	results	result	NOUN
dpc-2120	73	3	showed	show	VERB
dpc-2120	73	4	that	that	SCONJ
dpc-2120	73	5	subcutaneous	subcutaneous	ADJ
dpc-2120	73	6	administration	administration	NOUN
dpc-2120	73	7	of	of	ADP
dpc-2120	73	8	nemolizumab	nemolizumab	NOUN
dpc-2120	73	9	was	be	AUX
dpc-2120	73	10	well	well	ADV
dpc-2120	73	11	tolerated	tolerate	VERB
dpc-2120	73	12	by	by	ADP
dpc-2120	73	13	all	all	DET
dpc-2120	73	14	subjects	subject	NOUN
dpc-2120	73	15	.	.	PUNCT
dpc-2120	74	1	nemolizumab	nemolizumab	PROPN
dpc-2120	74	2	significantly	significantly	ADV
dpc-2120	74	3	decreased	decrease	VERB
dpc-2120	74	4	pruritus	pruritus	PROPN
dpc-2120	74	5	compared	compare	VERB
dpc-2120	74	6	to	to	ADP
dpc-2120	74	7	placebo	placebo	NOUN
dpc-2120	74	8	(	(	PUNCT
dpc-2120	74	9	p	p	X
dpc-2120	74	10	<	<	X
dpc-2120	74	11	0.01	0.01	NUM
dpc-2120	74	12	)	)	PUNCT
dpc-2120	74	13	,	,	PUNCT
dpc-2120	74	14	but	but	CCONJ
dpc-2120	74	15	no	no	DET
dpc-2120	74	16	significant	significant	ADJ
dpc-2120	74	17	reduction	reduction	NOUN
dpc-2120	74	18	in	in	ADP
dpc-2120	74	19	easi	easi	NOUN
dpc-2120	74	20	was	be	AUX
dpc-2120	74	21	observed	observe	VERB
dpc-2120	74	22	.	.	PUNCT
dpc-2120	75	1	accordingly	accordingly	ADV
dpc-2120	75	2	,	,	PUNCT
dpc-2120	75	3	nemolizumab	nemolizumab	NOUN
dpc-2120	75	4	appears	appear	VERB
dpc-2120	75	5	to	to	PART
dpc-2120	75	6	be	be	AUX
dpc-2120	75	7	another	another	DET
dpc-2120	75	8	therapeutic	therapeutic	ADJ
dpc-2120	75	9	option	option	NOUN
dpc-2120	75	10	,	,	PUNCT
dpc-2120	75	11	especially	especially	ADV
dpc-2120	75	12	for	for	ADP
dpc-2120	75	13	ad	ad	NOUN
dpc-2120	75	14	patients	patient	NOUN
dpc-2120	75	15	suffering	suffer	VERB
dpc-2120	75	16	from	from	ADP
dpc-2120	75	17	pruritus	pruritus	PROPN
dpc-2120	75	18	[	[	X
dpc-2120	75	19	24	24	NUM
dpc-2120	75	20	,	,	PUNCT
dpc-2120	75	21	25	25	NUM
dpc-2120	75	22	]	]	PUNCT
dpc-2120	75	23	.	.	PUNCT
dpc-2120	76	1	currently	currently	ADV
dpc-2120	76	2	,	,	PUNCT
dpc-2120	76	3	there	there	PRON
dpc-2120	76	4	are	be	VERB
dpc-2120	76	5	3	3	NUM
dpc-2120	76	6	ongoing	ongoing	ADJ
dpc-2120	76	7	clinical	clinical	ADJ
dpc-2120	76	8	phase-3	phase-3	NUM
dpc-2120	76	9	studies	study	NOUN
dpc-2120	76	10	to	to	PART
dpc-2120	76	11	prove	prove	VERB
dpc-2120	76	12	nemolizumab	nemolizumab	NOUN
dpc-2120	76	13	safety	safety	NOUN
dpc-2120	76	14	and	and	CCONJ
dpc-2120	76	15	efficacy	efficacy	NOUN
dpc-2120	76	16	among	among	ADP
dpc-2120	76	17	a	a	DET
dpc-2120	76	18	larger	large	ADJ
dpc-2120	76	19	number	number	NOUN
dpc-2120	76	20	of	of	ADP
dpc-2120	76	21	patients	patient	NOUN
dpc-2120	76	22	suffering	suffer	VERB
dpc-2120	76	23	from	from	ADP
dpc-2120	76	24	ad	ad	NOUN
dpc-2120	76	25	(	(	PUNCT
dpc-2120	76	26	nct03989349	nct03989349	NOUN
dpc-2120	76	27	,	,	PUNCT
dpc-2120	76	28	nct03989206	nct03989206	NOUN
dpc-2120	76	29	,	,	PUNCT
dpc-2120	76	30	nct03985943	nct03985943	NOUN
dpc-2120	76	31	,	,	PUNCT
dpc-2120	76	32	clinicaltrials.gov	clinicaltrials.gov	NOUN
dpc-2120	76	33	)	)	PUNCT
dpc-2120	76	34	.	.	PUNCT
dpc-2120	77	1	thymic	thymic	ADJ
dpc-2120	77	2	stromal	stromal	ADJ
dpc-2120	77	3	lymphopoietin	lymphopoietin	NOUN
dpc-2120	77	4	and	and	CCONJ
dpc-2120	77	5	ox40	ox40	PROPN
dpc-2120	77	6	the	the	DET
dpc-2120	77	7	tslp	tslp	NOUN
dpc-2120	77	8	is	be	AUX
dpc-2120	77	9	a	a	DET
dpc-2120	77	10	cytokine	cytokine	NOUN
dpc-2120	77	11	that	that	PRON
dpc-2120	77	12	is	be	AUX
dpc-2120	77	13	upregulated	upregulate	VERB
dpc-2120	77	14	by	by	ADP
dpc-2120	77	15	il-13	il-13	ADV
dpc-2120	77	16	and	and	CCONJ
dpc-2120	77	17	directly	directly	ADV
dpc-2120	77	18	leads	lead	VERB
dpc-2120	77	19	epidermic	epidermic	ADJ
dpc-2120	77	20	dendritic	dendritic	ADJ
dpc-2120	77	21	cells	cell	NOUN
dpc-2120	77	22	(	(	PUNCT
dpc-2120	77	23	dc	dc	PROPN
dpc-2120	77	24	)	)	PUNCT
dpc-2120	77	25	to	to	ADP
dpc-2120	77	26	a	a	DET
dpc-2120	77	27	th-2	th-2	PRON
dpc-2120	77	28	-	-	PUNCT
dpc-2120	77	29	response	response	NOUN
dpc-2120	77	30	.	.	PUNCT
dpc-2120	78	1	tslp	tslp	PROPN
dpc-2120	78	2	is	be	AUX
dpc-2120	78	3	mainly	mainly	ADV
dpc-2120	78	4	produced	produce	VERB
dpc-2120	78	5	in	in	ADP
dpc-2120	78	6	keratinocytes	keratinocyte	NOUN
dpc-2120	78	7	and	and	CCONJ
dpc-2120	78	8	appears	appear	VERB
dpc-2120	78	9	to	to	PART
dpc-2120	78	10	play	play	VERB
dpc-2120	78	11	a	a	DET
dpc-2120	78	12	key	key	ADJ
dpc-2120	78	13	role	role	NOUN
dpc-2120	78	14	in	in	ADP
dpc-2120	78	15	the	the	DET
dpc-2120	78	16	activation	activation	NOUN
dpc-2120	78	17	of	of	ADP
dpc-2120	78	18	dc	dc	PROPN
dpc-2120	78	19	.	.	PUNCT
dpc-2120	79	1	due	due	ADP
dpc-2120	79	2	to	to	ADP
dpc-2120	79	3	allergen	allergen	NOUN
dpc-2120	79	4	damage	damage	NOUN
dpc-2120	79	5	,	,	PUNCT
dpc-2120	79	6	keratinocytes	keratinocyte	NOUN
dpc-2120	79	7	express	express	VERB
dpc-2120	79	8	tslp	tslp	ADJ
dpc-2120	79	9	,	,	PUNCT
dpc-2120	79	10	which	which	PRON
dpc-2120	79	11	in	in	ADP
dpc-2120	79	12	turn	turn	NOUN
dpc-2120	79	13	activates	activate	VERB
dpc-2120	79	14	dc	dc	PROPN
dpc-2120	79	15	,	,	PUNCT
dpc-2120	79	16	thus	thus	ADV
dpc-2120	79	17	increasing	increase	VERB
dpc-2120	79	18	their	their	PRON
dpc-2120	79	19	expression	expression	NOUN
dpc-2120	79	20	of	of	ADP
dpc-2120	79	21	ox40l	ox40l	PROPN
dpc-2120	79	22	.	.	PUNCT
dpc-2120	79	23	ox40l	ox40l	PROPN
dpc-2120	79	24	leads	lead	VERB
dpc-2120	79	25	to	to	ADP
dpc-2120	79	26	the	the	DET
dpc-2120	79	27	differentiation	differentiation	NOUN
dpc-2120	79	28	of	of	ADP
dpc-2120	79	29	naive	naive	ADJ
dpc-2120	79	30	cd4	cd4	PROPN
dpc-2120	79	31	+	+	ADJ
dpc-2120	79	32	-cells	-cell	NOUN
dpc-2120	79	33	into	into	ADP
dpc-2120	79	34	inflammatory	inflammatory	ADJ
dpc-2120	79	35	th-2	th-2	NOUN
dpc-2120	79	36	-	-	PUNCT
dpc-2120	79	37	memory	memory	NOUN
dpc-2120	79	38	cells	cell	NOUN
dpc-2120	79	39	.	.	PUNCT
dpc-2120	80	1	ox40l	ox40l	PROPN
dpc-2120	80	2	is	be	AUX
dpc-2120	80	3	expressed	express	VERB
dpc-2120	80	4	by	by	ADP
dpc-2120	80	5	dc	dc	PROPN
dpc-2120	80	6	and	and	CCONJ
dpc-2120	80	7	activates	activate	VERB
dpc-2120	80	8	t	t	PROPN
dpc-2120	80	9	-	-	PUNCT
dpc-2120	80	10	cells	cell	NOUN
dpc-2120	80	11	and	and	CCONJ
dpc-2120	80	12	memory	memory	NOUN
dpc-2120	80	13	cells	cell	NOUN
dpc-2120	80	14	.	.	PUNCT
dpc-2120	81	1	the	the	DET
dpc-2120	81	2	interaction	interaction	NOUN
dpc-2120	81	3	between	between	ADP
dpc-2120	81	4	ox40	ox40	PROPN
dpc-2120	81	5	and	and	CCONJ
dpc-2120	81	6	ox40l	ox40l	NUM
dpc-2120	81	7	appears	appear	VERB
dpc-2120	81	8	to	to	PART
dpc-2120	81	9	be	be	AUX
dpc-2120	81	10	critical	critical	ADJ
dpc-2120	81	11	for	for	ADP
dpc-2120	81	12	the	the	DET
dpc-2120	81	13	long	long	ADJ
dpc-2120	81	14	-	-	PUNCT
dpc-2120	81	15	term	term	NOUN
dpc-2120	81	16	survival	survival	NOUN
dpc-2120	81	17	of	of	ADP
dpc-2120	81	18	cd4	cd4	PROPN
dpc-2120	81	19	+	+	PROPN
dpc-2120	81	20	t	t	PROPN
dpc-2120	81	21	-	-	PUNCT
dpc-2120	81	22	cells	cell	NOUN
dpc-2120	81	23	,	,	PUNCT
dpc-2120	81	24	which	which	PRON
dpc-2120	81	25	are	be	AUX
dpc-2120	81	26	responsible	responsible	ADJ
dpc-2120	81	27	for	for	ADP
dpc-2120	81	28	inflammation	inflammation	NOUN
dpc-2120	81	29	in	in	ADP
dpc-2120	81	30	ad	ad	NOUN
dpc-2120	81	31	[	[	X
dpc-2120	81	32	17	17	NUM
dpc-2120	81	33	,	,	PUNCT
dpc-2120	81	34	18	18	NUM
dpc-2120	81	35	]	]	PUNCT
dpc-2120	81	36	.	.	PUNCT
dpc-2120	82	1	there	there	PRON
dpc-2120	82	2	is	be	VERB
dpc-2120	82	3	evidence	evidence	NOUN
dpc-2120	82	4	that	that	SCONJ
dpc-2120	82	5	mice	mouse	NOUN
dpc-2120	82	6	overexpressing	overexpresse	VERB
dpc-2120	82	7	tslp	tslp	NOUN
dpc-2120	82	8	develop	develop	VERB
dpc-2120	82	9	ad	ad	NOUN
dpc-2120	82	10	and	and	CCONJ
dpc-2120	82	11	that	that	SCONJ
dpc-2120	82	12	their	their	PRON
dpc-2120	82	13	lesional	lesional	ADJ
dpc-2120	82	14	skin	skin	NOUN
dpc-2120	82	15	contains	contain	VERB
dpc-2120	82	16	increased	increase	VERB
dpc-2120	82	17	numbers	number	NOUN
dpc-2120	82	18	of	of	ADP
dpc-2120	82	19	th-2	th-2	NOUN
dpc-2120	82	20	cells	cell	NOUN
dpc-2120	82	21	.	.	PUNCT
dpc-2120	83	1	current	current	ADJ
dpc-2120	83	2	studies	study	NOUN
dpc-2120	83	3	are	be	AUX
dpc-2120	83	4	investigating	investigate	VERB
dpc-2120	83	5	whether	whether	SCONJ
dpc-2120	83	6	this	this	DET
dpc-2120	83	7	pathway	pathway	NOUN
dpc-2120	83	8	can	can	AUX
dpc-2120	83	9	be	be	AUX
dpc-2120	83	10	used	use	VERB
dpc-2120	83	11	for	for	ADP
dpc-2120	83	12	new	new	ADJ
dpc-2120	83	13	therapeutic	therapeutic	ADJ
dpc-2120	83	14	options	option	NOUN
dpc-2120	83	15	for	for	ADP
dpc-2120	83	16	the	the	DET
dpc-2120	83	17	treatment	treatment	NOUN
dpc-2120	83	18	of	of	ADP
dpc-2120	83	19	ad	ad	NOUN
dpc-2120	83	20	.	.	PUNCT
dpc-2120	84	1	guttman	guttman	ADJ
dpc-2120	84	2	-	-	PUNCT
dpc-2120	84	3	yassky	yassky	NOUN
dpc-2120	84	4	et	et	NOUN
dpc-2120	84	5	al	al	PROPN
dpc-2120	84	6	investigated	investigate	VERB
dpc-2120	84	7	the	the	DET
dpc-2120	84	8	efficacy	efficacy	NOUN
dpc-2120	84	9	and	and	CCONJ
dpc-2120	84	10	safety	safety	NOUN
dpc-2120	84	11	of	of	ADP
dpc-2120	84	12	gbr830	gbr830	PROPN
dpc-2120	84	13	,	,	PUNCT
dpc-2120	84	14	a	a	DET
dpc-2120	84	15	humanized	humanize	VERB
dpc-2120	84	16	antibody	antibody	NOUN
dpc-2120	84	17	against	against	ADP
dpc-2120	84	18	ox40	ox40	PROPN
dpc-2120	84	19	,	,	PUNCT
dpc-2120	84	20	in	in	ADP
dpc-2120	84	21	an	an	DET
dpc-2120	84	22	explorative	explorative	ADJ
dpc-2120	84	23	phase-2a	phase-2a	NOUN
dpc-2120	84	24	,	,	PUNCT
dpc-2120	84	25	placebo	placebo	NOUN
dpc-2120	84	26	-	-	PUNCT
dpc-2120	84	27	controlled	control	VERB
dpc-2120	84	28	study	study	NOUN
dpc-2120	84	29	among	among	ADP
dpc-2120	84	30	patients	patient	NOUN
dpc-2120	84	31	with	with	ADP
dpc-2120	84	32	moderate	moderate	ADJ
dpc-2120	84	33	to	to	ADP
dpc-2120	84	34	severe	severe	ADJ
dpc-2120	84	35	ad	ad	NOUN
dpc-2120	84	36	.	.	PUNCT
dpc-2120	85	1	first	first	ADJ
dpc-2120	85	2	results	result	NOUN
dpc-2120	85	3	showed	show	VERB
dpc-2120	85	4	that	that	SCONJ
dpc-2120	85	5	gbr380	gbr380	NOUN
dpc-2120	85	6	was	be	AUX
dpc-2120	85	7	well	well	ADV
dpc-2120	85	8	tolerated	tolerate	VERB
dpc-2120	85	9	and	and	CCONJ
dpc-2120	85	10	showed	show	VERB
dpc-2120	85	11	a	a	DET
dpc-2120	85	12	significant	significant	ADJ
dpc-2120	85	13	reduction	reduction	NOUN
dpc-2120	85	14	in	in	ADP
dpc-2120	85	15	th1-	th1-	PROPN
dpc-2120	85	16	,	,	PUNCT
dpc-2120	85	17	th2	th2	PROPN
dpc-2120	85	18	,	,	PUNCT
dpc-2120	85	19	and	and	CCONJ
dpc-2120	85	20	th17/22	th17/22	X
dpc-2120	85	21	expression	expression	NOUN
dpc-2120	85	22	in	in	ADP
dpc-2120	85	23	lesional	lesional	ADJ
dpc-2120	85	24	skin	skin	NOUN
dpc-2120	85	25	compared	compare	VERB
dpc-2120	85	26	to	to	ADP
dpc-2120	85	27	placebo	placebo	NOUN
dpc-2120	85	28	(	(	PUNCT
dpc-2120	85	29	p	p	X
dpc-2120	85	30	<	<	X
dpc-2120	85	31	0.01	0.01	NUM
dpc-2120	85	32	)	)	PUNCT
dpc-2120	85	33	.	.	PUNCT
dpc-2120	86	1	furthermore	furthermore	ADV
dpc-2120	86	2	,	,	PUNCT
dpc-2120	86	3	a	a	DET
dpc-2120	86	4	significant	significant	ADJ
dpc-2120	86	5	reduction	reduction	NOUN
dpc-2120	86	6	in	in	ADP
dpc-2120	86	7	the	the	DET
dpc-2120	86	8	epidermal	epidermal	ADJ
dpc-2120	86	9	thickness	thickness	NOUN
dpc-2120	86	10	could	could	AUX
dpc-2120	86	11	be	be	AUX
dpc-2120	86	12	observed	observe	VERB
dpc-2120	86	13	(	(	PUNCT
dpc-2120	86	14	p	p	X
dpc-2120	86	15	<	<	X
dpc-2120	86	16	0.001)[26	0.001)[26	NUM
dpc-2120	86	17	]	]	PUNCT
dpc-2120	86	18	.	.	PUNCT
dpc-2120	87	1	the	the	DET
dpc-2120	87	2	phase-2b	phase-2b	NOUN
dpc-2120	87	3	trial	trial	NOUN
dpc-2120	87	4	is	be	AUX
dpc-2120	87	5	completed	complete	VERB
dpc-2120	87	6	,	,	PUNCT
dpc-2120	87	7	but	but	CCONJ
dpc-2120	87	8	results	result	NOUN
dpc-2120	87	9	have	have	AUX
dpc-2120	87	10	not	not	PART
dpc-2120	87	11	yet	yet	ADV
dpc-2120	87	12	been	be	AUX
dpc-2120	87	13	published	publish	VERB
dpc-2120	87	14	(	(	PUNCT
dpc-2120	87	15	nct03568162	nct03568162	NOUN
dpc-2120	87	16	)	)	PUNCT
dpc-2120	87	17	.	.	PUNCT
dpc-2120	88	1	a	a	DET
dpc-2120	88	2	phase-2a	phase-2a	ADJ
dpc-2120	88	3	study	study	NOUN
dpc-2120	88	4	from	from	ADP
dpc-2120	88	5	japan	japan	PROPN
dpc-2120	88	6	,	,	PUNCT
dpc-2120	88	7	which	which	PRON
dpc-2120	88	8	also	also	ADV
dpc-2120	88	9	showed	show	VERB
dpc-2120	88	10	promising	promising	ADJ
dpc-2120	88	11	results	result	NOUN
dpc-2120	88	12	,	,	PUNCT
dpc-2120	88	13	investigated	investigate	VERB
dpc-2120	88	14	khk4083	khk4083	NOUN
dpc-2120	88	15	,	,	PUNCT
dpc-2120	88	16	a	a	DET
dpc-2120	88	17	monoclonal	monoclonal	NOUN
dpc-2120	88	18	antibody	antibody	NOUN
dpc-2120	88	19	against	against	ADP
dpc-2120	88	20	ox40	ox40	PROPN
dpc-2120	88	21	.	.	PUNCT
dpc-2120	89	1	a	a	DET
dpc-2120	89	2	continuous	continuous	ADJ
dpc-2120	89	3	reduction	reduction	NOUN
dpc-2120	89	4	of	of	ADP
dpc-2120	89	5	easi	easi	NOUN
dpc-2120	89	6	and	and	CCONJ
dpc-2120	89	7	iga	iga	PROPN
dpc-2120	89	8	scores	score	NOUN
dpc-2120	89	9	was	be	AUX
dpc-2120	89	10	achieved	achieve	VERB
dpc-2120	89	11	in	in	ADP
dpc-2120	89	12	this	this	DET
dpc-2120	89	13	study	study	NOUN
dpc-2120	89	14	.	.	PUNCT
dpc-2120	90	1	furthermore	furthermore	ADV
dpc-2120	90	2	,	,	PUNCT
dpc-2120	90	3	khk4083	khk4083	PROPN
dpc-2120	90	4	showed	show	VERB
dpc-2120	90	5	an	an	DET
dpc-2120	90	6	acceptable	acceptable	ADJ
dpc-2120	90	7	safety	safety	NOUN
dpc-2120	90	8	profile	profile	NOUN
dpc-2120	90	9	[	[	X
dpc-2120	90	10	27	27	NUM
dpc-2120	90	11	]	]	PUNCT
dpc-2120	90	12	.	.	PUNCT
dpc-2120	91	1	tepezelumab	tepezelumab	NOUN
dpc-2120	91	2	,	,	PUNCT
dpc-2120	91	3	a	a	DET
dpc-2120	91	4	monoclonal	monoclonal	NOUN
dpc-2120	91	5	antibody	antibody	NOUN
dpc-2120	91	6	,	,	PUNCT
dpc-2120	91	7	is	be	AUX
dpc-2120	91	8	another	another	DET
dpc-2120	91	9	medication	medication	NOUN
dpc-2120	91	10	targeting	target	VERB
dpc-2120	91	11	tslp	tslp	VERB
dpc-2120	91	12	.	.	PUNCT
dpc-2120	92	1	in	in	ADP
dpc-2120	92	2	a	a	DET
dpc-2120	92	3	phase-2	phase-2	NUM
dpc-2120	92	4	study	study	NOUN
dpc-2120	92	5	,	,	PUNCT
dpc-2120	92	6	113	113	NUM
dpc-2120	92	7	patients	patient	NOUN
dpc-2120	92	8	were	be	AUX
dpc-2120	92	9	1:1	1:1	NUM
dpc-2120	92	10	randomized	randomize	VERB
dpc-2120	92	11	and	and	CCONJ
dpc-2120	92	12	treated	treat	VERB
dpc-2120	92	13	either	either	CCONJ
dpc-2120	92	14	with	with	ADP
dpc-2120	92	15	placebo	placebo	NOUN
dpc-2120	92	16	or	or	CCONJ
dpc-2120	92	17	subcutaneous	subcutaneous	ADJ
dpc-2120	92	18	tepezelumab	tepezelumab	NOUN
dpc-2120	92	19	every	every	DET
dpc-2120	92	20	2	2	NUM
dpc-2120	92	21	weeks	week	NOUN
dpc-2120	92	22	.	.	PUNCT
dpc-2120	93	1	results	result	NOUN
dpc-2120	93	2	of	of	ADP
dpc-2120	93	3	this	this	DET
dpc-2120	93	4	trial	trial	NOUN
dpc-2120	93	5	showed	show	VERB
dpc-2120	93	6	that	that	SCONJ
dpc-2120	93	7	a	a	DET
dpc-2120	93	8	higher	high	ADJ
dpc-2120	93	9	percentage	percentage	NOUN
dpc-2120	93	10	of	of	ADP
dpc-2120	93	11	patients	patient	NOUN
dpc-2120	93	12	treated	treat	VERB
dpc-2120	93	13	with	with	ADP
dpc-2120	93	14	tepezelumab	tepezelumab	NOUN
dpc-2120	93	15	reached	reach	VERB
dpc-2120	93	16	an	an	DET
dpc-2120	93	17	easi50	easi50	NOUN
dpc-2120	93	18	after	after	ADP
dpc-2120	93	19	12	12	NUM
dpc-2120	93	20	weeks	week	NOUN
dpc-2120	93	21	compared	compare	VERB
dpc-2120	93	22	to	to	ADP
dpc-2120	93	23	the	the	DET
dpc-2120	93	24	placebo	placebo	NOUN
dpc-2120	93	25	group	group	NOUN
dpc-2120	93	26	;	;	PUNCT
dpc-2120	93	27	however	however	ADV
dpc-2120	93	28	,	,	PUNCT
dpc-2120	93	29	the	the	DET
dpc-2120	93	30	effect	effect	NOUN
dpc-2120	93	31	was	be	AUX
dpc-2120	93	32	not	not	PART
dpc-2120	93	33	significant	significant	ADJ
dpc-2120	93	34	(	(	PUNCT
dpc-2120	93	35	p	p	X
dpc-2120	93	36	=	=	NOUN
dpc-2120	93	37	0.91	0.91	NUM
dpc-2120	93	38	)	)	PUNCT
dpc-2120	94	1	[	[	X
dpc-2120	94	2	28	28	NUM
dpc-2120	94	3	]	]	PUNCT
dpc-2120	94	4	.	.	PUNCT
dpc-2120	95	1	to	to	PART
dpc-2120	95	2	show	show	VERB
dpc-2120	95	3	possible	possible	ADJ
dpc-2120	95	4	beneficial	beneficial	ADJ
dpc-2120	95	5	effects	effect	NOUN
dpc-2120	95	6	of	of	ADP
dpc-2120	95	7	this	this	DET
dpc-2120	95	8	treatment	treatment	NOUN
dpc-2120	95	9	option	option	NOUN
dpc-2120	95	10	,	,	PUNCT
dpc-2120	95	11	larger	large	ADJ
dpc-2120	95	12	studies	study	NOUN
dpc-2120	95	13	need	need	VERB
dpc-2120	95	14	to	to	PART
dpc-2120	95	15	be	be	AUX
dpc-2120	95	16	conducted	conduct	VERB
dpc-2120	95	17	.	.	PUNCT
dpc-2120	96	1	il-33	il-33	VERB
dpc-2120	96	2	il-33	il-33	VERB
dpc-2120	96	3	is	be	AUX
dpc-2120	96	4	another	another	DET
dpc-2120	96	5	key	key	ADJ
dpc-2120	96	6	cytokine	cytokine	NOUN
dpc-2120	96	7	involved	involve	VERB
dpc-2120	96	8	in	in	ADP
dpc-2120	96	9	ad	ad	NOUN
dpc-2120	96	10	pathogenesis	pathogenesis	NOUN
dpc-2120	96	11	.	.	PUNCT
dpc-2120	97	1	increased	increase	VERB
dpc-2120	97	2	amounts	amount	NOUN
dpc-2120	97	3	of	of	ADP
dpc-2120	97	4	il-33	il-33	PUNCT
dpc-2120	97	5	have	have	AUX
dpc-2120	97	6	been	be	AUX
dpc-2120	97	7	detected	detect	VERB
dpc-2120	97	8	in	in	ADP
dpc-2120	97	9	ad	ad	NOUN
dpc-2120	97	10	patients	patient	NOUN
dpc-2120	97	11	’	'	PUNCT
dpc-2120	97	12	lesional	lesional	ADJ
dpc-2120	97	13	skin	skin	NOUN
dpc-2120	97	14	as	as	ADV
dpc-2120	97	15	well	well	ADV
dpc-2120	97	16	as	as	ADP
dpc-2120	97	17	in	in	ADP
dpc-2120	97	18	mice	mice	NOUN
dpc-2120	97	19	models	model	NOUN
dpc-2120	97	20	.	.	PUNCT
dpc-2120	98	1	furthermore	furthermore	ADV
dpc-2120	98	2	,	,	PUNCT
dpc-2120	98	3	il-33	il-33	ADJ
dpc-2120	98	4	has	have	AUX
dpc-2120	98	5	been	be	AUX
dpc-2120	98	6	shown	show	VERB
dpc-2120	98	7	to	to	PART
dpc-2120	98	8	induce	induce	VERB
dpc-2120	98	9	th-2	th-2	DET
dpc-2120	98	10	immune	immune	ADJ
dpc-2120	98	11	response	response	NOUN
dpc-2120	98	12	and	and	CCONJ
dpc-2120	98	13	significantly	significantly	ADV
dpc-2120	98	14	promote	promote	VERB
dpc-2120	98	15	the	the	DET
dpc-2120	98	16	release	release	NOUN
dpc-2120	98	17	of	of	ADP
dpc-2120	98	18	il-4	il-4	NOUN
dpc-2120	98	19	,	,	PUNCT
dpc-2120	98	20	il-5	il-5	NOUN
dpc-2120	98	21	,	,	PUNCT
dpc-2120	98	22	and	and	CCONJ
dpc-2120	98	23	il-13	il-13	X
dpc-2120	98	24	as	as	ADV
dpc-2120	98	25	well	well	ADV
dpc-2120	98	26	as	as	ADP
dpc-2120	98	27	increase	increase	VERB
dpc-2120	98	28	the	the	DET
dpc-2120	98	29	activity	activity	NOUN
dpc-2120	98	30	of	of	ADP
dpc-2120	98	31	ox40l	ox40l	NUM
dpc-2120	98	32	.	.	PUNCT
dpc-2120	99	1	blocking	block	VERB
dpc-2120	99	2	il-33	il-33	PUNCT
dpc-2120	99	3	and	and	CCONJ
dpc-2120	99	4	subsequently	subsequently	ADV
dpc-2120	99	5	suppressing	suppress	VERB
dpc-2120	99	6	the	the	DET
dpc-2120	99	7	mentioned	mention	VERB
dpc-2120	99	8	cytokines	cytokine	NOUN
dpc-2120	99	9	could	could	AUX
dpc-2120	99	10	also	also	ADV
dpc-2120	99	11	be	be	AUX
dpc-2120	99	12	leveraged	leverage	VERB
dpc-2120	99	13	in	in	ADP
dpc-2120	99	14	the	the	DET
dpc-2120	99	15	therapy	therapy	NOUN
dpc-2120	99	16	of	of	ADP
dpc-2120	99	17	ad	ad	NOUN
dpc-2120	99	18	[	[	X
dpc-2120	99	19	29	29	NUM
dpc-2120	99	20	-	-	SYM
dpc-2120	99	21	31	31	NUM
dpc-2120	99	22	]	]	PUNCT
dpc-2120	99	23	.	.	PUNCT
dpc-2120	100	1	the	the	DET
dpc-2120	100	2	first	first	ADJ
dpc-2120	100	3	effects	effect	NOUN
dpc-2120	100	4	of	of	ADP
dpc-2120	100	5	an	an	DET
dpc-2120	100	6	il-33	il-33	ADJ
dpc-2120	100	7	inhibition	inhibition	NOUN
dpc-2120	100	8	were	be	AUX
dpc-2120	100	9	showed	show	VERB
dpc-2120	100	10	in	in	ADP
dpc-2120	100	11	a	a	DET
dpc-2120	100	12	mouse	mouse	NOUN
dpc-2120	100	13	model	model	NOUN
dpc-2120	100	14	[	[	X
dpc-2120	100	15	32	32	NUM
dpc-2120	100	16	]	]	PUNCT
dpc-2120	100	17	.	.	PUNCT
dpc-2120	101	1	in	in	ADP
dpc-2120	101	2	a	a	DET
dpc-2120	101	3	phase-2a	phase-2a	ADJ
dpc-2120	101	4	study	study	NOUN
dpc-2120	101	5	,	,	PUNCT
dpc-2120	101	6	chen	chen	PROPN
dpc-2120	101	7	et	et	PROPN
dpc-2120	101	8	al	al	PROPN
dpc-2120	101	9	examined	examine	VERB
dpc-2120	101	10	the	the	DET
dpc-2120	101	11	in	in	ADP
dpc-2120	101	12	-	-	PUNCT
dpc-2120	101	13	vivo	vivo	ADJ
dpc-2120	101	14	effect	effect	NOUN
dpc-2120	101	15	of	of	ADP
dpc-2120	101	16	etokimab	etokimab	NOUN
dpc-2120	101	17	,	,	PUNCT
dpc-2120	101	18	(	(	PUNCT
dpc-2120	101	19	anb020	anb020	PROPN
dpc-2120	101	20	)	)	PUNCT
dpc-2120	101	21	,	,	PUNCT
dpc-2120	101	22	a	a	DET
dpc-2120	101	23	monoclonal	monoclonal	NOUN
dpc-2120	101	24	igg	igg	NOUN
dpc-2120	101	25	-	-	PUNCT
dpc-2120	101	26	antibody	antibody	NOUN
dpc-2120	101	27	,	,	PUNCT
dpc-2120	101	28	in	in	ADP
dpc-2120	101	29	12	12	NUM
dpc-2120	101	30	patients	patient	NOUN
dpc-2120	101	31	with	with	ADP
dpc-2120	101	32	moderate	moderate	ADJ
dpc-2120	101	33	to	to	ADP
dpc-2120	101	34	severe	severe	ADJ
dpc-2120	101	35	ad	ad	NOUN
dpc-2120	101	36	.	.	PUNCT
dpc-2120	102	1	after	after	ADP
dpc-2120	102	2	a	a	DET
dpc-2120	102	3	single	single	ADJ
dpc-2120	102	4	systemic	systemic	ADJ
dpc-2120	102	5	administration	administration	NOUN
dpc-2120	102	6	of	of	ADP
dpc-2120	102	7	etokimab	etokimab	PROPN
dpc-2120	102	8	,	,	PUNCT
dpc-2120	102	9	83	83	NUM
dpc-2120	102	10	%	%	NOUN
dpc-2120	102	11	of	of	ADP
dpc-2120	102	12	patients	patient	NOUN
dpc-2120	102	13	achieved	achieve	VERB
dpc-2120	102	14	easi50	easi50	NOUN
dpc-2120	102	15	and	and	CCONJ
dpc-2120	102	16	33	33	NUM
dpc-2120	102	17	%	%	NOUN
dpc-2120	102	18	easi-75	easi-75	PROPN
dpc-2120	102	19	at	at	ADP
dpc-2120	102	20	day	day	NOUN
dpc-2120	102	21	29	29	NUM
dpc-2120	102	22	.	.	PUNCT
dpc-2120	103	1	a	a	DET
dpc-2120	103	2	significant	significant	ADJ
dpc-2120	103	3	reduction	reduction	NOUN
dpc-2120	103	4	in	in	ADP
dpc-2120	103	5	4	4	NUM
dpc-2120	103	6	review	review	NOUN
dpc-2120	103	7	|	|	ADV
dpc-2120	103	8	dermatol	dermatol	ADJ
dpc-2120	103	9	pract	pract	NOUN
dpc-2120	103	10	concept	concept	NOUN
dpc-2120	103	11	.	.	PUNCT
dpc-2120	104	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	104	2	neutrophile	neutrophile	ADJ
dpc-2120	104	3	infiltration	infiltration	NOUN
dpc-2120	104	4	of	of	ADP
dpc-2120	104	5	the	the	DET
dpc-2120	104	6	skin	skin	NOUN
dpc-2120	104	7	was	be	AUX
dpc-2120	104	8	also	also	ADV
dpc-2120	104	9	observed	observe	VERB
dpc-2120	104	10	compared	compare	VERB
dpc-2120	104	11	to	to	ADP
dpc-2120	104	12	placebo	placebo	NOUN
dpc-2120	104	13	.	.	PUNCT
dpc-2120	105	1	these	these	DET
dpc-2120	105	2	results	result	NOUN
dpc-2120	105	3	suggested	suggest	VERB
dpc-2120	105	4	that	that	SCONJ
dpc-2120	105	5	il-31	il-31	ADJ
dpc-2120	105	6	suppression	suppression	NOUN
dpc-2120	105	7	can	can	AUX
dpc-2120	105	8	positively	positively	ADV
dpc-2120	105	9	affect	affect	VERB
dpc-2120	105	10	inflammatory	inflammatory	ADJ
dpc-2120	105	11	responses	response	NOUN
dpc-2120	105	12	and	and	CCONJ
dpc-2120	105	13	may	may	AUX
dpc-2120	105	14	represent	represent	VERB
dpc-2120	105	15	another	another	DET
dpc-2120	105	16	component	component	NOUN
dpc-2120	105	17	of	of	ADP
dpc-2120	105	18	ad	ad	NOUN
dpc-2120	105	19	therapy	therapy	NOUN
dpc-2120	105	20	[	[	X
dpc-2120	105	21	33	33	NUM
dpc-2120	105	22	]	]	PUNCT
dpc-2120	105	23	.	.	PUNCT
dpc-2120	106	1	a	a	DET
dpc-2120	106	2	phase-2	phase-2	PROPN
dpc-2120	106	3	trial	trial	NOUN
dpc-2120	106	4	has	have	AUX
dpc-2120	106	5	been	be	AUX
dpc-2120	106	6	initiated	initiate	VERB
dpc-2120	106	7	and	and	CCONJ
dpc-2120	106	8	is	be	AUX
dpc-2120	106	9	currently	currently	ADV
dpc-2120	106	10	in	in	ADP
dpc-2120	106	11	the	the	DET
dpc-2120	106	12	recruiting	recruiting	NOUN
dpc-2120	106	13	phase	phase	NOUN
dpc-2120	106	14	(	(	PUNCT
dpc-2120	106	15	nct03533751	nct03533751	NOUN
dpc-2120	106	16	)	)	PUNCT
dpc-2120	106	17	.	.	PUNCT
dpc-2120	107	1	th-22	th-22	ADV
dpc-2120	107	2	/	/	SYM
dpc-2120	107	3	il-22	il-22	NOUN
dpc-2120	107	4	ad	ad	NOUN
dpc-2120	107	5	is	be	AUX
dpc-2120	107	6	traditionally	traditionally	ADV
dpc-2120	107	7	considered	consider	VERB
dpc-2120	107	8	a	a	DET
dpc-2120	107	9	th-2	th-2	PRON
dpc-2120	107	10	-	-	PUNCT
dpc-2120	107	11	mediated	mediate	VERB
dpc-2120	107	12	disease	disease	NOUN
dpc-2120	107	13	.	.	PUNCT
dpc-2120	108	1	however	however	ADV
dpc-2120	108	2	,	,	PUNCT
dpc-2120	108	3	it	it	PRON
dpc-2120	108	4	has	have	AUX
dpc-2120	108	5	previously	previously	ADV
dpc-2120	108	6	been	be	AUX
dpc-2120	108	7	shown	show	VERB
dpc-2120	108	8	that	that	SCONJ
dpc-2120	108	9	th-22	th-22	ADJ
dpc-2120	108	10	cells	cell	NOUN
dpc-2120	108	11	also	also	ADV
dpc-2120	108	12	play	play	VERB
dpc-2120	108	13	an	an	DET
dpc-2120	108	14	important	important	ADJ
dpc-2120	108	15	role	role	NOUN
dpc-2120	108	16	in	in	ADP
dpc-2120	108	17	pathogenesis	pathogenesis	NOUN
dpc-2120	108	18	.	.	PUNCT
dpc-2120	109	1	th-22	th-22	ADJ
dpc-2120	109	2	cells	cell	NOUN
dpc-2120	109	3	express	express	VERB
dpc-2120	109	4	il-22	il-22	NOUN
dpc-2120	109	5	,	,	PUNCT
dpc-2120	109	6	which	which	PRON
dpc-2120	109	7	in	in	ADP
dpc-2120	109	8	turn	turn	NOUN
dpc-2120	109	9	activates	activate	VERB
dpc-2120	109	10	a	a	DET
dpc-2120	109	11	receptor	receptor	NOUN
dpc-2120	109	12	responsible	responsible	ADJ
dpc-2120	109	13	for	for	ADP
dpc-2120	109	14	epidermal	epidermal	ADJ
dpc-2120	109	15	hyperplasia	hyperplasia	NOUN
dpc-2120	109	16	,	,	PUNCT
dpc-2120	109	17	migration	migration	NOUN
dpc-2120	109	18	of	of	ADP
dpc-2120	109	19	keratinocytes	keratinocyte	NOUN
dpc-2120	109	20	,	,	PUNCT
dpc-2120	109	21	downregulation	downregulation	NOUN
dpc-2120	109	22	of	of	ADP
dpc-2120	109	23	keratinocytic	keratinocytic	ADJ
dpc-2120	109	24	differentiation	differentiation	NOUN
dpc-2120	109	25	,	,	PUNCT
dpc-2120	109	26	and	and	CCONJ
dpc-2120	109	27	elevation	elevation	NOUN
dpc-2120	109	28	of	of	ADP
dpc-2120	109	29	proinflammatory	proinflammatory	ADJ
dpc-2120	109	30	cytokines	cytokine	NOUN
dpc-2120	109	31	.	.	PUNCT
dpc-2120	110	1	in	in	ADP
dpc-2120	110	2	vitro	vitro	X
dpc-2120	110	3	analyses	analysis	NOUN
dpc-2120	110	4	of	of	ADP
dpc-2120	110	5	skin	skin	NOUN
dpc-2120	110	6	biopsies	biopsy	NOUN
dpc-2120	110	7	of	of	ADP
dpc-2120	110	8	patients	patient	NOUN
dpc-2120	110	9	showed	show	VERB
dpc-2120	110	10	a	a	DET
dpc-2120	110	11	correlation	correlation	NOUN
dpc-2120	110	12	between	between	ADP
dpc-2120	110	13	the	the	DET
dpc-2120	110	14	severity	severity	NOUN
dpc-2120	110	15	of	of	ADP
dpc-2120	110	16	ad	ad	NOUN
dpc-2120	110	17	with	with	ADP
dpc-2120	110	18	the	the	DET
dpc-2120	110	19	presence	presence	NOUN
dpc-2120	110	20	of	of	ADP
dpc-2120	110	21	cd8	cd8	PROPN
dpc-2120	110	22	+	+	PROPN
dpc-2120	110	23	-il-22	-il-22	ADJ
dpc-2120	110	24	-	-	PUNCT
dpc-2120	110	25	cells	cell	NOUN
dpc-2120	110	26	[	[	X
dpc-2120	110	27	17	17	NUM
dpc-2120	110	28	,	,	PUNCT
dpc-2120	110	29	34	34	NUM
dpc-2120	110	30	,	,	PUNCT
dpc-2120	110	31	35	35	NUM
dpc-2120	110	32	]	]	PUNCT
dpc-2120	110	33	.	.	PUNCT
dpc-2120	111	1	guttmann	guttmann	NOUN
dpc-2120	111	2	-	-	PUNCT
dpc-2120	111	3	yasky	yasky	NOUN
dpc-2120	111	4	et	et	PROPN
dpc-2120	111	5	al	al	PROPN
dpc-2120	111	6	performed	perform	VERB
dpc-2120	111	7	a	a	DET
dpc-2120	111	8	randomized	randomized	ADJ
dpc-2120	111	9	,	,	PUNCT
dpc-2120	111	10	double	double	ADJ
dpc-2120	111	11	-	-	PUNCT
dpc-2120	111	12	blind	blind	ADJ
dpc-2120	111	13	,	,	PUNCT
dpc-2120	111	14	placebo	placebo	NOUN
dpc-2120	111	15	-	-	PUNCT
dpc-2120	111	16	controlled	control	VERB
dpc-2120	111	17	trial	trial	NOUN
dpc-2120	111	18	testing	test	VERB
dpc-2120	111	19	the	the	DET
dpc-2120	111	20	efficacy	efficacy	NOUN
dpc-2120	111	21	and	and	CCONJ
dpc-2120	111	22	safety	safety	NOUN
dpc-2120	111	23	of	of	ADP
dpc-2120	111	24	fezakinumab	fezakinumab	NOUN
dpc-2120	111	25	,	,	PUNCT
dpc-2120	111	26	a	a	DET
dpc-2120	111	27	monoclonal	monoclonal	NOUN
dpc-2120	111	28	igg	igg	NOUN
dpc-2120	111	29	-	-	PUNCT
dpc-2120	111	30	antibody	antibody	NOUN
dpc-2120	111	31	against	against	ADP
dpc-2120	111	32	il-22	il-22	NOUN
dpc-2120	111	33	.	.	PUNCT
dpc-2120	112	1	a	a	DET
dpc-2120	112	2	significant	significant	ADJ
dpc-2120	112	3	reduction	reduction	NOUN
dpc-2120	112	4	in	in	ADP
dpc-2120	112	5	the	the	DET
dpc-2120	112	6	scorad	scorad	NOUN
dpc-2120	112	7	(	(	PUNCT
dpc-2120	112	8	≥	≥	NOUN
dpc-2120	112	9	50	50	NUM
dpc-2120	112	10	)	)	PUNCT
dpc-2120	112	11	was	be	AUX
dpc-2120	112	12	found	find	VERB
dpc-2120	112	13	in	in	ADP
dpc-2120	112	14	the	the	DET
dpc-2120	112	15	subgroup	subgroup	NOUN
dpc-2120	112	16	of	of	ADP
dpc-2120	112	17	patients	patient	NOUN
dpc-2120	112	18	with	with	ADP
dpc-2120	112	19	severe	severe	ADJ
dpc-2120	112	20	ad	ad	NOUN
dpc-2120	112	21	compared	compare	VERB
dpc-2120	112	22	to	to	ADP
dpc-2120	112	23	placebo	placebo	NOUN
dpc-2120	112	24	(	(	PUNCT
dpc-2120	112	25	p	p	X
dpc-2120	112	26	<	<	X
dpc-2120	112	27	0.029	0.029	NUM
dpc-2120	112	28	)	)	PUNCT
dpc-2120	112	29	,	,	PUNCT
dpc-2120	112	30	but	but	CCONJ
dpc-2120	112	31	this	this	DET
dpc-2120	112	32	effect	effect	NOUN
dpc-2120	112	33	was	be	AUX
dpc-2120	112	34	not	not	PART
dpc-2120	112	35	found	find	VERB
dpc-2120	112	36	for	for	ADP
dpc-2120	112	37	the	the	DET
dpc-2120	112	38	entire	entire	ADJ
dpc-2120	112	39	study	study	NOUN
dpc-2120	112	40	population	population	NOUN
dpc-2120	112	41	.	.	PUNCT
dpc-2120	113	1	at	at	ADP
dpc-2120	113	2	week	week	NOUN
dpc-2120	113	3	12	12	NUM
dpc-2120	113	4	,	,	PUNCT
dpc-2120	113	5	a	a	DET
dpc-2120	113	6	significant	significant	ADJ
dpc-2120	113	7	reduction	reduction	NOUN
dpc-2120	113	8	of	of	ADP
dpc-2120	113	9	the	the	DET
dpc-2120	113	10	body	body	NOUN
dpc-2120	113	11	surface	surface	NOUN
dpc-2120	113	12	area	area	NOUN
dpc-2120	113	13	involvement	involvement	NOUN
dpc-2120	113	14	was	be	AUX
dpc-2120	113	15	observed	observe	VERB
dpc-2120	113	16	in	in	ADP
dpc-2120	113	17	all	all	DET
dpc-2120	113	18	patients	patient	NOUN
dpc-2120	113	19	receiving	receive	VERB
dpc-2120	113	20	fezakinumab	fezakinumab	NOUN
dpc-2120	113	21	compared	compare	VERB
dpc-2120	113	22	to	to	ADP
dpc-2120	113	23	placebo	placebo	NOUN
dpc-2120	113	24	.	.	PUNCT
dpc-2120	114	1	in	in	ADP
dpc-2120	114	2	addition	addition	NOUN
dpc-2120	114	3	,	,	PUNCT
dpc-2120	114	4	fezakinumab	fezakinumab	NOUN
dpc-2120	114	5	demonstrated	demonstrate	VERB
dpc-2120	114	6	a	a	DET
dpc-2120	114	7	beneficial	beneficial	ADJ
dpc-2120	114	8	safety	safety	NOUN
dpc-2120	114	9	profile	profile	NOUN
dpc-2120	114	10	,	,	PUNCT
dpc-2120	114	11	with	with	ADP
dpc-2120	114	12	upper	upper	ADJ
dpc-2120	114	13	respiratory	respiratory	ADJ
dpc-2120	114	14	tract	tract	NOUN
dpc-2120	114	15	infections	infection	NOUN
dpc-2120	114	16	being	be	AUX
dpc-2120	114	17	the	the	DET
dpc-2120	114	18	most	most	ADV
dpc-2120	114	19	reported	reported	ADJ
dpc-2120	114	20	adverse	adverse	ADJ
dpc-2120	114	21	event	event	NOUN
dpc-2120	114	22	,	,	PUNCT
dpc-2120	114	23	which	which	PRON
dpc-2120	114	24	will	will	AUX
dpc-2120	114	25	require	require	VERB
dpc-2120	114	26	further	further	ADJ
dpc-2120	114	27	investigation	investigation	NOUN
dpc-2120	114	28	in	in	ADP
dpc-2120	114	29	a	a	DET
dpc-2120	114	30	larger	large	ADJ
dpc-2120	114	31	study	study	NOUN
dpc-2120	114	32	population	population	NOUN
dpc-2120	115	1	[	[	X
dpc-2120	115	2	36	36	NUM
dpc-2120	115	3	]	]	PUNCT
dpc-2120	115	4	.	.	PUNCT
dpc-2120	116	1	conclusion	conclusion	VERB
dpc-2120	116	2	new	new	ADJ
dpc-2120	116	3	findings	finding	NOUN
dpc-2120	116	4	on	on	ADP
dpc-2120	116	5	the	the	DET
dpc-2120	116	6	pathogenesis	pathogenesis	NOUN
dpc-2120	116	7	of	of	ADP
dpc-2120	116	8	ad	ad	NOUN
dpc-2120	116	9	introduce	introduce	VERB
dpc-2120	116	10	new	new	ADJ
dpc-2120	116	11	therapeutic	therapeutic	ADJ
dpc-2120	116	12	approaches	approach	NOUN
dpc-2120	116	13	almost	almost	ADV
dpc-2120	116	14	daily	daily	ADJ
dpc-2120	116	15	as	as	SCONJ
dpc-2120	116	16	summarized	summarize	VERB
dpc-2120	116	17	in	in	ADP
dpc-2120	116	18	table	table	NOUN
dpc-2120	116	19	1	1	NUM
dpc-2120	116	20	and	and	CCONJ
dpc-2120	116	21	figure	figure	VERB
dpc-2120	116	22	1	1	NUM
dpc-2120	116	23	.	.	PUNCT
dpc-2120	117	1	for	for	ADP
dpc-2120	117	2	example	example	NOUN
dpc-2120	117	3	,	,	PUNCT
dpc-2120	117	4	the	the	DET
dpc-2120	117	5	th-17	th-17	NOUN
dpc-2120	117	6	/	/	SYM
dpc-2120	117	7	il-23	il-23	NOUN
dpc-2120	117	8	axis	axis	NOUN
dpc-2120	117	9	,	,	PUNCT
dpc-2120	117	10	which	which	PRON
dpc-2120	117	11	was	be	AUX
dpc-2120	117	12	long	long	ADV
dpc-2120	117	13	considered	consider	VERB
dpc-2120	117	14	pathognomonic	pathognomonic	ADJ
dpc-2120	117	15	for	for	ADP
dpc-2120	117	16	psoriasis	psoriasis	NOUN
dpc-2120	117	17	,	,	PUNCT
dpc-2120	117	18	could	could	AUX
dpc-2120	117	19	now	now	ADV
dpc-2120	117	20	also	also	ADV
dpc-2120	117	21	be	be	AUX
dpc-2120	117	22	proven	prove	VERB
dpc-2120	117	23	to	to	PART
dpc-2120	117	24	play	play	VERB
dpc-2120	117	25	a	a	DET
dpc-2120	117	26	role	role	NOUN
dpc-2120	117	27	in	in	ADP
dpc-2120	117	28	the	the	DET
dpc-2120	117	29	pathogenesis	pathogenesis	NOUN
dpc-2120	117	30	of	of	ADP
dpc-2120	117	31	ad	ad	NOUN
dpc-2120	117	32	[	[	X
dpc-2120	117	33	37	37	NUM
dpc-2120	117	34	]	]	PUNCT
dpc-2120	117	35	.	.	PUNCT
dpc-2120	118	1	already	already	ADV
dpc-2120	118	2	proven	prove	VERB
dpc-2120	118	3	agents	agent	NOUN
dpc-2120	118	4	for	for	ADP
dpc-2120	118	5	the	the	DET
dpc-2120	118	6	therapy	therapy	NOUN
dpc-2120	118	7	of	of	ADP
dpc-2120	118	8	psoriasis	psoriasis	NOUN
dpc-2120	118	9	are	be	AUX
dpc-2120	118	10	available	available	ADJ
dpc-2120	118	11	and	and	CCONJ
dpc-2120	118	12	may	may	AUX
dpc-2120	118	13	be	be	AUX
dpc-2120	118	14	used	use	VERB
dpc-2120	118	15	for	for	ADP
dpc-2120	118	16	therapeutic	therapeutic	ADJ
dpc-2120	118	17	approaches	approach	NOUN
dpc-2120	118	18	for	for	ADP
dpc-2120	118	19	patients	patient	NOUN
dpc-2120	118	20	suffering	suffer	VERB
dpc-2120	118	21	table	table	NOUN
dpc-2120	118	22	1	1	NUM
dpc-2120	118	23	.	.	PUNCT
dpc-2120	118	24	overview	overview	NOUN
dpc-2120	118	25	of	of	ADP
dpc-2120	118	26	biologicals	biological	NOUN
dpc-2120	118	27	approved	approve	VERB
dpc-2120	118	28	or	or	CCONJ
dpc-2120	118	29	tested	test	VERB
dpc-2120	118	30	for	for	ADP
dpc-2120	118	31	atopic	atopic	NOUN
dpc-2120	118	32	dermatitis	dermatitis	NOUN
dpc-2120	118	33	treatment	treatment	NOUN
dpc-2120	118	34	.	.	PUNCT
dpc-2120	119	1	biological	biological	ADJ
dpc-2120	119	2	target	target	NOUN
dpc-2120	119	3	current	current	ADJ
dpc-2120	119	4	phase	phase	NOUN
dpc-2120	119	5	of	of	ADP
dpc-2120	119	6	clinical	clinical	ADJ
dpc-2120	119	7	trials	trial	NOUN
dpc-2120	119	8	main	main	ADJ
dpc-2120	119	9	findings	finding	NOUN
dpc-2120	119	10	in	in	ADP
dpc-2120	119	11	clinical	clinical	ADJ
dpc-2120	119	12	trials	trial	NOUN
dpc-2120	119	13	dupilumab	dupilumab	NOUN
dpc-2120	119	14	il-4	il-4	PROPN
dpc-2120	119	15	/	/	SYM
dpc-2120	119	16	il-13	il-13	VERB
dpc-2120	119	17	approved	approve	VERB
dpc-2120	119	18	for	for	ADP
dpc-2120	119	19	clinical	clinical	ADJ
dpc-2120	119	20	use	use	NOUN
dpc-2120	119	21	by	by	ADP
dpc-2120	119	22	ema	ema	PROPN
dpc-2120	119	23	easi-75	easi-75	PROPN
dpc-2120	119	24	improvement	improvement	NOUN
dpc-2120	119	25	after	after	ADP
dpc-2120	119	26	16	16	NUM
dpc-2120	119	27	-	-	PUNCT
dpc-2120	119	28	weeks	week	NOUN
dpc-2120	119	29	of	of	ADP
dpc-2120	119	30	trial	trial	NOUN
dpc-2120	119	31	(	(	PUNCT
dpc-2120	119	32	phase	phase	NOUN
dpc-2120	119	33	iii	iii	NOUN
dpc-2120	119	34	)	)	PUNCT
dpc-2120	120	1	[	[	X
dpc-2120	120	2	11	11	NUM
dpc-2120	120	3	]	]	SYM
dpc-2120	120	4	tralokinumab	tralokinumab	NOUN
dpc-2120	120	5	il-13	il-13	PUNCT
dpc-2120	120	6	approved	approve	VERB
dpc-2120	120	7	for	for	ADP
dpc-2120	120	8	clinical	clinical	ADJ
dpc-2120	120	9	use	use	NOUN
dpc-2120	120	10	by	by	ADP
dpc-2120	120	11	ema	ema	PROPN
dpc-2120	120	12	easi-75	easi-75	PROPN
dpc-2120	120	13	improvement	improvement	PROPN
dpc-2120	120	14	&	&	CCONJ
dpc-2120	120	15	iga	iga	PROPN
dpc-2120	120	16	0	0	NUM
dpc-2120	120	17	or	or	CCONJ
dpc-2120	120	18	1	1	NUM
dpc-2120	120	19	after	after	ADP
dpc-2120	120	20	16	16	NUM
dpc-2120	120	21	-	-	PUNCT
dpc-2120	120	22	weeks	week	NOUN
dpc-2120	120	23	of	of	ADP
dpc-2120	120	24	trial	trial	NOUN
dpc-2120	120	25	compared	compare	VERB
dpc-2120	120	26	to	to	ADP
dpc-2120	120	27	placebo	placebo	NOUN
dpc-2120	120	28	(	(	PUNCT
dpc-2120	120	29	phase	phase	NOUN
dpc-2120	120	30	iii	iii	NOUN
dpc-2120	120	31	)	)	PUNCT
dpc-2120	121	1	[	[	X
dpc-2120	121	2	19	19	NUM
dpc-2120	121	3	]	]	X
dpc-2120	121	4	lebrikizumab	lebrikizumab	NOUN
dpc-2120	121	5	il-13	il-13	ADP
dpc-2120	121	6	3	3	NUM
dpc-2120	121	7	,	,	PUNCT
dpc-2120	121	8	still	still	ADV
dpc-2120	121	9	recruiting	recruit	VERB
dpc-2120	121	10	up	up	ADV
dpc-2120	121	11	to	to	ADP
dpc-2120	121	12	72.1	72.1	NUM
dpc-2120	121	13	%	%	NOUN
dpc-2120	121	14	improvement	improvement	NOUN
dpc-2120	121	15	easi	easi	NOUN
dpc-2120	121	16	(	(	PUNCT
dpc-2120	121	17	250	250	NUM
dpc-2120	121	18	mg	mg	PROPN
dpc-2120	121	19	dose	dose	PROPN
dpc-2120	121	20	)	)	PUNCT
dpc-2120	121	21	after	after	ADP
dpc-2120	121	22	16	16	NUM
dpc-2120	121	23	-	-	PUNCT
dpc-2120	121	24	weeks	week	NOUN
dpc-2120	121	25	of	of	ADP
dpc-2120	121	26	trial	trial	NOUN
dpc-2120	121	27	compared	compare	VERB
dpc-2120	121	28	to	to	ADP
dpc-2120	121	29	placebo	placebo	NOUN
dpc-2120	121	30	(	(	PUNCT
dpc-2120	121	31	phase	phase	NOUN
dpc-2120	121	32	iib	iib	NOUN
dpc-2120	121	33	)	)	PUNCT
dpc-2120	122	1	[	[	X
dpc-2120	122	2	20	20	NUM
dpc-2120	122	3	]	]	PUNCT
dpc-2120	122	4	nemolizumab	nemolizumab	NOUN
dpc-2120	122	5	il-31	il-31	ADJ
dpc-2120	122	6	3	3	NUM
dpc-2120	122	7	,	,	PUNCT
dpc-2120	122	8	still	still	ADV
dpc-2120	122	9	recruiting	recruit	VERB
dpc-2120	122	10	up	up	ADV
dpc-2120	122	11	to	to	ADP
dpc-2120	122	12	63.1	63.1	NUM
dpc-2120	122	13	%	%	NOUN
dpc-2120	122	14	change	change	NOUN
dpc-2120	122	15	in	in	ADP
dpc-2120	122	16	the	the	DET
dpc-2120	122	17	pruritus	pruritus	PROPN
dpc-2120	122	18	vas	vas	X
dpc-2120	122	19	score	score	NOUN
dpc-2120	122	20	after	after	ADP
dpc-2120	122	21	12	12	NUM
dpc-2120	122	22	-	-	PUNCT
dpc-2120	122	23	weeks	week	NOUN
dpc-2120	122	24	compared	compare	VERB
dpc-2120	122	25	to	to	ADP
dpc-2120	122	26	placebo	placebo	NOUN
dpc-2120	122	27	(	(	PUNCT
dpc-2120	122	28	phase	phase	NOUN
dpc-2120	122	29	iib	iib	NOUN
dpc-2120	122	30	)	)	PUNCT
dpc-2120	123	1	[	[	X
dpc-2120	123	2	24	24	NUM
dpc-2120	123	3	]	]	X
dpc-2120	123	4	gbr830	gbr830	PROPN
dpc-2120	123	5	/	/	SYM
dpc-2120	123	6	ibs830	ibs830	PROPN
dpc-2120	123	7	ox40	ox40	PROPN
dpc-2120	123	8	2b	2b	NUM
dpc-2120	123	9	,	,	PUNCT
dpc-2120	123	10	finished	finish	VERB
dpc-2120	123	11	,	,	PUNCT
dpc-2120	123	12	results	result	NOUN
dpc-2120	123	13	not	not	PART
dpc-2120	123	14	published	publish	VERB
dpc-2120	123	15	easi-50	easi-50	ADJ
dpc-2120	123	16	improvement	improvement	NOUN
dpc-2120	123	17	after	after	ADP
dpc-2120	123	18	71	71	NUM
dpc-2120	123	19	days	day	NOUN
dpc-2120	123	20	compared	compare	VERB
dpc-2120	123	21	to	to	ADP
dpc-2120	123	22	placebo	placebo	NOUN
dpc-2120	123	23	(	(	PUNCT
dpc-2120	123	24	phase	phase	NOUN
dpc-2120	123	25	iia	iia	NOUN
dpc-2120	123	26	)	)	PUNCT
dpc-2120	124	1	[	[	X
dpc-2120	124	2	26	26	NUM
dpc-2120	124	3	]	]	PUNCT
dpc-2120	124	4	khk4083	khk4083	X
dpc-2120	125	1	ox40	ox40	PROPN
dpc-2120	125	2	2a	2a	NUM
dpc-2120	125	3	,	,	PUNCT
dpc-2120	125	4	completed	complete	VERB
dpc-2120	125	5	,	,	PUNCT
dpc-2120	125	6	results	result	NOUN
dpc-2120	125	7	not	not	PART
dpc-2120	125	8	published	publish	VERB
dpc-2120	125	9	continued	continue	VERB
dpc-2120	125	10	improvement	improvement	NOUN
dpc-2120	125	11	in	in	ADP
dpc-2120	125	12	easi	easi	NOUN
dpc-2120	125	13	and	and	CCONJ
dpc-2120	125	14	iga	iga	PROPN
dpc-2120	125	15	(	(	PUNCT
dpc-2120	125	16	phase	phase	NOUN
dpc-2120	125	17	i	i	PRON
dpc-2120	125	18	)	)	PUNCT
dpc-2120	126	1	[	[	X
dpc-2120	126	2	27	27	NUM
dpc-2120	126	3	]	]	PUNCT
dpc-2120	126	4	tepezelumab	tepezelumab	NOUN
dpc-2120	126	5	tslp	tslp	PROPN
dpc-2120	126	6	2b	2b	NOUN
dpc-2120	126	7	,	,	PUNCT
dpc-2120	126	8	still	still	ADV
dpc-2120	126	9	recruiting	recruit	VERB
dpc-2120	126	10	numerical	numerical	ADJ
dpc-2120	126	11	easi50	easi50	PROPN
dpc-2120	126	12	improvement	improvement	NOUN
dpc-2120	126	13	after	after	ADP
dpc-2120	126	14	12	12	NUM
dpc-2120	126	15	-	-	PUNCT
dpc-2120	126	16	weeks	week	NOUN
dpc-2120	126	17	of	of	ADP
dpc-2120	126	18	trial	trial	NOUN
dpc-2120	126	19	compared	compare	VERB
dpc-2120	126	20	to	to	ADP
dpc-2120	126	21	placebo	placebo	NOUN
dpc-2120	126	22	(	(	PUNCT
dpc-2120	126	23	phase	phase	NOUN
dpc-2120	126	24	iia	iia	NOUN
dpc-2120	126	25	)	)	PUNCT
dpc-2120	127	1	[	[	X
dpc-2120	127	2	28	28	NUM
dpc-2120	127	3	]	]	PUNCT
dpc-2120	127	4	etokimab	etokimab	NOUN
dpc-2120	127	5	il-31	il-31	PART
dpc-2120	127	6	2b	2b	NOUN
dpc-2120	127	7	,	,	PUNCT
dpc-2120	127	8	still	still	ADV
dpc-2120	127	9	recruiting	recruit	VERB
dpc-2120	127	10	83	83	NUM
dpc-2120	127	11	%	%	NOUN
dpc-2120	127	12	improvement	improvement	NOUN
dpc-2120	127	13	of	of	ADP
dpc-2120	127	14	easi50	easi50	NOUN
dpc-2120	127	15	and	and	CCONJ
dpc-2120	127	16	33	33	NUM
dpc-2120	127	17	%	%	NOUN
dpc-2120	127	18	easi75	easi75	NOUN
dpc-2120	127	19	after	after	ADP
dpc-2120	127	20	29	29	NUM
dpc-2120	127	21	-	-	PUNCT
dpc-2120	127	22	days	day	NOUN
dpc-2120	127	23	of	of	ADP
dpc-2120	127	24	a	a	DET
dpc-2120	127	25	single	single	ADJ
dpc-2120	127	26	dose	dose	NOUN
dpc-2120	127	27	(	(	PUNCT
dpc-2120	127	28	phase	phase	NOUN
dpc-2120	127	29	iia	iia	NOUN
dpc-2120	127	30	)	)	PUNCT
dpc-2120	128	1	[	[	X
dpc-2120	128	2	33	33	NUM
dpc-2120	128	3	]	]	PUNCT
dpc-2120	128	4	fezakinumab	fezakinumab	NOUN
dpc-2120	128	5	il-22	il-22	ADP
dpc-2120	128	6	2a	2a	NUM
dpc-2120	128	7	,	,	PUNCT
dpc-2120	128	8	completed	complete	VERB
dpc-2120	128	9	scorad	scorad	NOUN
dpc-2120	128	10	improvement	improvement	NOUN
dpc-2120	128	11	greater	great	ADJ
dpc-2120	128	12	compared	compare	VERB
dpc-2120	128	13	to	to	ADP
dpc-2120	128	14	placebo	placebo	NOUN
dpc-2120	128	15	at	at	ADP
dpc-2120	128	16	12	12	NUM
dpc-2120	128	17	-	-	PUNCT
dpc-2120	128	18	weeks	week	NOUN
dpc-2120	128	19	of	of	ADP
dpc-2120	128	20	trial	trial	NOUN
dpc-2120	128	21	(	(	PUNCT
dpc-2120	128	22	phase	phase	NOUN
dpc-2120	128	23	iia	iia	NOUN
dpc-2120	128	24	)	)	PUNCT
dpc-2120	129	1	[	[	X
dpc-2120	129	2	36	36	NUM
dpc-2120	129	3	]	]	SYM
dpc-2120	129	4	*	*	PUNCT
dpc-2120	129	5	data	datum	NOUN
dpc-2120	129	6	from	from	ADP
dpc-2120	129	7	clinicaltrials.gov	clinicaltrials.gov	NOUN
dpc-2120	129	8	,	,	PUNCT
dpc-2120	129	9	worm	worm	NOUN
dpc-2120	129	10	et	et	PROPN
dpc-2120	129	11	al	al	PROPN
dpc-2120	130	1	[	[	X
dpc-2120	130	2	18	18	NUM
dpc-2120	130	3	]	]	PUNCT
dpc-2120	130	4	,	,	PUNCT
dpc-2120	130	5	&	&	CCONJ
dpc-2120	130	6	li	li	PROPN
dpc-2120	130	7	et	et	PROPN
dpc-2120	130	8	al	al	PROPN
dpc-2120	131	1	[	[	X
dpc-2120	131	2	17	17	NUM
dpc-2120	131	3	]	]	PUNCT
dpc-2120	131	4	.	.	PUNCT
dpc-2120	132	1	allergens	allergen	NOUN
dpc-2120	132	2	epidermis	epidermis	NOUN
dpc-2120	132	3	:	:	PUNCT
dpc-2120	132	4	barrier	barrier	NOUN
dpc-2120	132	5	defects	defect	NOUN
dpc-2120	132	6	tslp	tslp	VERB
dpc-2120	132	7	tezepelumab	tezepelumab	NOUN
dpc-2120	132	8	gbr830	gbr830	PROPN
dpc-2120	132	9	/	/	SYM
dpc-2120	132	10	ibs830	ibs830	PROPN
dpc-2120	132	11	khk4083	khk4083	NOUN
dpc-2120	132	12	dupilumab	dupilumab	NOUN
dpc-2120	132	13	ox40	ox40	PROPN
dpc-2120	132	14	il-4	il-4	PART
dpc-2120	132	15	il-13	il-13	PRON
dpc-2120	132	16	il-31	il-31	PUNCT
dpc-2120	132	17	il-33	il-33	VERB
dpc-2120	132	18	il-22	il-22	ADJ
dpc-2120	132	19	th22	th22	PROPN
dpc-2120	132	20	th2	th2	PROPN
dpc-2120	132	21	th1	th1	PROPN
dpc-2120	132	22	dc	dc	PROPN
dpc-2120	132	23	th17	th17	PROPN
dpc-2120	132	24	b	b	PROPN
dpc-2120	132	25	-	-	PUNCT
dpc-2120	132	26	cellil-12	cellil-12	NOUN
dpc-2120	132	27	il-23	il-23	NOUN
dpc-2120	132	28	il-17	il-17	NUM
dpc-2120	132	29	ige	ige	PROPN
dpc-2120	132	30	tralokinumab	tralokinumab	PROPN
dpc-2120	132	31	nemolizumab	nemolizumab	PROPN
dpc-2120	132	32	etokimab	etokimab	PROPN
dpc-2120	132	33	lebrikizumab	lebrikizumab	PROPN
dpc-2120	132	34	fezakinumab	fezakinumab	PROPN
dpc-2120	132	35	ustekinumab	ustekinumab	PROPN
dpc-2120	132	36	omalizumab	omalizumab	PROPN
dpc-2120	132	37	secukinumab	secukinumab	NOUN
dpc-2120	132	38	figure	figure	NOUN
dpc-2120	132	39	1	1	NUM
dpc-2120	132	40	.	.	PUNCT
dpc-2120	133	1	pathogenesis	pathogenesis	NOUN
dpc-2120	133	2	and	and	CCONJ
dpc-2120	133	3	therapeutic	therapeutic	ADJ
dpc-2120	133	4	targets	target	NOUN
dpc-2120	133	5	in	in	ADP
dpc-2120	133	6	atopic	atopic	NOUN
dpc-2120	133	7	dermatitis	dermatitis	NOUN
dpc-2120	133	8	(	(	PUNCT
dpc-2120	133	9	ad	ad	NOUN
dpc-2120	133	10	)	)	PUNCT
dpc-2120	133	11	.	.	PUNCT
dpc-2120	134	1	modified	modify	VERB
dpc-2120	134	2	according	accord	VERB
dpc-2120	134	3	to	to	ADP
dpc-2120	134	4	worm	worm	NOUN
dpc-2120	134	5	et	et	PROPN
dpc-2120	134	6	al	al	PROPN
dpc-2120	135	1	[	[	X
dpc-2120	135	2	35	35	NUM
dpc-2120	135	3	]	]	PUNCT
dpc-2120	135	4	and	and	CCONJ
dpc-2120	135	5	li	li	PROPN
dpc-2120	135	6	et	et	PROPN
dpc-2120	135	7	al	al	PROPN
dpc-2120	136	1	[	[	X
dpc-2120	136	2	14	14	NUM
dpc-2120	136	3	]	]	PUNCT
dpc-2120	136	4	.	.	PUNCT
dpc-2120	137	1	increased	increase	VERB
dpc-2120	137	2	skin	skin	NOUN
dpc-2120	137	3	penetration	penetration	NOUN
dpc-2120	137	4	of	of	ADP
dpc-2120	137	5	allergens	allergen	NOUN
dpc-2120	137	6	due	due	ADJ
dpc-2120	137	7	to	to	ADP
dpc-2120	137	8	epidermal	epidermal	ADJ
dpc-2120	137	9	barrier	barrier	NOUN
dpc-2120	137	10	defects	defect	NOUN
dpc-2120	137	11	results	result	NOUN
dpc-2120	137	12	in	in	ADP
dpc-2120	137	13	type-2	type-2	PROPN
dpc-2120	137	14	-	-	PUNCT
dpc-2120	137	15	t	t	NOUN
dpc-2120	137	16	-	-	PUNCT
dpc-2120	137	17	helper	helper	NOUN
dpc-2120	137	18	-	-	PUNCT
dpc-2120	137	19	cells	cell	NOUN
dpc-2120	137	20	(	(	PUNCT
dpc-2120	137	21	th2)-predominant	th2)-predominant	NUM
dpc-2120	137	22	inflammation	inflammation	NOUN
dpc-2120	137	23	with	with	ADP
dpc-2120	137	24	and	and	CCONJ
dpc-2120	137	25	without	without	ADP
dpc-2120	137	26	activation	activation	NOUN
dpc-2120	137	27	of	of	ADP
dpc-2120	137	28	dendritic	dendritic	ADJ
dpc-2120	137	29	cells	cell	NOUN
dpc-2120	137	30	(	(	PUNCT
dpc-2120	137	31	dc	dc	PROPN
dpc-2120	137	32	)	)	PUNCT
dpc-2120	137	33	.	.	PUNCT
dpc-2120	138	1	various	various	ADJ
dpc-2120	138	2	cytokines	cytokine	NOUN
dpc-2120	138	3	contribute	contribute	VERB
dpc-2120	138	4	in	in	ADP
dpc-2120	138	5	the	the	DET
dpc-2120	138	6	pathogenesis	pathogenesis	NOUN
dpc-2120	138	7	of	of	ADP
dpc-2120	138	8	ad	ad	NOUN
dpc-2120	138	9	,	,	PUNCT
dpc-2120	138	10	representing	represent	VERB
dpc-2120	138	11	effective	effective	ADJ
dpc-2120	138	12	and	and	CCONJ
dpc-2120	138	13	future	future	ADJ
dpc-2120	138	14	possible	possible	ADJ
dpc-2120	138	15	therapeutic	therapeutic	ADJ
dpc-2120	138	16	targets	target	NOUN
dpc-2120	138	17	for	for	ADP
dpc-2120	138	18	biologics	biologic	NOUN
dpc-2120	138	19	in	in	ADP
dpc-2120	138	20	combating	combat	VERB
dpc-2120	138	21	ad	ad	NOUN
dpc-2120	138	22	.	.	PUNCT
dpc-2120	139	1	cells	cell	NOUN
dpc-2120	139	2	that	that	PRON
dpc-2120	139	3	activate	activate	VERB
dpc-2120	139	4	dc	dc	NOUN
dpc-2120	139	5	or	or	CCONJ
dpc-2120	139	6	those	those	PRON
dpc-2120	139	7	that	that	PRON
dpc-2120	139	8	are	be	AUX
dpc-2120	139	9	activated	activate	VERB
dpc-2120	139	10	by	by	ADP
dpc-2120	139	11	them	they	PRON
dpc-2120	139	12	,	,	PUNCT
dpc-2120	139	13	such	such	ADJ
dpc-2120	139	14	as	as	ADP
dpc-2120	139	15	tslp	tslp	ADJ
dpc-2120	139	16	or	or	CCONJ
dpc-2120	139	17	ox40	ox40	PROPN
dpc-2120	139	18	,	,	PUNCT
dpc-2120	139	19	represent	represent	VERB
dpc-2120	139	20	potential	potential	ADJ
dpc-2120	139	21	targets	target	NOUN
dpc-2120	139	22	.	.	PUNCT
dpc-2120	140	1	review	review	VERB
dpc-2120	140	2	|	|	ADV
dpc-2120	140	3	dermatol	dermatol	ADJ
dpc-2120	140	4	pract	pract	NOUN
dpc-2120	140	5	concept	concept	NOUN
dpc-2120	140	6	.	.	PUNCT
dpc-2120	141	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	141	2	5	5	NUM
dpc-2120	141	3	from	from	ADP
dpc-2120	141	4	ad	ad	NOUN
dpc-2120	141	5	.	.	PUNCT
dpc-2120	141	6	described	describe	VERB
dpc-2120	141	7	findings	finding	NOUN
dpc-2120	141	8	and	and	CCONJ
dpc-2120	141	9	clinical	clinical	ADJ
dpc-2120	141	10	results	result	NOUN
dpc-2120	141	11	illustrate	illustrate	VERB
dpc-2120	141	12	the	the	DET
dpc-2120	141	13	viability	viability	NOUN
dpc-2120	141	14	of	of	ADP
dpc-2120	141	15	biologicals	biological	NOUN
dpc-2120	141	16	and	and	CCONJ
dpc-2120	141	17	support	support	VERB
dpc-2120	141	18	the	the	DET
dpc-2120	141	19	endeavor	endeavor	NOUN
dpc-2120	141	20	of	of	ADP
dpc-2120	141	21	targeted	targeted	ADJ
dpc-2120	141	22	,	,	PUNCT
dpc-2120	141	23	patient	patient	NOUN
dpc-2120	141	24	-	-	PUNCT
dpc-2120	141	25	specific	specific	ADJ
dpc-2120	141	26	medication	medication	NOUN
dpc-2120	141	27	for	for	ADP
dpc-2120	141	28	the	the	DET
dpc-2120	141	29	treatment	treatment	NOUN
dpc-2120	141	30	of	of	ADP
dpc-2120	141	31	ad	ad	NOUN
dpc-2120	141	32	.	.	PUNCT
dpc-2120	142	1	references	reference	NOUN
dpc-2120	142	2	1	1	NUM
dpc-2120	142	3	.	.	PUNCT
dpc-2120	142	4	ring	ring	PROPN
dpc-2120	142	5	j	j	PROPN
dpc-2120	142	6	,	,	PUNCT
dpc-2120	142	7	zink	zink	NOUN
dpc-2120	142	8	a	a	X
dpc-2120	142	9	,	,	PUNCT
dpc-2120	142	10	arents	arents	PROPN
dpc-2120	142	11	bwm	bwm	PROPN
dpc-2120	142	12	,	,	PUNCT
dpc-2120	142	13	et	et	PROPN
dpc-2120	142	14	al	al	PROPN
dpc-2120	142	15	.	.	PUNCT
dpc-2120	143	1	atopic	atopic	PROPN
dpc-2120	143	2	eczema	eczema	NOUN
dpc-2120	143	3	:	:	PUNCT
dpc-2120	143	4	burden	burden	NOUN
dpc-2120	143	5	of	of	ADP
dpc-2120	143	6	disease	disease	NOUN
dpc-2120	143	7	and	and	CCONJ
dpc-2120	143	8	individual	individual	ADJ
dpc-2120	143	9	suffering	suffering	NOUN
dpc-2120	143	10	results	result	NOUN
dpc-2120	143	11	from	from	ADP
dpc-2120	143	12	a	a	DET
dpc-2120	143	13	large	large	ADJ
dpc-2120	143	14	eu	eu	PROPN
dpc-2120	143	15	study	study	NOUN
dpc-2120	143	16	in	in	ADP
dpc-2120	143	17	adults	adult	NOUN
dpc-2120	143	18	.	.	PUNCT
dpc-2120	144	1	j	j	PROPN
dpc-2120	144	2	eur	eur	PROPN
dpc-2120	144	3	acad	acad	PROPN
dpc-2120	144	4	dermatol	dermatol	NOUN
dpc-2120	144	5	venereol	venereol	NOUN
dpc-2120	144	6	.	.	PUNCT
dpc-2120	145	1	2019;33(7):1331	2019;33(7):1331	NUM
dpc-2120	145	2	-	-	SYM
dpc-2120	145	3	1340	1340	NUM
dpc-2120	145	4	.	.	PUNCT
dpc-2120	146	1	doi	doi	NOUN
dpc-2120	146	2	:	:	PUNCT
dpc-2120	146	3	10.1111	10.1111	NUM
dpc-2120	146	4	/	/	SYM
dpc-2120	146	5	jdv.15634.pmid	jdv.15634.pmid	ADJ
dpc-2120	146	6	:	:	PUNCT
dpc-2120	146	7	31002197	31002197	NUM
dpc-2120	146	8	.	.	PUNCT
dpc-2120	147	1	2	2	X
dpc-2120	147	2	.	.	X
dpc-2120	147	3	zink	zink	NOUN
dpc-2120	147	4	ags	ag	NOUN
dpc-2120	147	5	,	,	PUNCT
dpc-2120	147	6	arents	arents	PROPN
dpc-2120	147	7	b	b	NUM
dpc-2120	147	8	,	,	PUNCT
dpc-2120	147	9	fink	fink	PROPN
dpc-2120	147	10	-	-	PUNCT
dpc-2120	147	11	wagner	wagner	PROPN
dpc-2120	147	12	a	a	PROPN
dpc-2120	147	13	,	,	PUNCT
dpc-2120	147	14	seitz	seitz	PROPN
dpc-2120	147	15	ia	ia	PROPN
dpc-2120	147	16	,	,	PUNCT
dpc-2120	147	17	mensing	mense	VERB
dpc-2120	147	18	u	u	NOUN
dpc-2120	147	19	,	,	PUNCT
dpc-2120	147	20	wettemann	wettemann	PROPN
dpc-2120	147	21	n	n	CCONJ
dpc-2120	147	22	,	,	PUNCT
dpc-2120	147	23	de	de	PROPN
dpc-2120	147	24	carlo	carlo	PROPN
dpc-2120	147	25	g	g	PROPN
dpc-2120	147	26	,	,	PUNCT
dpc-2120	147	27	ring	ring	NOUN
dpc-2120	147	28	j.	j.	PROPN
dpc-2120	147	29	out	out	PROPN
dpc-2120	147	30	-	-	PUNCT
dpc-2120	147	31	of	of	ADP
dpc-2120	147	32	-	-	PUNCT
dpc-2120	147	33	pocket	pocket	NOUN
dpc-2120	147	34	costs	cost	NOUN
dpc-2120	147	35	for	for	ADP
dpc-2120	147	36	individuals	individual	NOUN
dpc-2120	147	37	with	with	ADP
dpc-2120	147	38	atopic	atopic	ADJ
dpc-2120	147	39	eczema	eczema	NOUN
dpc-2120	147	40	:	:	PUNCT
dpc-2120	147	41	a	a	DET
dpc-2120	147	42	cross	cross	ADJ
dpc-2120	147	43	-	-	ADJ
dpc-2120	147	44	sectional	sectional	ADJ
dpc-2120	147	45	study	study	NOUN
dpc-2120	147	46	in	in	ADP
dpc-2120	147	47	nine	nine	NUM
dpc-2120	147	48	european	european	ADJ
dpc-2120	147	49	countries	country	NOUN
dpc-2120	147	50	.	.	PUNCT
dpc-2120	148	1	acta	acta	PROPN
dpc-2120	148	2	derm	derm	PROPN
dpc-2120	148	3	venereol	venereol	NOUN
dpc-2120	148	4	.	.	PUNCT
dpc-2120	149	1	2019;99(3	2019;99(3	NUM
dpc-2120	149	2	):	):	PUNCT
dpc-2120	149	3	263	263	NUM
dpc-2120	149	4	-	-	SYM
dpc-2120	149	5	267	267	NUM
dpc-2120	149	6	.	.	PUNCT
dpc-2120	149	7	doi	doi	NOUN
dpc-2120	149	8	:	:	PUNCT
dpc-2120	149	9	10.2340/00015555	10.2340/00015555	NUM
dpc-2120	149	10	-	-	SYM
dpc-2120	149	11	3102	3102	NUM
dpc-2120	149	12	.	.	PUNCT
dpc-2120	150	1	pmid	pmid	NOUN
dpc-2120	150	2	:	:	PUNCT
dpc-2120	150	3	30521060	30521060	NUM
dpc-2120	150	4	.	.	PUNCT
dpc-2120	151	1	3	3	X
dpc-2120	151	2	.	.	X
dpc-2120	151	3	langan	langan	PROPN
dpc-2120	151	4	sm	sm	PROPN
dpc-2120	151	5	,	,	PUNCT
dpc-2120	151	6	irvine	irvine	PROPN
dpc-2120	151	7	ad	ad	NOUN
dpc-2120	151	8	,	,	PUNCT
dpc-2120	151	9	weidinger	weidinger	NOUN
dpc-2120	151	10	s.	s.	PROPN
dpc-2120	151	11	atopic	atopic	PROPN
dpc-2120	151	12	dermatitis	dermatitis	PROPN
dpc-2120	151	13	.	.	PUNCT
dpc-2120	152	1	lancet	lancet	PROPN
dpc-2120	152	2	.	.	PUNCT
dpc-2120	153	1	2020	2020	NUM
dpc-2120	153	2	;	;	PUNCT
dpc-2120	153	3	396(10247):345	396(10247):345	NUM
dpc-2120	153	4	-	-	SYM
dpc-2120	153	5	360	360	NUM
dpc-2120	153	6	.	.	PUNCT
dpc-2120	154	1	doi	doi	NOUN
dpc-2120	154	2	:	:	PUNCT
dpc-2120	154	3	10.1016	10.1016	NUM
dpc-2120	154	4	/	/	SYM
dpc-2120	154	5	s01406736(20)31286	s01406736(20)31286	PROPN
dpc-2120	154	6	-	-	PUNCT
dpc-2120	154	7	1	1	NUM
dpc-2120	154	8	.	.	NOUN
dpc-2120	154	9	4	4	NUM
dpc-2120	154	10	.	.	PUNCT
dpc-2120	154	11	paternoster	paternoster	PROPN
dpc-2120	154	12	l	l	PROPN
dpc-2120	154	13	,	,	PUNCT
dpc-2120	154	14	standl	standl	PROPN
dpc-2120	154	15	m	m	NOUN
dpc-2120	154	16	,	,	PUNCT
dpc-2120	154	17	waage	waage	NOUN
dpc-2120	154	18	j	j	PROPN
dpc-2120	154	19	,	,	PUNCT
dpc-2120	154	20	et	et	PROPN
dpc-2120	154	21	al	al	PROPN
dpc-2120	154	22	.	.	PUNCT
dpc-2120	155	1	multi	multi	ADJ
dpc-2120	155	2	-	-	NOUN
dpc-2120	155	3	ancestry	ancestry	NOUN
dpc-2120	155	4	genome	genome	NOUN
dpc-2120	155	5	-	-	PUNCT
dpc-2120	155	6	wide	wide	ADJ
dpc-2120	155	7	association	association	NOUN
dpc-2120	155	8	study	study	NOUN
dpc-2120	155	9	of	of	ADP
dpc-2120	155	10	21,000	21,000	NUM
dpc-2120	155	11	cases	case	NOUN
dpc-2120	155	12	and	and	CCONJ
dpc-2120	155	13	95,000	95,000	NUM
dpc-2120	155	14	controls	control	NOUN
dpc-2120	155	15	identifies	identify	VERB
dpc-2120	155	16	new	new	ADJ
dpc-2120	155	17	risk	risk	NOUN
dpc-2120	155	18	loci	loci	NOUN
dpc-2120	155	19	for	for	ADP
dpc-2120	155	20	atopic	atopic	NOUN
dpc-2120	155	21	dermatitis	dermatitis	NOUN
dpc-2120	155	22	.	.	PUNCT
dpc-2120	156	1	nat	nat	PROPN
dpc-2120	156	2	genet	genet	PROPN
dpc-2120	156	3	.	.	PUNCT
dpc-2120	157	1	2015	2015	NUM
dpc-2120	157	2	;	;	PUNCT
dpc-2120	157	3	47(12	47(12	NUM
dpc-2120	157	4	):	):	PUNCT
dpc-2120	157	5	1449	1449	NUM
dpc-2120	157	6	-	-	SYM
dpc-2120	157	7	1456	1456	NUM
dpc-2120	157	8	.	.	PUNCT
dpc-2120	158	1	doi	doi	NOUN
dpc-2120	158	2	:	:	PUNCT
dpc-2120	158	3	10.1038	10.1038	NUM
dpc-2120	158	4	/	/	SYM
dpc-2120	158	5	ng.3424	ng.3424	PROPN
dpc-2120	158	6	.	.	NOUN
dpc-2120	158	7	5	5	NUM
dpc-2120	158	8	.	.	NUM
dpc-2120	158	9	jungersted	jungerste	VERB
dpc-2120	158	10	jm	jm	PROPN
dpc-2120	158	11	,	,	PUNCT
dpc-2120	158	12	scheer	scheer	PROPN
dpc-2120	158	13	h	h	PROPN
dpc-2120	158	14	,	,	PUNCT
dpc-2120	158	15	mempel	mempel	PROPN
dpc-2120	158	16	m	m	PROPN
dpc-2120	158	17	,	,	PUNCT
dpc-2120	158	18	et	et	PROPN
dpc-2120	158	19	al	al	PROPN
dpc-2120	158	20	.	.	PROPN
dpc-2120	158	21	stratum	stratum	PROPN
dpc-2120	158	22	corneum	corneum	PROPN
dpc-2120	158	23	lipids	lipids	PROPN
dpc-2120	158	24	,	,	PUNCT
dpc-2120	158	25	skin	skin	NOUN
dpc-2120	158	26	barrier	barrier	NOUN
dpc-2120	158	27	function	function	NOUN
dpc-2120	158	28	and	and	CCONJ
dpc-2120	158	29	filaggrin	filaggrin	NOUN
dpc-2120	158	30	mutations	mutation	NOUN
dpc-2120	158	31	in	in	ADP
dpc-2120	158	32	patients	patient	NOUN
dpc-2120	158	33	with	with	ADP
dpc-2120	158	34	atopic	atopic	NOUN
dpc-2120	158	35	eczema	eczema	NOUN
dpc-2120	158	36	.	.	PUNCT
dpc-2120	159	1	allergy	allergy	NOUN
dpc-2120	159	2	.	.	PUNCT
dpc-2120	160	1	2010;65(7):911	2010;65(7):911	NUM
dpc-2120	160	2	-	-	SYM
dpc-2120	160	3	8	8	NUM
dpc-2120	160	4	.	.	PUNCT
dpc-2120	161	1	doi	doi	NOUN
dpc-2120	161	2	:	:	PUNCT
dpc-2120	161	3	10.1111	10.1111	NUM
dpc-2120	161	4	/	/	SYM
dpc-2120	161	5	j.13989995.2010.02326.x	j.13989995.2010.02326.x	PROPN
dpc-2120	161	6	.	.	PUNCT
dpc-2120	162	1	pmid	pmid	NOUN
dpc-2120	162	2	:	:	PUNCT
dpc-2120	162	3	20132155	20132155	NUM
dpc-2120	162	4	.	.	PUNCT
dpc-2120	163	1	6	6	X
dpc-2120	163	2	.	.	X
dpc-2120	163	3	geoghegan	geoghegan	PROPN
dpc-2120	163	4	ja	ja	PROPN
dpc-2120	163	5	,	,	PUNCT
dpc-2120	163	6	irvine	irvine	PROPN
dpc-2120	163	7	ad	ad	NOUN
dpc-2120	163	8	,	,	PUNCT
dpc-2120	163	9	foster	foster	PROPN
dpc-2120	163	10	tj	tj	PROPN
dpc-2120	163	11	.	.	PROPN
dpc-2120	163	12	staphylococcus	staphylococcus	NOUN
dpc-2120	163	13	aureus	aureus	PROPN
dpc-2120	163	14	and	and	CCONJ
dpc-2120	163	15	atopic	atopic	NOUN
dpc-2120	163	16	dermatitis	dermatitis	NOUN
dpc-2120	163	17	:	:	PUNCT
dpc-2120	163	18	a	a	DET
dpc-2120	163	19	complex	complex	ADJ
dpc-2120	163	20	and	and	CCONJ
dpc-2120	163	21	evolving	evolve	VERB
dpc-2120	163	22	relationship	relationship	NOUN
dpc-2120	163	23	.	.	PUNCT
dpc-2120	164	1	trends	trend	NOUN
dpc-2120	164	2	microbiol	microbiol	PROPN
dpc-2120	164	3	.	.	PUNCT
dpc-2120	165	1	2018;26(6):484	2018;26(6):484	NOUN
dpc-2120	165	2	-	-	SYM
dpc-2120	165	3	497	497	NUM
dpc-2120	165	4	.	.	PUNCT
dpc-2120	166	1	doi	doi	NOUN
dpc-2120	166	2	:	:	PUNCT
dpc-2120	166	3	10.1016	10.1016	NUM
dpc-2120	166	4	/	/	SYM
dpc-2120	166	5	j.	j.	PROPN
dpc-2120	167	1	tim.2017.11.008.pmid	tim.2017.11.008.pmid	PROPN
dpc-2120	167	2	:	:	PUNCT
dpc-2120	167	3	29233606	29233606	NUM
dpc-2120	167	4	.	.	PUNCT
dpc-2120	168	1	7	7	X
dpc-2120	168	2	.	.	X
dpc-2120	168	3	ho	ho	PROPN
dpc-2120	168	4	ic	ic	PROPN
dpc-2120	168	5	,	,	PUNCT
dpc-2120	168	6	miaw	miaw	PROPN
dpc-2120	168	7	sc	sc	PROPN
dpc-2120	168	8	.	.	PUNCT
dpc-2120	168	9	regulation	regulation	NOUN
dpc-2120	168	10	of	of	ADP
dpc-2120	168	11	il-4	il-4	NOUN
dpc-2120	168	12	expression	expression	NOUN
dpc-2120	168	13	in	in	ADP
dpc-2120	168	14	immunity	immunity	NOUN
dpc-2120	168	15	and	and	CCONJ
dpc-2120	168	16	diseases	disease	NOUN
dpc-2120	168	17	.	.	PUNCT
dpc-2120	169	1	adv	adv	PROPN
dpc-2120	169	2	exp	exp	PROPN
dpc-2120	169	3	med	med	PROPN
dpc-2120	169	4	biol.2016	biol.2016	PROPN
dpc-2120	169	5	;	;	PUNCT
dpc-2120	169	6	941	941	NUM
dpc-2120	169	7	:	:	PUNCT
dpc-2120	169	8	31	31	NUM
dpc-2120	169	9	-	-	SYM
dpc-2120	169	10	77	77	NUM
dpc-2120	169	11	.	.	PUNCT
dpc-2120	170	1	doi	doi	NOUN
dpc-2120	170	2	:	:	PUNCT
dpc-2120	170	3	10.1007/978	10.1007/978	NUM
dpc-2120	170	4	-	-	SYM
dpc-2120	170	5	94	94	NUM
dpc-2120	170	6	-	-	PUNCT
dpc-2120	170	7	024	024	NUM
dpc-2120	170	8	-	-	PUNCT
dpc-2120	170	9	0921	0921	NUM
dpc-2120	170	10	-	-	PUNCT
dpc-2120	170	11	5_3	5_3	NUM
dpc-2120	170	12	.	.	PUNCT
dpc-2120	171	1	pmid	pmid	NOUN
dpc-2120	171	2	:	:	PUNCT
dpc-2120	171	3	27734408	27734408	NUM
dpc-2120	171	4	.	.	PUNCT
dpc-2120	172	1	8	8	X
dpc-2120	172	2	.	.	X
dpc-2120	172	3	gandhi	gandhi	PROPN
dpc-2120	172	4	na	na	PROPN
dpc-2120	172	5	,	,	PUNCT
dpc-2120	172	6	bennett	bennett	PROPN
dpc-2120	172	7	bl	bl	PROPN
dpc-2120	172	8	,	,	PUNCT
dpc-2120	172	9	graham	graham	PROPN
dpc-2120	172	10	nmh	nmh	PROPN
dpc-2120	172	11	,	,	PUNCT
dpc-2120	172	12	pirozzi	pirozzi	NOUN
dpc-2120	172	13	g	g	PROPN
dpc-2120	172	14	,	,	PUNCT
dpc-2120	172	15	stahl	stahl	PROPN
dpc-2120	172	16	n	n	CCONJ
dpc-2120	172	17	,	,	PUNCT
dpc-2120	172	18	yancopoulos	yancopoulos	PROPN
dpc-2120	172	19	gd	gd	NOUN
dpc-2120	172	20	.	.	PUNCT
dpc-2120	173	1	targeting	target	VERB
dpc-2120	173	2	key	key	ADJ
dpc-2120	173	3	proximal	proximal	ADJ
dpc-2120	173	4	drivers	driver	NOUN
dpc-2120	173	5	of	of	ADP
dpc-2120	173	6	type	type	NOUN
dpc-2120	173	7	2	2	NUM
dpc-2120	173	8	inflammation	inflammation	NOUN
dpc-2120	173	9	in	in	ADP
dpc-2120	173	10	disease	disease	NOUN
dpc-2120	173	11	.	.	PUNCT
dpc-2120	174	1	nature	nature	NOUN
dpc-2120	174	2	reviews	review	VERB
dpc-2120	174	3	drug	drug	NOUN
dpc-2120	174	4	discovery	discovery	NOUN
dpc-2120	174	5	.	.	PUNCT
dpc-2120	175	1	2016;15(1):3550	2016;15(1):3550	NUM
dpc-2120	175	2	.	.	PUNCT
dpc-2120	175	3	doi	doi	NOUN
dpc-2120	175	4	:	:	PUNCT
dpc-2120	175	5	10.1038	10.1038	NUM
dpc-2120	175	6	/	/	SYM
dpc-2120	175	7	nrd4624.pmid	nrd4624.pmid	NOUN
dpc-2120	175	8	:	:	PUNCT
dpc-2120	175	9	26471366	26471366	NUM
dpc-2120	175	10	.	.	PUNCT
dpc-2120	176	1	9	9	X
dpc-2120	176	2	.	.	X
dpc-2120	176	3	beck	beck	PROPN
dpc-2120	176	4	la	la	PROPN
dpc-2120	176	5	,	,	PUNCT
dpc-2120	176	6	thaçi	thaçi	NOUN
dpc-2120	176	7	d	d	PROPN
dpc-2120	176	8	,	,	PUNCT
dpc-2120	176	9	hamilton	hamilton	PROPN
dpc-2120	176	10	jd	jd	PROPN
dpc-2120	176	11	,	,	PUNCT
dpc-2120	176	12	et	et	PROPN
dpc-2120	176	13	al	al	PROPN
dpc-2120	176	14	.	.	PROPN
dpc-2120	176	15	dupilumab	dupilumab	NOUN
dpc-2120	176	16	treatment	treatment	NOUN
dpc-2120	176	17	in	in	ADP
dpc-2120	176	18	adults	adult	NOUN
dpc-2120	176	19	with	with	ADP
dpc-2120	176	20	moderate	moderate	ADJ
dpc-2120	176	21	-	-	PUNCT
dpc-2120	176	22	to	to	ADP
dpc-2120	176	23	-	-	PUNCT
dpc-2120	176	24	severe	severe	ADJ
dpc-2120	176	25	atopic	atopic	NOUN
dpc-2120	176	26	dermatitis	dermatitis	NOUN
dpc-2120	176	27	.	.	PUNCT
dpc-2120	177	1	n	n	PROPN
dpc-2120	177	2	engl	engl	PROPN
dpc-2120	177	3	j	j	PROPN
dpc-2120	177	4	med	med	PROPN
dpc-2120	177	5	.	.	PROPN
dpc-2120	177	6	2014	2014	NUM
dpc-2120	177	7	;	;	PUNCT
dpc-2120	178	1	371(2):130	371(2):130	NOUN
dpc-2120	178	2	-	-	SYM
dpc-2120	178	3	9	9	NUM
dpc-2120	178	4	.	.	PUNCT
dpc-2120	178	5	doi	doi	NOUN
dpc-2120	178	6	:	:	PUNCT
dpc-2120	178	7	10.1056	10.1056	NUM
dpc-2120	178	8	/	/	SYM
dpc-2120	178	9	nejmoa1314768	nejmoa1314768	NOUN
dpc-2120	178	10	.	.	PUNCT
dpc-2120	179	1	pmid	pmid	NOUN
dpc-2120	179	2	:	:	PUNCT
dpc-2120	179	3	25006719	25006719	NUM
dpc-2120	179	4	.	.	PUNCT
dpc-2120	180	1	10	10	NUM
dpc-2120	180	2	.	.	X
dpc-2120	181	1	wenzel	wenzel	PROPN
dpc-2120	181	2	s	s	PROPN
dpc-2120	181	3	,	,	PUNCT
dpc-2120	181	4	ford	ford	PROPN
dpc-2120	181	5	l	l	PROPN
dpc-2120	181	6	,	,	PUNCT
dpc-2120	181	7	pearlman	pearlman	PROPN
dpc-2120	181	8	d	d	PROPN
dpc-2120	181	9	,	,	PUNCT
dpc-2120	181	10	et	et	PROPN
dpc-2120	181	11	al	al	PROPN
dpc-2120	181	12	.	.	PROPN
dpc-2120	181	13	dupilumab	dupilumab	NOUN
dpc-2120	181	14	in	in	ADP
dpc-2120	181	15	persistent	persistent	ADJ
dpc-2120	181	16	asthma	asthma	NOUN
dpc-2120	181	17	with	with	ADP
dpc-2120	181	18	elevated	elevated	ADJ
dpc-2120	181	19	eosinophil	eosinophil	ADJ
dpc-2120	181	20	levels	level	NOUN
dpc-2120	181	21	.	.	PUNCT
dpc-2120	182	1	new	new	PROPN
dpc-2120	182	2	england	england	PROPN
dpc-2120	182	3	journal	journal	PROPN
dpc-2120	182	4	of	of	ADP
dpc-2120	182	5	medicine	medicine	NOUN
dpc-2120	182	6	.	.	PUNCT
dpc-2120	183	1	2013;368(26	2013;368(26	PROPN
dpc-2120	183	2	):	):	PUNCT
dpc-2120	183	3	2455	2455	NUM
dpc-2120	183	4	-	-	SYM
dpc-2120	183	5	2466	2466	NUM
dpc-2120	183	6	.	.	PUNCT
dpc-2120	184	1	doi	doi	NOUN
dpc-2120	184	2	:	:	PUNCT
dpc-2120	184	3	10.1056	10.1056	NUM
dpc-2120	184	4	/	/	SYM
dpc-2120	184	5	nejmoa1304048	nejmoa1304048	PROPN
dpc-2120	184	6	.	.	PUNCT
dpc-2120	185	1	pmid	pmid	NOUN
dpc-2120	185	2	:	:	PUNCT
dpc-2120	185	3	23688323	23688323	NUM
dpc-2120	185	4	.	.	PUNCT
dpc-2120	186	1	11	11	NUM
dpc-2120	186	2	.	.	PUNCT
dpc-2120	187	1	simpson	simpson	PROPN
dpc-2120	187	2	el	el	PROPN
dpc-2120	187	3	,	,	PUNCT
dpc-2120	187	4	bieber	bieber	PROPN
dpc-2120	187	5	t	t	PROPN
dpc-2120	187	6	,	,	PUNCT
dpc-2120	187	7	guttman	guttman	ADJ
dpc-2120	187	8	-	-	PUNCT
dpc-2120	187	9	yassky	yassky	NOUN
dpc-2120	187	10	e	e	NOUN
dpc-2120	187	11	,	,	PUNCT
dpc-2120	187	12	et	et	PROPN
dpc-2120	187	13	al	al	PROPN
dpc-2120	187	14	.	.	PROPN
dpc-2120	188	1	two	two	NUM
dpc-2120	188	2	phase	phase	NOUN
dpc-2120	188	3	3	3	NUM
dpc-2120	188	4	trials	trial	NOUN
dpc-2120	188	5	of	of	ADP
dpc-2120	188	6	dupilumab	dupilumab	NOUN
dpc-2120	188	7	versus	versus	ADP
dpc-2120	188	8	placebo	placebo	NOUN
dpc-2120	188	9	in	in	ADP
dpc-2120	188	10	atopic	atopic	NOUN
dpc-2120	188	11	dermatitis	dermatitis	NOUN
dpc-2120	188	12	.	.	PUNCT
dpc-2120	189	1	new	new	PROPN
dpc-2120	189	2	england	england	PROPN
dpc-2120	189	3	journal	journal	PROPN
dpc-2120	189	4	of	of	ADP
dpc-2120	189	5	medicine	medicine	NOUN
dpc-2120	189	6	.	.	PUNCT
dpc-2120	190	1	2016;375(24):2335	2016;375(24):2335	NUM
dpc-2120	190	2	-	-	SYM
dpc-2120	190	3	2348	2348	NUM
dpc-2120	190	4	.	.	PUNCT
dpc-2120	191	1	doi	doi	NOUN
dpc-2120	191	2	:	:	PUNCT
dpc-2120	191	3	10.1056/	10.1056/	NUM
dpc-2120	191	4	nejmoa1610020	nejmoa1610020	PROPN
dpc-2120	191	5	.	.	PUNCT
dpc-2120	192	1	pmid	pmid	NOUN
dpc-2120	192	2	:	:	PUNCT
dpc-2120	192	3	27690741	27690741	NUM
dpc-2120	192	4	.	.	PUNCT
dpc-2120	193	1	12	12	NUM
dpc-2120	193	2	.	.	PUNCT
dpc-2120	193	3	simpson	simpson	PROPN
dpc-2120	193	4	el	el	PROPN
dpc-2120	193	5	,	,	PUNCT
dpc-2120	193	6	paller	paller	NOUN
dpc-2120	193	7	as	as	ADP
dpc-2120	193	8	,	,	PUNCT
dpc-2120	193	9	siegfried	siegfried	PROPN
dpc-2120	193	10	ec	ec	PROPN
dpc-2120	193	11	,	,	PUNCT
dpc-2120	193	12	et	et	PROPN
dpc-2120	193	13	al	al	PROPN
dpc-2120	193	14	.	.	PROPN
dpc-2120	193	15	efficacy	efficacy	NOUN
dpc-2120	193	16	and	and	CCONJ
dpc-2120	193	17	safety	safety	NOUN
dpc-2120	193	18	of	of	ADP
dpc-2120	193	19	dupilumab	dupilumab	NOUN
dpc-2120	193	20	in	in	ADP
dpc-2120	193	21	adolescents	adolescent	NOUN
dpc-2120	193	22	with	with	ADP
dpc-2120	193	23	uncontrolled	uncontrolled	ADJ
dpc-2120	193	24	moderate	moderate	ADJ
dpc-2120	193	25	to	to	ADP
dpc-2120	193	26	severe	severe	ADJ
dpc-2120	193	27	atopic	atopic	NOUN
dpc-2120	193	28	dermatitis	dermatitis	NOUN
dpc-2120	193	29	:	:	PUNCT
dpc-2120	193	30	a	a	DET
dpc-2120	193	31	phase	phase	NOUN
dpc-2120	193	32	3	3	NUM
dpc-2120	193	33	randomized	randomize	VERB
dpc-2120	193	34	clinical	clinical	ADJ
dpc-2120	193	35	trial	trial	NOUN
dpc-2120	193	36	.	.	PUNCT
dpc-2120	194	1	jama	jama	PROPN
dpc-2120	194	2	dermatol	dermatol	NOUN
dpc-2120	194	3	.	.	PUNCT
dpc-2120	195	1	2020;156(1	2020;156(1	NUM
dpc-2120	195	2	):	):	PUNCT
dpc-2120	195	3	44	44	NUM
dpc-2120	195	4	-	-	SYM
dpc-2120	195	5	56	56	NUM
dpc-2120	195	6	.	.	PUNCT
dpc-2120	196	1	doi	doi	NOUN
dpc-2120	196	2	:	:	PUNCT
dpc-2120	196	3	10.1001	10.1001	NUM
dpc-2120	196	4	/	/	SYM
dpc-2120	196	5	jamadermatol.2019.3336	jamadermatol.2019.3336	PROPN
dpc-2120	196	6	.	.	PUNCT
dpc-2120	197	1	pmid	pmid	NOUN
dpc-2120	197	2	:	:	PUNCT
dpc-2120	197	3	31693077	31693077	NUM
dpc-2120	197	4	.	.	PUNCT
dpc-2120	198	1	pmcid	pmcid	NOUN
dpc-2120	198	2	:	:	PUNCT
dpc-2120	198	3	pmc6865265	pmc6865265	VERB
dpc-2120	198	4	.	.	PUNCT
dpc-2120	199	1	13	13	NUM
dpc-2120	199	2	.	.	X
dpc-2120	199	3	paller	paller	NOUN
dpc-2120	199	4	as	as	ADP
dpc-2120	199	5	,	,	PUNCT
dpc-2120	199	6	siegfried	siegfried	PROPN
dpc-2120	199	7	ec	ec	PROPN
dpc-2120	199	8	,	,	PUNCT
dpc-2120	199	9	thaçi	thaçi	PROPN
dpc-2120	199	10	d	d	PROPN
dpc-2120	199	11	,	,	PUNCT
dpc-2120	199	12	et	et	PROPN
dpc-2120	199	13	al	al	PROPN
dpc-2120	199	14	.	.	PROPN
dpc-2120	199	15	efficacy	efficacy	NOUN
dpc-2120	199	16	and	and	CCONJ
dpc-2120	199	17	safety	safety	NOUN
dpc-2120	199	18	of	of	ADP
dpc-2120	199	19	dupilumab	dupilumab	NOUN
dpc-2120	199	20	with	with	ADP
dpc-2120	199	21	concomitant	concomitant	ADJ
dpc-2120	199	22	topical	topical	ADJ
dpc-2120	199	23	corticosteroids	corticosteroid	NOUN
dpc-2120	199	24	in	in	ADP
dpc-2120	199	25	children	child	NOUN
dpc-2120	199	26	6	6	NUM
dpc-2120	199	27	to	to	PART
dpc-2120	199	28	11	11	NUM
dpc-2120	199	29	 	 	SPACE
dpc-2120	199	30	years	year	NOUN
dpc-2120	199	31	old	old	ADJ
dpc-2120	199	32	with	with	ADP
dpc-2120	199	33	severe	severe	ADJ
dpc-2120	199	34	atopic	atopic	NOUN
dpc-2120	199	35	dermatitis	dermatitis	NOUN
dpc-2120	199	36	:	:	PUNCT
dpc-2120	199	37	a	a	DET
dpc-2120	199	38	randomized	randomized	ADJ
dpc-2120	199	39	,	,	PUNCT
dpc-2120	199	40	double	double	ADJ
dpc-2120	199	41	-	-	PUNCT
dpc-2120	199	42	blinded	blind	VERB
dpc-2120	199	43	,	,	PUNCT
dpc-2120	199	44	placebo	placebo	NOUN
dpc-2120	199	45	-	-	PUNCT
dpc-2120	199	46	controlled	control	VERB
dpc-2120	199	47	phase	phase	NOUN
dpc-2120	199	48	3	3	NUM
dpc-2120	199	49	trial	trial	NOUN
dpc-2120	199	50	.	.	PUNCT
dpc-2120	200	1	j	j	PROPN
dpc-2120	200	2	am	be	AUX
dpc-2120	200	3	acad	acad	ADJ
dpc-2120	200	4	dermatol	dermatol	NOUN
dpc-2120	200	5	.	.	PUNCT
dpc-2120	201	1	2020;83(5):1282	2020;83(5):1282	PROPN
dpc-2120	201	2	-	-	SYM
dpc-2120	201	3	1293	1293	NUM
dpc-2120	201	4	.	.	PUNCT
dpc-2120	202	1	doi	doi	NOUN
dpc-2120	202	2	:	:	PUNCT
dpc-2120	202	3	10.1016	10.1016	NUM
dpc-2120	202	4	/	/	SYM
dpc-2120	202	5	j.jaad.2020.06.054	j.jaad.2020.06.054	PROPN
dpc-2120	202	6	.	.	PUNCT
dpc-2120	203	1	pmid	pmid	NOUN
dpc-2120	203	2	:	:	PUNCT
dpc-2120	203	3	32574587	32574587	NUM
dpc-2120	203	4	.	.	PUNCT
dpc-2120	204	1	14	14	NUM
dpc-2120	204	2	.	.	X
dpc-2120	204	3	paller	paller	NOUN
dpc-2120	204	4	as	as	ADP
dpc-2120	204	5	,	,	PUNCT
dpc-2120	204	6	siegfried	siegfried	PROPN
dpc-2120	204	7	ec	ec	PROPN
dpc-2120	204	8	,	,	PUNCT
dpc-2120	204	9	simpson	simpson	PROPN
dpc-2120	204	10	el	el	PROPN
dpc-2120	204	11	,	,	PUNCT
dpc-2120	204	12	et	et	PROPN
dpc-2120	204	13	al	al	PROPN
dpc-2120	204	14	.	.	PUNCT
dpc-2120	205	1	a	a	DET
dpc-2120	205	2	phase	phase	NOUN
dpc-2120	205	3	2	2	NUM
dpc-2120	205	4	,	,	PUNCT
dpc-2120	205	5	open	open	ADJ
dpc-2120	205	6	-	-	PUNCT
dpc-2120	205	7	label	label	NOUN
dpc-2120	205	8	study	study	NOUN
dpc-2120	205	9	of	of	ADP
dpc-2120	205	10	single	single	ADJ
dpc-2120	205	11	-	-	PUNCT
dpc-2120	205	12	dose	dose	NOUN
dpc-2120	205	13	dupilumab	dupilumab	NOUN
dpc-2120	205	14	in	in	ADP
dpc-2120	205	15	children	child	NOUN
dpc-2120	205	16	aged	age	VERB
dpc-2120	205	17	6	6	NUM
dpc-2120	205	18	 	 	SPACE
dpc-2120	205	19	months	month	NOUN
dpc-2120	205	20	to	to	ADP
dpc-2120	205	21	<	<	X
dpc-2120	205	22	6	6	NUM
dpc-2120	205	23	 	 	SPACE
dpc-2120	205	24	years	year	NOUN
dpc-2120	205	25	with	with	ADP
dpc-2120	205	26	severe	severe	ADJ
dpc-2120	205	27	uncontrolled	uncontrolled	ADJ
dpc-2120	205	28	atopic	atopic	NOUN
dpc-2120	205	29	dermatitis	dermatitis	NOUN
dpc-2120	205	30	:	:	PUNCT
dpc-2120	205	31	pharmacokinetics	pharmacokinetic	NOUN
dpc-2120	205	32	,	,	PUNCT
dpc-2120	205	33	safety	safety	NOUN
dpc-2120	205	34	and	and	CCONJ
dpc-2120	205	35	efficacy	efficacy	NOUN
dpc-2120	205	36	.	.	PUNCT
dpc-2120	206	1	j	j	PROPN
dpc-2120	206	2	eur	eur	PROPN
dpc-2120	206	3	acad	acad	PROPN
dpc-2120	206	4	dermatol	dermatol	NOUN
dpc-2120	206	5	venereol	venereol	NOUN
dpc-2120	206	6	.	.	PUNCT
dpc-2120	207	1	2021;35(2):464	2021;35(2):464	NUM
dpc-2120	207	2	-	-	PUNCT
dpc-2120	207	3	475	475	NUM
dpc-2120	207	4	.	.	PUNCT
dpc-2120	208	1	doi	doi	NOUN
dpc-2120	208	2	:	:	PUNCT
dpc-2120	208	3	10.1111	10.1111	NUM
dpc-2120	208	4	/	/	SYM
dpc-2120	208	5	jdv.16928	jdv.16928	ADJ
dpc-2120	208	6	.	.	PUNCT
dpc-2120	209	1	pmid	pmid	NOUN
dpc-2120	209	2	:	:	PUNCT
dpc-2120	209	3	32893393	32893393	NUM
dpc-2120	209	4	.	.	PUNCT
dpc-2120	210	1	pmcid	pmcid	ADJ
dpc-2120	210	2	:	:	PUNCT
dpc-2120	210	3	pmc7894166	pmc7894166	ADJ
dpc-2120	210	4	.	.	PUNCT
dpc-2120	211	1	15	15	X
dpc-2120	211	2	.	.	PUNCT
dpc-2120	212	1	zheng	zheng	PROPN
dpc-2120	212	2	t	t	PROPN
dpc-2120	212	3	,	,	PUNCT
dpc-2120	212	4	oh	oh	INTJ
dpc-2120	212	5	mh	mh	PROPN
dpc-2120	212	6	,	,	PUNCT
dpc-2120	212	7	oh	oh	INTJ
dpc-2120	212	8	sy	sy	INTJ
dpc-2120	212	9	,	,	PUNCT
dpc-2120	212	10	schroeder	schroeder	PROPN
dpc-2120	212	11	jt	jt	PROPN
dpc-2120	212	12	,	,	PUNCT
dpc-2120	212	13	glick	glick	PROPN
dpc-2120	212	14	ab	ab	PROPN
dpc-2120	212	15	,	,	PUNCT
dpc-2120	212	16	zhu	zhu	PROPN
dpc-2120	212	17	z.	z.	NOUN
dpc-2120	212	18	transgenic	transgenic	NOUN
dpc-2120	212	19	expression	expression	NOUN
dpc-2120	212	20	of	of	ADP
dpc-2120	212	21	interleukin-13	interleukin-13	PROPN
dpc-2120	212	22	in	in	ADP
dpc-2120	212	23	the	the	DET
dpc-2120	212	24	skin	skin	NOUN
dpc-2120	212	25	induces	induce	VERB
dpc-2120	212	26	a	a	DET
dpc-2120	212	27	pruritic	pruritic	ADJ
dpc-2120	212	28	dermatitis	dermatitis	NOUN
dpc-2120	212	29	and	and	CCONJ
dpc-2120	212	30	skin	skin	NOUN
dpc-2120	212	31	remodeling	remodeling	NOUN
dpc-2120	212	32	.	.	PUNCT
dpc-2120	213	1	j	j	PROPN
dpc-2120	213	2	invest	invest	VERB
dpc-2120	213	3	dermatol	dermatol	NOUN
dpc-2120	213	4	.	.	PUNCT
dpc-2120	214	1	2009;129(3	2009;129(3	NUM
dpc-2120	214	2	):	):	PUNCT
dpc-2120	214	3	742	742	NUM
dpc-2120	214	4	-	-	SYM
dpc-2120	214	5	51	51	NUM
dpc-2120	214	6	.	.	PUNCT
dpc-2120	214	7	doi	doi	NOUN
dpc-2120	214	8	:	:	PUNCT
dpc-2120	214	9	10.1038	10.1038	NUM
dpc-2120	214	10	/	/	SYM
dpc-2120	214	11	jid.2008.295	jid.2008.295	PROPN
dpc-2120	214	12	.	.	PUNCT
dpc-2120	215	1	pmid	pmid	NOUN
dpc-2120	215	2	:	:	PUNCT
dpc-2120	215	3	18830273	18830273	NUM
dpc-2120	215	4	.	.	PUNCT
dpc-2120	216	1	pmcid	pmcid	NOUN
dpc-2120	216	2	:	:	PUNCT
dpc-2120	217	1	pmc4356214	pmc4356214	ADJ
dpc-2120	217	2	.	.	PUNCT
dpc-2120	218	1	16	16	NUM
dpc-2120	218	2	.	.	PUNCT
dpc-2120	218	3	tazawa	tazawa	PROPN
dpc-2120	218	4	t	t	PROPN
dpc-2120	218	5	,	,	PUNCT
dpc-2120	218	6	sugiura	sugiura	NOUN
dpc-2120	218	7	h	h	PROPN
dpc-2120	218	8	,	,	PUNCT
dpc-2120	218	9	sugiura	sugiura	NOUN
dpc-2120	218	10	y	y	PROPN
dpc-2120	218	11	,	,	PUNCT
dpc-2120	218	12	uehara	uehara	PROPN
dpc-2120	218	13	m.	m.	PROPN
dpc-2120	218	14	relative	relative	ADJ
dpc-2120	218	15	importance	importance	NOUN
dpc-2120	218	16	of	of	ADP
dpc-2120	218	17	il-4	il-4	NOUN
dpc-2120	218	18	and	and	CCONJ
dpc-2120	218	19	il-13	il-13	ADP
dpc-2120	218	20	in	in	ADP
dpc-2120	218	21	lesional	lesional	ADJ
dpc-2120	218	22	skin	skin	NOUN
dpc-2120	218	23	of	of	ADP
dpc-2120	218	24	atopic	atopic	NOUN
dpc-2120	218	25	dermatitis	dermatitis	NOUN
dpc-2120	218	26	.	.	PUNCT
dpc-2120	219	1	arch	arch	ADJ
dpc-2120	219	2	dermatol	dermatol	NOUN
dpc-2120	219	3	res	re	NOUN
dpc-2120	219	4	.	.	PUNCT
dpc-2120	220	1	2004;295(11	2004;295(11	NOUN
dpc-2120	220	2	):	):	PUNCT
dpc-2120	220	3	459	459	NUM
dpc-2120	220	4	-	-	SYM
dpc-2120	220	5	64	64	NUM
dpc-2120	220	6	.	.	PUNCT
dpc-2120	221	1	doi	doi	NOUN
dpc-2120	221	2	:	:	PUNCT
dpc-2120	221	3	10.1007	10.1007	NUM
dpc-2120	221	4	/	/	SYM
dpc-2120	221	5	s00403004	s00403004	NOUN
dpc-2120	221	6	-	-	PUNCT
dpc-2120	221	7	0455	0455	NUM
dpc-2120	221	8	-	-	PUNCT
dpc-2120	221	9	6	6	NUM
dpc-2120	221	10	.	.	PUNCT
dpc-2120	222	1	pmid	pmid	NOUN
dpc-2120	222	2	:	:	PUNCT
dpc-2120	222	3	15014952	15014952	NUM
dpc-2120	222	4	.	.	PUNCT
dpc-2120	223	1	17	17	NUM
dpc-2120	223	2	.	.	PUNCT
dpc-2120	224	1	li	li	PROPN
dpc-2120	224	2	r	r	PROPN
dpc-2120	224	3	,	,	PUNCT
dpc-2120	224	4	hadi	hadi	PROPN
dpc-2120	224	5	s	s	PROPN
dpc-2120	224	6	,	,	PUNCT
dpc-2120	224	7	guttman	guttman	ADJ
dpc-2120	224	8	-	-	PUNCT
dpc-2120	224	9	yassky	yassky	NOUN
dpc-2120	224	10	e.	e.	PROPN
dpc-2120	224	11	current	current	PROPN
dpc-2120	224	12	and	and	CCONJ
dpc-2120	224	13	emerging	emerge	VERB
dpc-2120	224	14	biologic	biologic	NOUN
dpc-2120	224	15	and	and	CCONJ
dpc-2120	224	16	small	small	ADJ
dpc-2120	224	17	molecule	molecule	NOUN
dpc-2120	224	18	therapies	therapy	NOUN
dpc-2120	224	19	for	for	ADP
dpc-2120	224	20	atopic	atopic	NOUN
dpc-2120	224	21	dermatitis	dermatitis	NOUN
dpc-2120	224	22	.	.	PUNCT
dpc-2120	225	1	expert	expert	NOUN
dpc-2120	225	2	opin	opin	NOUN
dpc-2120	225	3	biol	biol	NOUN
dpc-2120	225	4	ther	ther	ADV
dpc-2120	225	5	.	.	PUNCT
dpc-2120	226	1	2019;19(4):367	2019;19(4):367	NUM
dpc-2120	226	2	-	-	SYM
dpc-2120	226	3	380	380	NUM
dpc-2120	226	4	.	.	PUNCT
dpc-2120	227	1	doi	doi	NOUN
dpc-2120	227	2	:	:	PUNCT
dpc-2120	227	3	10.1080/14712598.2019.1573422	10.1080/14712598.2019.1573422	NUM
dpc-2120	227	4	.	.	PUNCT
dpc-2120	228	1	pmid	pmid	NOUN
dpc-2120	228	2	:	:	PUNCT
dpc-2120	228	3	30672355	30672355	NUM
dpc-2120	228	4	.	.	PUNCT
dpc-2120	229	1	18	18	NUM
dpc-2120	229	2	.	.	X
dpc-2120	229	3	worm	worm	PROPN
dpc-2120	229	4	m	m	PROPN
dpc-2120	229	5	,	,	PUNCT
dpc-2120	229	6	francuzik	francuzik	PROPN
dpc-2120	229	7	w	w	PROPN
dpc-2120	229	8	,	,	PUNCT
dpc-2120	229	9	kraft	kraft	NOUN
dpc-2120	229	10	m	m	PROPN
dpc-2120	229	11	,	,	PUNCT
dpc-2120	229	12	alexiou	alexiou	NOUN
dpc-2120	229	13	a.	a.	NOUN
dpc-2120	229	14	modern	modern	ADJ
dpc-2120	229	15	therapies	therapy	NOUN
dpc-2120	229	16	in	in	ADP
dpc-2120	229	17	atopic	atopic	NOUN
dpc-2120	229	18	dermatitis	dermatitis	NOUN
dpc-2120	229	19	:	:	PUNCT
dpc-2120	229	20	biologics	biologic	NOUN
dpc-2120	229	21	and	and	CCONJ
dpc-2120	229	22	small	small	ADJ
dpc-2120	229	23	molecule	molecule	NOUN
dpc-2120	229	24	drugs	drug	NOUN
dpc-2120	229	25	.	.	PUNCT
dpc-2120	230	1	j	j	PROPN
dpc-2120	230	2	dtsch	dtsch	PROPN
dpc-2120	230	3	dermatol	dermatol	NOUN
dpc-2120	230	4	ges	ge	NOUN
dpc-2120	230	5	.	.	PROPN
dpc-2120	230	6	2020;18(10	2020;18(10	NUM
dpc-2120	230	7	):	):	PUNCT
dpc-2120	230	8	1085	1085	NUM
dpc-2120	230	9	-	-	SYM
dpc-2120	230	10	1092	1092	NUM
dpc-2120	230	11	.	.	PUNCT
dpc-2120	231	1	doi	doi	NOUN
dpc-2120	231	2	:	:	PUNCT
dpc-2120	231	3	10.1111/	10.1111/	NUM
dpc-2120	231	4	ddg.14175	ddg.14175	NUM
dpc-2120	231	5	.	.	PROPN
dpc-2120	232	1	19	19	NUM
dpc-2120	232	2	.	.	PUNCT
dpc-2120	233	1	wollenberg	wollenberg	PROPN
dpc-2120	233	2	a	a	PROPN
dpc-2120	233	3	,	,	PUNCT
dpc-2120	233	4	blauvelt	blauvelt	PROPN
dpc-2120	233	5	a	a	DET
dpc-2120	233	6	,	,	PUNCT
dpc-2120	233	7	guttman	guttman	ADJ
dpc-2120	233	8	-	-	PUNCT
dpc-2120	233	9	yassky	yassky	NOUN
dpc-2120	233	10	e	e	NOUN
dpc-2120	233	11	,	,	PUNCT
dpc-2120	233	12	et	et	PROPN
dpc-2120	233	13	al	al	PROPN
dpc-2120	233	14	.	.	PROPN
dpc-2120	233	15	tralokinumab	tralokinumab	NOUN
dpc-2120	233	16	for	for	ADP
dpc-2120	233	17	moderate	moderate	ADJ
dpc-2120	233	18	-	-	PUNCT
dpc-2120	233	19	to	to	ADP
dpc-2120	233	20	-	-	PUNCT
dpc-2120	233	21	severe	severe	ADJ
dpc-2120	233	22	atopic	atopic	NOUN
dpc-2120	233	23	dermatitis	dermatitis	NOUN
dpc-2120	233	24	:	:	PUNCT
dpc-2120	233	25	results	result	VERB
dpc-2120	233	26	from	from	ADP
dpc-2120	233	27	two	two	NUM
dpc-2120	233	28	52	52	NUM
dpc-2120	233	29	-	-	PUNCT
dpc-2120	233	30	week	week	NOUN
dpc-2120	233	31	,	,	PUNCT
dpc-2120	233	32	randomized	randomize	VERB
dpc-2120	233	33	,	,	PUNCT
dpc-2120	233	34	double	double	ADJ
dpc-2120	233	35	-	-	PUNCT
dpc-2120	233	36	blind	blind	ADJ
dpc-2120	233	37	,	,	PUNCT
dpc-2120	233	38	multicentre	multicentre	NOUN
dpc-2120	233	39	,	,	PUNCT
dpc-2120	233	40	placebo	placebo	NOUN
dpc-2120	233	41	-	-	PUNCT
dpc-2120	233	42	controlled	control	VERB
dpc-2120	233	43	phase	phase	NOUN
dpc-2120	233	44	iii	iii	NUM
dpc-2120	233	45	trials	trial	NOUN
dpc-2120	233	46	(	(	PUNCT
dpc-2120	233	47	ecztra	ecztra	NOUN
dpc-2120	233	48	1	1	NUM
dpc-2120	233	49	and	and	CCONJ
dpc-2120	233	50	ecztra	ecztra	NOUN
dpc-2120	233	51	2	2	NUM
dpc-2120	233	52	)	)	PUNCT
dpc-2120	233	53	.	.	PUNCT
dpc-2120	234	1	br	br	PROPN
dpc-2120	234	2	j	j	PROPN
dpc-2120	234	3	dermatol	dermatol	NOUN
dpc-2120	234	4	.	.	PUNCT
dpc-2120	235	1	2021	2021	NUM
dpc-2120	235	2	;	;	PUNCT
dpc-2120	235	3	184(3	184(3	NUM
dpc-2120	235	4	):	):	PUNCT
dpc-2120	235	5	437	437	NUM
dpc-2120	235	6	-	-	SYM
dpc-2120	235	7	449	449	NUM
dpc-2120	235	8	.	.	PUNCT
dpc-2120	236	1	doi	doi	NOUN
dpc-2120	236	2	:	:	PUNCT
dpc-2120	236	3	10.1111	10.1111	NUM
dpc-2120	236	4	/	/	SYM
dpc-2120	236	5	bjd.19574	bjd.19574	NUM
dpc-2120	236	6	.	.	PUNCT
dpc-2120	237	1	pmid	pmid	NOUN
dpc-2120	237	2	:	:	PUNCT
dpc-2120	237	3	33000465	33000465	NUM
dpc-2120	237	4	.	.	PUNCT
dpc-2120	238	1	pmcid	pmcid	NOUN
dpc-2120	238	2	:	:	PUNCT
dpc-2120	238	3	pmc7986411	pmc7986411	ADJ
dpc-2120	238	4	.	.	PUNCT
dpc-2120	239	1	20	20	NUM
dpc-2120	239	2	.	.	X
dpc-2120	240	1	guttman	guttman	ADJ
dpc-2120	240	2	-	-	PUNCT
dpc-2120	240	3	yassky	yassky	NOUN
dpc-2120	240	4	e	e	NOUN
dpc-2120	240	5	,	,	PUNCT
dpc-2120	240	6	blauvelt	blauvelt	VERB
dpc-2120	240	7	a	a	PRON
dpc-2120	240	8	,	,	PUNCT
dpc-2120	240	9	eichenfield	eichenfield	PROPN
dpc-2120	240	10	lf	lf	PROPN
dpc-2120	240	11	,	,	PUNCT
dpc-2120	240	12	et	et	PROPN
dpc-2120	240	13	al	al	PROPN
dpc-2120	240	14	.	.	PROPN
dpc-2120	240	15	efficacy	efficacy	NOUN
dpc-2120	240	16	and	and	CCONJ
dpc-2120	240	17	safety	safety	NOUN
dpc-2120	240	18	of	of	ADP
dpc-2120	240	19	lebrikizumab	lebrikizumab	NOUN
dpc-2120	240	20	,	,	PUNCT
dpc-2120	240	21	a	a	DET
dpc-2120	240	22	high	high	ADJ
dpc-2120	240	23	-	-	PUNCT
dpc-2120	240	24	affinity	affinity	NOUN
dpc-2120	240	25	interleukin	interleukin	NOUN
dpc-2120	240	26	13	13	NUM
dpc-2120	240	27	inhibitor	inhibitor	NOUN
dpc-2120	240	28	,	,	PUNCT
dpc-2120	240	29	in	in	ADP
dpc-2120	240	30	adults	adult	NOUN
dpc-2120	240	31	with	with	ADP
dpc-2120	240	32	moderate	moderate	ADJ
dpc-2120	240	33	to	to	ADP
dpc-2120	240	34	severe	severe	ADJ
dpc-2120	240	35	atopic	atopic	NOUN
dpc-2120	240	36	dermatitis	dermatitis	NOUN
dpc-2120	240	37	:	:	PUNCT
dpc-2120	240	38	a	a	DET
dpc-2120	240	39	phase	phase	NOUN
dpc-2120	240	40	2b	2b	NOUN
dpc-2120	240	41	randomized	randomize	VERB
dpc-2120	240	42	clinical	clinical	ADJ
dpc-2120	240	43	trial	trial	NOUN
dpc-2120	240	44	.	.	PUNCT
dpc-2120	241	1	jama	jama	PROPN
dpc-2120	241	2	dermatol	dermatol	NOUN
dpc-2120	241	3	.	.	PUNCT
dpc-2120	242	1	2020;156(4):411420	2020;156(4):411420	NUM
dpc-2120	242	2	.	.	PUNCT
dpc-2120	243	1	doi	doi	NOUN
dpc-2120	243	2	:	:	PUNCT
dpc-2120	243	3	10.1001	10.1001	NUM
dpc-2120	243	4	/	/	SYM
dpc-2120	243	5	jamadermatol.2020.0079	jamadermatol.2020.0079	PROPN
dpc-2120	243	6	.	.	PUNCT
dpc-2120	244	1	pmid	pmid	PROPN
dpc-2120	244	2	:	:	PUNCT
dpc-2120	244	3	32101256	32101256	NUM
dpc-2120	244	4	.	.	PUNCT
dpc-2120	245	1	pmcid	pmcid	NOUN
dpc-2120	245	2	:	:	PUNCT
dpc-2120	245	3	pmc7142380	pmc7142380	ADJ
dpc-2120	245	4	.	.	PUNCT
dpc-2120	246	1	21	21	NUM
dpc-2120	246	2	.	.	X
dpc-2120	246	3	nobbe	nobbe	PROPN
dpc-2120	246	4	s	s	PROPN
dpc-2120	246	5	,	,	PUNCT
dpc-2120	246	6	dziunycz	dziunycz	PROPN
dpc-2120	246	7	p	p	NOUN
dpc-2120	246	8	,	,	PUNCT
dpc-2120	246	9	mühleisen	mühleisen	VERB
dpc-2120	246	10	b	b	NOUN
dpc-2120	246	11	,	,	PUNCT
dpc-2120	246	12	et	et	PROPN
dpc-2120	246	13	al	al	PROPN
dpc-2120	246	14	.	.	PROPN
dpc-2120	246	15	il-31	il-31	PART
dpc-2120	246	16	expression	expression	NOUN
dpc-2120	246	17	by	by	ADP
dpc-2120	246	18	inflammatory	inflammatory	ADJ
dpc-2120	246	19	cells	cell	NOUN
dpc-2120	246	20	is	be	AUX
dpc-2120	246	21	preferentially	preferentially	ADV
dpc-2120	246	22	elevated	elevate	VERB
dpc-2120	246	23	in	in	ADP
dpc-2120	246	24	atopic	atopic	NOUN
dpc-2120	246	25	dermatitis	dermatitis	NOUN
dpc-2120	246	26	.	.	PUNCT
dpc-2120	247	1	acta	acta	PROPN
dpc-2120	247	2	derm	derm	PROPN
dpc-2120	247	3	venereol	venereol	NOUN
dpc-2120	247	4	.	.	PUNCT
dpc-2120	248	1	2012	2012	NUM
dpc-2120	248	2	;	;	PUNCT
dpc-2120	249	1	92(1):24	92(1):24	NUM
dpc-2120	249	2	-	-	SYM
dpc-2120	249	3	8	8	NUM
dpc-2120	249	4	.	.	PUNCT
dpc-2120	250	1	doi	doi	NOUN
dpc-2120	250	2	:	:	PUNCT
dpc-2120	251	1	10.2340/000155551191	10.2340/000155551191	X
dpc-2120	251	2	.	.	PUNCT
dpc-2120	252	1	pmid	pmid	NOUN
dpc-2120	252	2	:	:	PUNCT
dpc-2120	252	3	22041865	22041865	NUM
dpc-2120	252	4	.	.	PUNCT
dpc-2120	253	1	22	22	NUM
dpc-2120	253	2	.	.	PUNCT
dpc-2120	253	3	takamori	takamori	PROPN
dpc-2120	253	4	a	a	PROPN
dpc-2120	253	5	,	,	PUNCT
dpc-2120	253	6	nambu	nambu	VERB
dpc-2120	253	7	a	a	PRON
dpc-2120	253	8	,	,	PUNCT
dpc-2120	253	9	sato	sato	PROPN
dpc-2120	253	10	k	k	PROPN
dpc-2120	253	11	,	,	PUNCT
dpc-2120	253	12	et	et	PROPN
dpc-2120	253	13	al	al	PROPN
dpc-2120	253	14	.	.	PROPN
dpc-2120	253	15	il-31	il-31	PUNCT
dpc-2120	253	16	is	be	AUX
dpc-2120	253	17	crucial	crucial	ADJ
dpc-2120	253	18	for	for	ADP
dpc-2120	253	19	induction	induction	NOUN
dpc-2120	253	20	of	of	ADP
dpc-2120	253	21	pruritus	pruritus	PROPN
dpc-2120	253	22	,	,	PUNCT
dpc-2120	253	23	but	but	CCONJ
dpc-2120	253	24	not	not	PART
dpc-2120	253	25	inflammation	inflammation	NOUN
dpc-2120	253	26	,	,	PUNCT
dpc-2120	253	27	in	in	ADP
dpc-2120	253	28	contact	contact	NOUN
dpc-2120	253	29	hypersensitivity	hypersensitivity	NOUN
dpc-2120	253	30	.	.	PUNCT
dpc-2120	254	1	scientific	scientific	ADJ
dpc-2120	254	2	reports	report	NOUN
dpc-2120	254	3	.	.	PUNCT
dpc-2120	255	1	2018	2018	NUM
dpc-2120	255	2	;	;	PUNCT
dpc-2120	255	3	8(1):6639	8(1):6639	PROPN
dpc-2120	255	4	.	.	PUNCT
dpc-2120	255	5	doi	doi	PROPN
dpc-2120	255	6	:	:	PUNCT
dpc-2120	255	7	10.1038	10.1038	NUM
dpc-2120	255	8	/	/	SYM
dpc-2120	255	9	s41598	s41598	NOUN
dpc-2120	255	10	-	-	PUNCT
dpc-2120	255	11	01825094	01825094	NUM
dpc-2120	255	12	-	-	PUNCT
dpc-2120	255	13	4	4	NUM
dpc-2120	255	14	.	.	PUNCT
dpc-2120	256	1	pmid	pmid	NOUN
dpc-2120	256	2	:	:	PUNCT
dpc-2120	256	3	29703903	29703903	NUM
dpc-2120	256	4	.	.	PUNCT
dpc-2120	257	1	pmcid	pmcid	ADJ
dpc-2120	257	2	:	:	PUNCT
dpc-2120	257	3	pmc5923199	pmc5923199	ADJ
dpc-2120	257	4	.	.	PUNCT
dpc-2120	258	1	23	23	NUM
dpc-2120	258	2	.	.	PUNCT
dpc-2120	259	1	grimstad	grimstad	NOUN
dpc-2120	259	2	o	o	PROPN
dpc-2120	259	3	,	,	PUNCT
dpc-2120	259	4	sawanobori	sawanobori	PROPN
dpc-2120	259	5	y	y	PROPN
dpc-2120	259	6	,	,	PUNCT
dpc-2120	259	7	vestergaard	vestergaard	PROPN
dpc-2120	259	8	c	c	NOUN
dpc-2120	259	9	,	,	PUNCT
dpc-2120	259	10	bilsborough	bilsborough	NOUN
dpc-2120	259	11	j	j	PROPN
dpc-2120	259	12	,	,	PUNCT
dpc-2120	259	13	olsen	olsen	NOUN
dpc-2120	259	14	ub	ub	PROPN
dpc-2120	259	15	,	,	PUNCT
dpc-2120	259	16	grønhøj	grønhøj	PROPN
dpc-2120	259	17	-	-	PUNCT
dpc-2120	259	18	larsen	larsen	PROPN
dpc-2120	259	19	c	c	PROPN
dpc-2120	259	20	,	,	PUNCT
dpc-2120	259	21	matsushima	matsushima	PROPN
dpc-2120	259	22	k.	k.	PROPN
dpc-2120	259	23	anti	anti	PROPN
dpc-2120	259	24	-	-	ADJ
dpc-2120	259	25	interleukin-31	interleukin-31	ADJ
dpc-2120	259	26	-	-	PUNCT
dpc-2120	259	27	antibodies	antibody	NOUN
dpc-2120	259	28	ameliorate	ameliorate	VERB
dpc-2120	259	29	scratching	scratch	VERB
dpc-2120	259	30	behaviour	behaviour	NOUN
dpc-2120	259	31	in	in	ADP
dpc-2120	259	32	nc	nc	PROPN
dpc-2120	259	33	/	/	SYM
dpc-2120	259	34	nga	nga	NOUN
dpc-2120	259	35	mice	mouse	NOUN
dpc-2120	259	36	:	:	PUNCT
dpc-2120	259	37	a	a	DET
dpc-2120	259	38	model	model	NOUN
dpc-2120	259	39	of	of	ADP
dpc-2120	259	40	atopic	atopic	NOUN
dpc-2120	259	41	dermatitis	dermatitis	NOUN
dpc-2120	259	42	.	.	PUNCT
dpc-2120	260	1	exp	exp	NOUN
dpc-2120	260	2	dermatol.2009	dermatol.2009	PROPN
dpc-2120	260	3	;	;	PUNCT
dpc-2120	260	4	18(1):35	18(1):35	PROPN
dpc-2120	260	5	-	-	PUNCT
dpc-2120	260	6	43	43	NUM
dpc-2120	260	7	.	.	PUNCT
dpc-2120	261	1	doi	doi	NOUN
dpc-2120	261	2	:	:	PUNCT
dpc-2120	261	3	10.1111	10.1111	NUM
dpc-2120	261	4	/	/	SYM
dpc-2120	261	5	j.1600	j.1600	NOUN
dpc-2120	261	6	-	-	PUNCT
dpc-2120	261	7	0625.2008.00766.x	0625.2008.00766.x	PROPN
dpc-2120	261	8	.	.	PUNCT
dpc-2120	262	1	pmid	pmid	NOUN
dpc-2120	262	2	:	:	PUNCT
dpc-2120	262	3	19054054	19054054	NUM
dpc-2120	262	4	.	.	PUNCT
dpc-2120	263	1	24	24	NUM
dpc-2120	263	2	.	.	PUNCT
dpc-2120	263	3	ruzicka	ruzicka	PROPN
dpc-2120	263	4	t	t	PROPN
dpc-2120	263	5	,	,	PUNCT
dpc-2120	263	6	hanifin	hanifin	PROPN
dpc-2120	263	7	jm	jm	PROPN
dpc-2120	263	8	,	,	PUNCT
dpc-2120	263	9	furue	furue	PROPN
dpc-2120	263	10	m	m	PROPN
dpc-2120	263	11	,	,	PUNCT
dpc-2120	263	12	et	et	PROPN
dpc-2120	263	13	al	al	PROPN
dpc-2120	263	14	.	.	PUNCT
dpc-2120	263	15	anti	anti	ADJ
dpc-2120	263	16	-	-	ADJ
dpc-2120	263	17	interleukin-31	interleukin-31	ADJ
dpc-2120	263	18	receptor	receptor	NOUN
dpc-2120	263	19	a	a	DET
dpc-2120	263	20	antibody	antibody	NOUN
dpc-2120	263	21	for	for	ADP
dpc-2120	263	22	atopic	atopic	NOUN
dpc-2120	263	23	dermatitis	dermatitis	NOUN
dpc-2120	263	24	.	.	PUNCT
dpc-2120	264	1	n	n	PROPN
dpc-2120	264	2	engl	engl	PROPN
dpc-2120	264	3	j	j	PROPN
dpc-2120	264	4	med	med	PROPN
dpc-2120	264	5	.	.	PUNCT
dpc-2120	265	1	2017;376(9):826	2017;376(9):826	NUM
dpc-2120	265	2	-	-	SYM
dpc-2120	265	3	835	835	NUM
dpc-2120	266	1	.	.	PUNCT
dpc-2120	266	2	doi	doi	NOUN
dpc-2120	266	3	:	:	PUNCT
dpc-2120	266	4	10.1056	10.1056	NUM
dpc-2120	266	5	/	/	SYM
dpc-2120	266	6	nejmoa1606490	nejmoa1606490	PROPN
dpc-2120	266	7	.	.	PUNCT
dpc-2120	267	1	pmid	pmid	NOUN
dpc-2120	267	2	:	:	PUNCT
dpc-2120	267	3	28249150	28249150	NUM
dpc-2120	267	4	.	.	PUNCT
dpc-2120	268	1	25	25	NUM
dpc-2120	268	2	.	.	PUNCT
dpc-2120	268	3	nemoto	nemoto	NOUN
dpc-2120	268	4	o	o	NOUN
dpc-2120	268	5	,	,	PUNCT
dpc-2120	268	6	furue	furue	PROPN
dpc-2120	268	7	m	m	PROPN
dpc-2120	268	8	,	,	PUNCT
dpc-2120	268	9	nakagawa	nakagawa	PROPN
dpc-2120	268	10	h	h	PROPN
dpc-2120	268	11	,	,	PUNCT
dpc-2120	268	12	et	et	PROPN
dpc-2120	268	13	al	al	PROPN
dpc-2120	268	14	.	.	PUNCT
dpc-2120	269	1	the	the	DET
dpc-2120	269	2	first	first	ADJ
dpc-2120	269	3	trial	trial	NOUN
dpc-2120	269	4	of	of	ADP
dpc-2120	269	5	cim331	cim331	PROPN
dpc-2120	269	6	,	,	PUNCT
dpc-2120	269	7	a	a	DET
dpc-2120	269	8	humanized	humanize	VERB
dpc-2120	269	9	antihuman	antihuman	NOUN
dpc-2120	269	10	interleukin-31	interleukin-31	PROPN
dpc-2120	269	11	receptor	receptor	VERB
dpc-2120	269	12	a	a	DET
dpc-2120	269	13	antibody	antibody	NOUN
dpc-2120	269	14	,	,	PUNCT
dpc-2120	269	15	in	in	ADP
dpc-2120	269	16	healthy	healthy	ADJ
dpc-2120	269	17	volunteers	volunteer	NOUN
dpc-2120	269	18	and	and	CCONJ
dpc-2120	269	19	patients	patient	NOUN
dpc-2120	269	20	with	with	ADP
dpc-2120	269	21	atopic	atopic	NOUN
dpc-2120	269	22	dermatitis	dermatitis	NOUN
dpc-2120	269	23	to	to	PART
dpc-2120	269	24	evaluate	evaluate	VERB
dpc-2120	269	25	safety	safety	NOUN
dpc-2120	269	26	,	,	PUNCT
dpc-2120	269	27	tolerability	tolerability	NOUN
dpc-2120	269	28	and	and	CCONJ
dpc-2120	269	29	pharmacokinetics	pharmacokinetic	NOUN
dpc-2120	269	30	of	of	ADP
dpc-2120	269	31	a	a	DET
dpc-2120	269	32	single	single	ADJ
dpc-2120	269	33	dose	dose	NOUN
dpc-2120	269	34	in	in	ADP
dpc-2120	269	35	a	a	DET
dpc-2120	269	36	randomized	randomized	ADJ
dpc-2120	269	37	,	,	PUNCT
dpc-2120	269	38	double	double	ADJ
dpc-2120	269	39	-	-	PUNCT
dpc-2120	269	40	blind	blind	ADJ
dpc-2120	269	41	,	,	PUNCT
dpc-2120	269	42	placebo	placebo	NOUN
dpc-2120	269	43	-	-	PUNCT
dpc-2120	269	44	controlled	control	VERB
dpc-2120	269	45	study	study	NOUN
dpc-2120	269	46	.	.	PUNCT
dpc-2120	270	1	br	br	PROPN
dpc-2120	270	2	j	j	PROPN
dpc-2120	270	3	dermatol	dermatol	NOUN
dpc-2120	270	4	.	.	PUNCT
dpc-2120	271	1	2016;174(2	2016;174(2	NUM
dpc-2120	271	2	):	):	PUNCT
dpc-2120	272	1	296	296	NUM
dpc-2120	272	2	-	-	SYM
dpc-2120	272	3	304	304	NUM
dpc-2120	272	4	.	.	PUNCT
dpc-2120	272	5	doi	doi	NOUN
dpc-2120	272	6	:	:	PUNCT
dpc-2120	272	7	10.1111	10.1111	NUM
dpc-2120	272	8	/	/	SYM
dpc-2120	272	9	bjd.14207	bjd.14207	PROPN
dpc-2120	272	10	.	.	PUNCT
dpc-2120	273	1	pmid	pmid	NOUN
dpc-2120	273	2	:	:	PUNCT
dpc-2120	273	3	26409172	26409172	NUM
dpc-2120	273	4	.	.	PUNCT
dpc-2120	274	1	26	26	NUM
dpc-2120	274	2	.	.	PUNCT
dpc-2120	275	1	guttman	guttman	ADJ
dpc-2120	275	2	-	-	PUNCT
dpc-2120	275	3	yassky	yassky	NOUN
dpc-2120	275	4	e	e	NOUN
dpc-2120	275	5	,	,	PUNCT
dpc-2120	275	6	pavel	pavel	PROPN
dpc-2120	275	7	ab	ab	PROPN
dpc-2120	275	8	,	,	PUNCT
dpc-2120	275	9	zhou	zhou	PROPN
dpc-2120	275	10	l	l	PROPN
dpc-2120	275	11	,	,	PUNCT
dpc-2120	275	12	et	et	PROPN
dpc-2120	275	13	al	al	PROPN
dpc-2120	275	14	.	.	PUNCT
dpc-2120	276	1	gbr	gbr	PROPN
dpc-2120	276	2	830	830	NUM
dpc-2120	276	3	,	,	PUNCT
dpc-2120	276	4	an	an	DET
dpc-2120	276	5	anti	anti	NOUN
dpc-2120	276	6	-	-	ADJ
dpc-2120	276	7	ox40	ox40	ADJ
dpc-2120	276	8	,	,	PUNCT
dpc-2120	276	9	improves	improve	VERB
dpc-2120	276	10	skin	skin	NOUN
dpc-2120	276	11	gene	gene	NOUN
dpc-2120	276	12	signatures	signature	NOUN
dpc-2120	276	13	and	and	CCONJ
dpc-2120	276	14	clinical	clinical	ADJ
dpc-2120	276	15	scores	score	NOUN
dpc-2120	276	16	6	6	NUM
dpc-2120	276	17	review	review	NOUN
dpc-2120	276	18	|	|	ADV
dpc-2120	276	19	dermatol	dermatol	ADJ
dpc-2120	276	20	pract	pract	NOUN
dpc-2120	276	21	concept	concept	NOUN
dpc-2120	276	22	.	.	PUNCT
dpc-2120	277	1	2021;11(4):e2021144	2021;11(4):e2021144	NUM
dpc-2120	277	2	in	in	ADP
dpc-2120	277	3	patients	patient	NOUN
dpc-2120	277	4	with	with	ADP
dpc-2120	277	5	atopic	atopic	NOUN
dpc-2120	277	6	dermatitis	dermatitis	NOUN
dpc-2120	277	7	.	.	PUNCT
dpc-2120	278	1	j	j	PROPN
dpc-2120	278	2	allergy	allergy	PROPN
dpc-2120	278	3	clin	clin	PROPN
dpc-2120	278	4	immunol	immunol	PROPN
dpc-2120	278	5	.	.	PUNCT
dpc-2120	279	1	2019;144(2):482	2019;144(2):482	NUM
dpc-2120	279	2	-	-	PUNCT
dpc-2120	279	3	493.e7	493.e7	PROPN
dpc-2120	279	4	.	.	PUNCT
dpc-2120	280	1	doi	doi	NOUN
dpc-2120	280	2	:	:	PUNCT
dpc-2120	280	3	10.1016	10.1016	NUM
dpc-2120	280	4	/	/	SYM
dpc-2120	280	5	j.jaci.2018.11.053	j.jaci.2018.11.053	PROPN
dpc-2120	280	6	.	.	PUNCT
dpc-2120	281	1	pmid	pmid	NOUN
dpc-2120	281	2	:	:	PUNCT
dpc-2120	281	3	30738171	30738171	NUM
dpc-2120	281	4	.	.	PUNCT
dpc-2120	282	1	27	27	NUM
dpc-2120	282	2	.	.	PUNCT
dpc-2120	283	1	nakagawa	nakagawa	PROPN
dpc-2120	283	2	h	h	PROPN
dpc-2120	283	3	,	,	PUNCT
dpc-2120	283	4	iizuka	iizuka	PROPN
dpc-2120	283	5	h	h	NOUN
dpc-2120	283	6	,	,	PUNCT
dpc-2120	283	7	nemoto	nemoto	NOUN
dpc-2120	283	8	o	o	NOUN
dpc-2120	283	9	,	,	PUNCT
dpc-2120	283	10	shimabe	shimabe	PROPN
dpc-2120	283	11	m	m	PROPN
dpc-2120	283	12	,	,	PUNCT
dpc-2120	283	13	furukawa	furukawa	PROPN
dpc-2120	283	14	y	y	PROPN
dpc-2120	283	15	,	,	PUNCT
dpc-2120	283	16	kikuta	kikuta	ADJ
dpc-2120	283	17	n	n	CCONJ
dpc-2120	283	18	,	,	PUNCT
dpc-2120	283	19	ootaki	ootaki	PROPN
dpc-2120	283	20	k.	k.	PROPN
dpc-2120	283	21	safety	safety	PROPN
dpc-2120	283	22	,	,	PUNCT
dpc-2120	283	23	tolerability	tolerability	NOUN
dpc-2120	283	24	and	and	CCONJ
dpc-2120	283	25	efficacy	efficacy	NOUN
dpc-2120	283	26	of	of	ADP
dpc-2120	283	27	repeated	repeat	VERB
dpc-2120	283	28	intravenous	intravenous	ADJ
dpc-2120	283	29	infusions	infusion	NOUN
dpc-2120	283	30	of	of	ADP
dpc-2120	283	31	khk4083	khk4083	NOUN
dpc-2120	283	32	,	,	PUNCT
dpc-2120	283	33	a	a	DET
dpc-2120	283	34	fully	fully	ADV
dpc-2120	283	35	human	human	ADJ
dpc-2120	283	36	anti	anti	ADJ
dpc-2120	283	37	-	-	ADJ
dpc-2120	283	38	ox40	ox40	ADJ
dpc-2120	283	39	monoclonal	monoclonal	NOUN
dpc-2120	283	40	antibody	antibody	NOUN
dpc-2120	283	41	,	,	PUNCT
dpc-2120	283	42	in	in	ADP
dpc-2120	283	43	japanese	japanese	ADJ
dpc-2120	283	44	patients	patient	NOUN
dpc-2120	283	45	with	with	ADP
dpc-2120	283	46	moderate	moderate	ADJ
dpc-2120	283	47	to	to	ADP
dpc-2120	283	48	severe	severe	ADJ
dpc-2120	283	49	atopic	atopic	NOUN
dpc-2120	283	50	dermatitis	dermatitis	NOUN
dpc-2120	283	51	.	.	PUNCT
dpc-2120	284	1	j	j	PROPN
dpc-2120	284	2	dermatol	dermatol	NOUN
dpc-2120	284	3	sci	sci	PROPN
dpc-2120	284	4	.	.	PUNCT
dpc-2120	285	1	2020;99(2):82	2020;99(2):82	PROPN
dpc-2120	285	2	-	-	SYM
dpc-2120	285	3	89	89	NUM
dpc-2120	285	4	.	.	PUNCT
dpc-2120	286	1	doi	doi	NOUN
dpc-2120	286	2	:	:	PUNCT
dpc-2120	286	3	10.1016	10.1016	NUM
dpc-2120	286	4	/	/	SYM
dpc-2120	286	5	j.jdermsci.2020.06.005	j.jdermsci.2020.06.005	PROPN
dpc-2120	286	6	.	.	PUNCT
dpc-2120	287	1	pmid	pmid	NOUN
dpc-2120	287	2	:	:	PUNCT
dpc-2120	287	3	32651105	32651105	NUM
dpc-2120	287	4	.	.	PUNCT
dpc-2120	288	1	28	28	NUM
dpc-2120	288	2	.	.	PUNCT
dpc-2120	289	1	simpson	simpson	PROPN
dpc-2120	289	2	el	el	PROPN
dpc-2120	289	3	,	,	PUNCT
dpc-2120	289	4	parnes	parne	VERB
dpc-2120	289	5	jr	jr	PROPN
dpc-2120	289	6	,	,	PUNCT
dpc-2120	289	7	she	she	PRON
dpc-2120	289	8	d	d	PROPN
dpc-2120	289	9	,	,	PUNCT
dpc-2120	289	10	crouch	crouch	PROPN
dpc-2120	289	11	s	s	PART
dpc-2120	289	12	,	,	PUNCT
dpc-2120	289	13	rees	rees	PROPN
dpc-2120	289	14	w	w	PROPN
dpc-2120	289	15	,	,	PUNCT
dpc-2120	289	16	mo	mo	PROPN
dpc-2120	289	17	m	m	PROPN
dpc-2120	289	18	,	,	PUNCT
dpc-2120	289	19	van	van	PROPN
dpc-2120	289	20	der	der	PROPN
dpc-2120	289	21	merwe	merwe	PROPN
dpc-2120	289	22	r.	r.	PROPN
dpc-2120	289	23	tezepelumab	tezepelumab	PROPN
dpc-2120	289	24	,	,	PUNCT
dpc-2120	289	25	an	an	DET
dpc-2120	289	26	anti	anti	ADJ
dpc-2120	289	27	-	-	ADJ
dpc-2120	289	28	thymic	thymic	ADJ
dpc-2120	289	29	stromal	stromal	ADJ
dpc-2120	289	30	lymphopoietin	lymphopoietin	NOUN
dpc-2120	289	31	monoclonal	monoclonal	NOUN
dpc-2120	289	32	antibody	antibody	NOUN
dpc-2120	289	33	,	,	PUNCT
dpc-2120	289	34	in	in	ADP
dpc-2120	289	35	the	the	DET
dpc-2120	289	36	treatment	treatment	NOUN
dpc-2120	289	37	of	of	ADP
dpc-2120	289	38	moderate	moderate	ADJ
dpc-2120	289	39	to	to	ADP
dpc-2120	289	40	severe	severe	ADJ
dpc-2120	289	41	atopic	atopic	NOUN
dpc-2120	289	42	dermatitis	dermatitis	NOUN
dpc-2120	289	43	:	:	PUNCT
dpc-2120	289	44	a	a	DET
dpc-2120	289	45	randomized	randomized	ADJ
dpc-2120	289	46	phase	phase	NOUN
dpc-2120	289	47	2a	2a	NUM
dpc-2120	289	48	clinical	clinical	ADJ
dpc-2120	289	49	trial	trial	NOUN
dpc-2120	289	50	.	.	PUNCT
dpc-2120	290	1	j	j	PROPN
dpc-2120	290	2	am	be	AUX
dpc-2120	290	3	acad	acad	ADJ
dpc-2120	290	4	dermatol	dermatol	NOUN
dpc-2120	290	5	.	.	PUNCT
dpc-2120	291	1	2019	2019	NUM
dpc-2120	291	2	;	;	PUNCT
dpc-2120	291	3	80(4	80(4	NUM
dpc-2120	291	4	):	):	PUNCT
dpc-2120	291	5	1013	1013	NUM
dpc-2120	291	6	-	-	SYM
dpc-2120	291	7	1021	1021	NUM
dpc-2120	291	8	.	.	PUNCT
dpc-2120	292	1	doi	doi	NOUN
dpc-2120	292	2	:	:	PUNCT
dpc-2120	292	3	10.1016	10.1016	NUM
dpc-2120	292	4	/	/	SYM
dpc-2120	292	5	j.	j.	PROPN
dpc-2120	292	6	jaad.2018.11.059	jaad.2018.11.059	PROPN
dpc-2120	292	7	.	.	PUNCT
dpc-2120	293	1	pmid	pmid	NOUN
dpc-2120	293	2	:	:	PUNCT
dpc-2120	293	3	30550828	30550828	NUM
dpc-2120	293	4	.	.	PUNCT
dpc-2120	294	1	29	29	NUM
dpc-2120	294	2	.	.	PUNCT
dpc-2120	295	1	schmitz	schmitz	PROPN
dpc-2120	295	2	j	j	PROPN
dpc-2120	295	3	,	,	PUNCT
dpc-2120	295	4	owyang	owyang	PROPN
dpc-2120	295	5	a	a	PROPN
dpc-2120	295	6	,	,	PUNCT
dpc-2120	295	7	oldham	oldham	PROPN
dpc-2120	295	8	e	e	NOUN
dpc-2120	295	9	,	,	PUNCT
dpc-2120	295	10	et	et	PROPN
dpc-2120	295	11	al	al	PROPN
dpc-2120	295	12	.	.	PROPN
dpc-2120	296	1	il-33	il-33	PROPN
dpc-2120	296	2	,	,	PUNCT
dpc-2120	296	3	an	an	DET
dpc-2120	296	4	interleukin-1	interleukin-1	NOUN
dpc-2120	296	5	-	-	PUNCT
dpc-2120	296	6	like	like	ADJ
dpc-2120	296	7	cytokine	cytokine	NOUN
dpc-2120	296	8	that	that	SCONJ
dpc-2120	296	9	signals	signal	NOUN
dpc-2120	296	10	via	via	ADP
dpc-2120	296	11	the	the	DET
dpc-2120	296	12	il-1	il-1	ADJ
dpc-2120	296	13	receptor	receptor	NOUN
dpc-2120	296	14	-	-	PUNCT
dpc-2120	296	15	related	relate	VERB
dpc-2120	296	16	protein	protein	NOUN
dpc-2120	296	17	st2	st2	NOUN
dpc-2120	296	18	and	and	CCONJ
dpc-2120	296	19	induces	induce	VERB
dpc-2120	296	20	t	t	PROPN
dpc-2120	296	21	helper	helper	NOUN
dpc-2120	296	22	type	type	NOUN
dpc-2120	296	23	2	2	NUM
dpc-2120	296	24	-	-	PUNCT
dpc-2120	296	25	associated	associate	VERB
dpc-2120	296	26	cytokines	cytokine	NOUN
dpc-2120	296	27	.	.	PUNCT
dpc-2120	297	1	immunity	immunity	NOUN
dpc-2120	297	2	.	.	PUNCT
dpc-2120	298	1	2005;23(5):479	2005;23(5):479	NUM
dpc-2120	298	2	-	-	SYM
dpc-2120	298	3	90	90	NUM
dpc-2120	298	4	.	.	PUNCT
dpc-2120	299	1	doi	doi	NOUN
dpc-2120	299	2	:	:	PUNCT
dpc-2120	299	3	10.1016	10.1016	NUM
dpc-2120	299	4	/	/	SYM
dpc-2120	299	5	j.immuni.2005.09.015	j.immuni.2005.09.015	PROPN
dpc-2120	299	6	.	.	PUNCT
dpc-2120	300	1	pmid	pmid	NOUN
dpc-2120	300	2	:	:	PUNCT
dpc-2120	300	3	16286016	16286016	NUM
dpc-2120	300	4	.	.	PUNCT
dpc-2120	301	1	30	30	NUM
dpc-2120	301	2	.	.	PUNCT
dpc-2120	301	3	murakami	murakami	NOUN
dpc-2120	301	4	-	-	PUNCT
dpc-2120	301	5	satsutani	satsutani	PROPN
dpc-2120	301	6	n	n	CCONJ
dpc-2120	301	7	,	,	PUNCT
dpc-2120	301	8	ito	ito	PROPN
dpc-2120	301	9	t	t	PROPN
dpc-2120	301	10	,	,	PUNCT
dpc-2120	301	11	nakanishi	nakanishi	PROPN
dpc-2120	301	12	t	t	PROPN
dpc-2120	301	13	,	,	PUNCT
dpc-2120	301	14	et	et	PROPN
dpc-2120	301	15	al	al	PROPN
dpc-2120	301	16	.	.	PROPN
dpc-2120	301	17	il-33	il-33	PROPN
dpc-2120	301	18	promotes	promote	VERB
dpc-2120	301	19	the	the	DET
dpc-2120	301	20	induction	induction	NOUN
dpc-2120	301	21	and	and	CCONJ
dpc-2120	301	22	maintenance	maintenance	NOUN
dpc-2120	301	23	of	of	ADP
dpc-2120	301	24	th2	th2	PROPN
dpc-2120	301	25	immune	immune	ADJ
dpc-2120	301	26	responses	response	NOUN
dpc-2120	301	27	by	by	ADP
dpc-2120	301	28	enhancing	enhance	VERB
dpc-2120	301	29	the	the	DET
dpc-2120	301	30	function	function	NOUN
dpc-2120	301	31	of	of	ADP
dpc-2120	301	32	ox40	ox40	PROPN
dpc-2120	301	33	ligand	ligand	NOUN
dpc-2120	301	34	.	.	PUNCT
dpc-2120	302	1	allergol	allergol	PROPN
dpc-2120	302	2	int	int	PROPN
dpc-2120	302	3	.	.	PUNCT
dpc-2120	303	1	2014;63(3):443	2014;63(3):443	NUM
dpc-2120	303	2	-	-	SYM
dpc-2120	303	3	55	55	NUM
dpc-2120	303	4	.	.	PUNCT
dpc-2120	304	1	doi	doi	NOUN
dpc-2120	304	2	:	:	PUNCT
dpc-2120	304	3	10.2332	10.2332	NUM
dpc-2120	304	4	/	/	SYM
dpc-2120	304	5	allergolint.13	allergolint.13	PROPN
dpc-2120	304	6	-	-	PUNCT
dpc-2120	304	7	oa-0672	oa-0672	NOUN
dpc-2120	304	8	.	.	PUNCT
dpc-2120	305	1	31	31	NUM
dpc-2120	305	2	.	.	PUNCT
dpc-2120	306	1	cherry	cherry	PROPN
dpc-2120	306	2	wb	wb	PROPN
dpc-2120	306	3	,	,	PUNCT
dpc-2120	306	4	yoon	yoon	PROPN
dpc-2120	306	5	j	j	PROPN
dpc-2120	306	6	,	,	PUNCT
dpc-2120	306	7	bartemes	bartemes	PROPN
dpc-2120	306	8	kr	kr	PROPN
dpc-2120	306	9	,	,	PUNCT
dpc-2120	306	10	iijima	iijima	PROPN
dpc-2120	306	11	k	k	PROPN
dpc-2120	306	12	,	,	PUNCT
dpc-2120	306	13	kita	kita	PROPN
dpc-2120	306	14	h.	h.	PROPN
dpc-2120	307	1	a	a	DET
dpc-2120	307	2	novel	novel	NOUN
dpc-2120	307	3	il-1	il-1	ADP
dpc-2120	307	4	family	family	NOUN
dpc-2120	307	5	cytokine	cytokine	NOUN
dpc-2120	307	6	,	,	PUNCT
dpc-2120	307	7	il-33	il-33	X
dpc-2120	307	8	,	,	PUNCT
dpc-2120	307	9	potently	potently	ADV
dpc-2120	307	10	activates	activate	VERB
dpc-2120	307	11	human	human	ADJ
dpc-2120	307	12	eosinophils	eosinophil	NOUN
dpc-2120	307	13	.	.	PUNCT
dpc-2120	308	1	j	j	PROPN
dpc-2120	308	2	allergy	allergy	PROPN
dpc-2120	308	3	clin	clin	PROPN
dpc-2120	308	4	immunol	immunol	NOUN
dpc-2120	308	5	.	.	PUNCT
dpc-2120	309	1	2008;121(6):1484	2008;121(6):1484	NUM
dpc-2120	309	2	-	-	SYM
dpc-2120	309	3	90	90	NUM
dpc-2120	309	4	.	.	PUNCT
dpc-2120	309	5	doi	doi	NOUN
dpc-2120	309	6	:	:	PUNCT
dpc-2120	309	7	10.1016	10.1016	NUM
dpc-2120	309	8	/	/	SYM
dpc-2120	309	9	j.	j.	PROPN
dpc-2120	309	10	jaci.2008.04.005	jaci.2008.04.005	PROPN
dpc-2120	309	11	.	.	PUNCT
dpc-2120	310	1	pmid	pmid	PROPN
dpc-2120	310	2	:	:	PUNCT
dpc-2120	310	3	18539196	18539196	NUM
dpc-2120	310	4	.	.	PUNCT
dpc-2120	311	1	pmcid	pmcid	NOUN
dpc-2120	311	2	:	:	PUNCT
dpc-2120	311	3	pmc2821937	pmc2821937	ADV
dpc-2120	311	4	.	.	PUNCT
dpc-2120	312	1	32	32	NUM
dpc-2120	312	2	.	.	PUNCT
dpc-2120	313	1	peng	peng	PROPN
dpc-2120	313	2	g	g	PROPN
dpc-2120	313	3	,	,	PUNCT
dpc-2120	313	4	mu	mu	PROPN
dpc-2120	313	5	z	z	PROPN
dpc-2120	313	6	,	,	PUNCT
dpc-2120	313	7	cui	cui	PROPN
dpc-2120	313	8	l	l	PROPN
dpc-2120	313	9	,	,	PUNCT
dpc-2120	313	10	liu	liu	PROPN
dpc-2120	313	11	p	p	PROPN
dpc-2120	313	12	,	,	PUNCT
dpc-2120	313	13	wang	wang	PROPN
dpc-2120	313	14	y	y	PROPN
dpc-2120	313	15	,	,	PUNCT
dpc-2120	313	16	wu	wu	PROPN
dpc-2120	313	17	w	w	PROPN
dpc-2120	313	18	,	,	PUNCT
dpc-2120	313	19	han	han	PROPN
dpc-2120	313	20	x.	x.	NOUN
dpc-2120	313	21	anti	anti	ADJ
dpc-2120	313	22	-	-	ADJ
dpc-2120	313	23	il-33	il-33	ADJ
dpc-2120	313	24	antibody	antibody	NOUN
dpc-2120	313	25	has	have	VERB
dpc-2120	313	26	a	a	DET
dpc-2120	313	27	therapeutic	therapeutic	ADJ
dpc-2120	313	28	effect	effect	NOUN
dpc-2120	313	29	in	in	ADP
dpc-2120	313	30	an	an	DET
dpc-2120	313	31	atopic	atopic	NOUN
dpc-2120	313	32	dermatitis	dermatitis	NOUN
dpc-2120	313	33	murine	murine	ADJ
dpc-2120	313	34	model	model	NOUN
dpc-2120	313	35	induced	induce	VERB
dpc-2120	313	36	by	by	ADP
dpc-2120	313	37	2	2	NUM
dpc-2120	313	38	,	,	PUNCT
dpc-2120	313	39	4	4	NUM
dpc-2120	313	40	-	-	PUNCT
dpc-2120	313	41	dinitrochlorobenzene	dinitrochlorobenzene	NOUN
dpc-2120	313	42	.	.	PUNCT
dpc-2120	314	1	inflammation	inflammation	NOUN
dpc-2120	314	2	.	.	PUNCT
dpc-2120	315	1	2018;41(1):154	2018;41(1):154	PROPN
dpc-2120	315	2	-	-	SYM
dpc-2120	315	3	163	163	NUM
dpc-2120	315	4	.	.	PUNCT
dpc-2120	316	1	doi	doi	NOUN
dpc-2120	316	2	:	:	PUNCT
dpc-2120	316	3	10.1007	10.1007	NUM
dpc-2120	316	4	/	/	SYM
dpc-2120	316	5	s10753	s10753	NOUN
dpc-2120	316	6	-	-	PUNCT
dpc-2120	316	7	017	017	NUM
dpc-2120	316	8	-	-	PUNCT
dpc-2120	316	9	0673	0673	NUM
dpc-2120	316	10	-	-	PUNCT
dpc-2120	316	11	7	7	NUM
dpc-2120	316	12	.	.	PUNCT
dpc-2120	317	1	pmid	pmid	NOUN
dpc-2120	317	2	:	:	PUNCT
dpc-2120	317	3	28952069	28952069	NUM
dpc-2120	317	4	.	.	PUNCT
dpc-2120	318	1	33	33	NUM
dpc-2120	318	2	.	.	PUNCT
dpc-2120	319	1	chen	chen	PROPN
dpc-2120	319	2	yl	yl	PROPN
dpc-2120	319	3	,	,	PUNCT
dpc-2120	319	4	gutowska	gutowska	NOUN
dpc-2120	319	5	-	-	PUNCT
dpc-2120	319	6	owsiak	owsiak	PROPN
dpc-2120	319	7	d	d	PROPN
dpc-2120	319	8	,	,	PUNCT
dpc-2120	319	9	hardman	hardman	PROPN
dpc-2120	319	10	cs	cs	PROPN
dpc-2120	319	11	,	,	PUNCT
dpc-2120	319	12	et	et	PROPN
dpc-2120	319	13	al	al	PROPN
dpc-2120	319	14	.	.	PUNCT
dpc-2120	320	1	proof	proof	ADJ
dpc-2120	320	2	-	-	PUNCT
dpc-2120	320	3	ofconcept	ofconcept	ADJ
dpc-2120	320	4	clinical	clinical	ADJ
dpc-2120	320	5	trial	trial	NOUN
dpc-2120	320	6	of	of	ADP
dpc-2120	320	7	etokimab	etokimab	NOUN
dpc-2120	320	8	shows	show	VERB
dpc-2120	320	9	a	a	DET
dpc-2120	320	10	key	key	ADJ
dpc-2120	320	11	role	role	NOUN
dpc-2120	320	12	for	for	ADP
dpc-2120	320	13	il-33	il-33	ADJ
dpc-2120	320	14	in	in	ADP
dpc-2120	320	15	atopic	atopic	NOUN
dpc-2120	320	16	dermatitis	dermatitis	NOUN
dpc-2120	320	17	pathogenesis	pathogenesis	NOUN
dpc-2120	320	18	.	.	PUNCT
dpc-2120	321	1	sci	sci	PROPN
dpc-2120	321	2	transl	transl	PROPN
dpc-2120	321	3	med	med	PROPN
dpc-2120	321	4	.	.	PUNCT
dpc-2120	322	1	2019;11(515	2019;11(515	NUM
dpc-2120	322	2	)	)	PUNCT
dpc-2120	322	3	.	.	PUNCT
dpc-2120	323	1	doi	doi	NOUN
dpc-2120	323	2	:	:	PUNCT
dpc-2120	323	3	10.1126	10.1126	NUM
dpc-2120	323	4	/	/	SYM
dpc-2120	323	5	scitranslmed.aax2945	scitranslmed.aax2945	NOUN
dpc-2120	323	6	.	.	PUNCT
dpc-2120	324	1	pmid	pmid	NOUN
dpc-2120	324	2	:	:	PUNCT
dpc-2120	324	3	31645451	31645451	NUM
dpc-2120	324	4	.	.	PUNCT
dpc-2120	325	1	34	34	NUM
dpc-2120	325	2	.	.	PUNCT
dpc-2120	325	3	nograles	nograles	PROPN
dpc-2120	325	4	ke	ke	PROPN
dpc-2120	325	5	,	,	PUNCT
dpc-2120	325	6	zaba	zaba	PROPN
dpc-2120	325	7	lc	lc	PROPN
dpc-2120	325	8	,	,	PUNCT
dpc-2120	325	9	shemer	shemer	NOUN
dpc-2120	325	10	a	a	NOUN
dpc-2120	325	11	,	,	PUNCT
dpc-2120	325	12	et	et	PROPN
dpc-2120	325	13	al	al	PROPN
dpc-2120	325	14	.	.	PROPN
dpc-2120	325	15	il-22	il-22	PROPN
dpc-2120	325	16	-	-	PUNCT
dpc-2120	325	17	producing	produce	VERB
dpc-2120	325	18	“	"	PUNCT
dpc-2120	325	19	t22	t22	PROPN
dpc-2120	325	20	”	"	PUNCT
dpc-2120	325	21	t	t	PROPN
dpc-2120	325	22	cells	cell	NOUN
dpc-2120	325	23	account	account	VERB
dpc-2120	325	24	for	for	ADP
dpc-2120	325	25	upregulated	upregulated	ADJ
dpc-2120	325	26	il-22	il-22	ADP
dpc-2120	325	27	in	in	ADP
dpc-2120	325	28	atopic	atopic	NOUN
dpc-2120	325	29	dermatitis	dermatitis	NOUN
dpc-2120	325	30	despite	despite	SCONJ
dpc-2120	325	31	reduced	reduce	VERB
dpc-2120	325	32	il-17	il-17	ADV
dpc-2120	325	33	-	-	PUNCT
dpc-2120	325	34	producing	produce	VERB
dpc-2120	325	35	th17	th17	PROPN
dpc-2120	325	36	t	t	NOUN
dpc-2120	325	37	cells	cell	NOUN
dpc-2120	325	38	.	.	PUNCT
dpc-2120	326	1	j	j	PROPN
dpc-2120	326	2	allergy	allergy	PROPN
dpc-2120	326	3	clin	clin	PROPN
dpc-2120	326	4	immunol	immunol	PROPN
dpc-2120	326	5	.	.	PUNCT
dpc-2120	327	1	2009;123(6	2009;123(6	NUM
dpc-2120	327	2	):	):	PUNCT
dpc-2120	327	3	1244-52.e2.doi	1244-52.e2.doi	NUM
dpc-2120	327	4	:	:	PUNCT
dpc-2120	327	5	10.1016	10.1016	NUM
dpc-2120	327	6	/	/	SYM
dpc-2120	327	7	j.jaci.2009.03.041	j.jaci.2009.03.041	PROPN
dpc-2120	327	8	.	.	PUNCT
dpc-2120	328	1	pmid	pmid	NOUN
dpc-2120	328	2	:	:	PUNCT
dpc-2120	328	3	19439349	19439349	NUM
dpc-2120	328	4	.	.	PUNCT
dpc-2120	329	1	pmcid	pmcid	ADJ
dpc-2120	329	2	:	:	PUNCT
dpc-2120	329	3	pmc2874584	pmc2874584	NOUN
dpc-2120	329	4	.	.	PUNCT
dpc-2120	330	1	35	35	NUM
dpc-2120	330	2	.	.	PUNCT
dpc-2120	331	1	noda	noda	PROPN
dpc-2120	331	2	s	s	PROPN
dpc-2120	331	3	,	,	PUNCT
dpc-2120	331	4	krueger	krueger	PROPN
dpc-2120	331	5	jg	jg	PROPN
dpc-2120	331	6	,	,	PUNCT
dpc-2120	331	7	guttman	guttman	ADJ
dpc-2120	331	8	-	-	PUNCT
dpc-2120	331	9	yassky	yassky	NOUN
dpc-2120	331	10	e.	e.	PROPN
dpc-2120	332	1	the	the	DET
dpc-2120	332	2	translational	translational	PROPN
dpc-2120	332	3	revolution	revolution	NOUN
dpc-2120	332	4	and	and	CCONJ
dpc-2120	332	5	use	use	NOUN
dpc-2120	332	6	of	of	ADP
dpc-2120	332	7	biologics	biologic	NOUN
dpc-2120	332	8	in	in	ADP
dpc-2120	332	9	patients	patient	NOUN
dpc-2120	332	10	with	with	ADP
dpc-2120	332	11	inflammatory	inflammatory	ADJ
dpc-2120	332	12	skin	skin	NOUN
dpc-2120	332	13	diseases	disease	NOUN
dpc-2120	332	14	.	.	PUNCT
dpc-2120	333	1	j	j	PROPN
dpc-2120	333	2	allergy	allergy	PROPN
dpc-2120	333	3	clin	clin	PROPN
dpc-2120	333	4	immunol	immunol	PROPN
dpc-2120	333	5	.	.	PUNCT
dpc-2120	334	1	2015	2015	NUM
dpc-2120	334	2	;	;	PUNCT
dpc-2120	334	3	135(2):324	135(2):324	NUM
dpc-2120	334	4	-	-	PUNCT
dpc-2120	334	5	36.doi	36.doi	PROPN
dpc-2120	334	6	:	:	PUNCT
dpc-2120	334	7	10.1016	10.1016	NUM
dpc-2120	334	8	/	/	SYM
dpc-2120	334	9	j.jaci.2014.11.015	j.jaci.2014.11.015	PROPN
dpc-2120	334	10	.	.	PUNCT
dpc-2120	335	1	pmid	pmid	NOUN
dpc-2120	335	2	:	:	PUNCT
dpc-2120	335	3	25541257	25541257	NUM
dpc-2120	335	4	.	.	PUNCT
dpc-2120	336	1	36	36	NUM
dpc-2120	336	2	.	.	PUNCT
dpc-2120	337	1	guttman	guttman	ADJ
dpc-2120	337	2	-	-	PUNCT
dpc-2120	337	3	yassky	yassky	NOUN
dpc-2120	337	4	e	e	NOUN
dpc-2120	337	5	,	,	PUNCT
dpc-2120	337	6	brunner	brunner	PROPN
dpc-2120	337	7	pm	pm	PROPN
dpc-2120	337	8	,	,	PUNCT
dpc-2120	337	9	neumann	neumann	PROPN
dpc-2120	337	10	au	au	PROPN
dpc-2120	337	11	,	,	PUNCT
dpc-2120	337	12	et	et	PROPN
dpc-2120	337	13	al	al	PROPN
dpc-2120	337	14	.	.	PROPN
dpc-2120	338	1	efficacy	efficacy	NOUN
dpc-2120	338	2	and	and	CCONJ
dpc-2120	338	3	safety	safety	NOUN
dpc-2120	338	4	of	of	ADP
dpc-2120	338	5	fezakinumab	fezakinumab	NOUN
dpc-2120	338	6	(	(	PUNCT
dpc-2120	338	7	an	an	DET
dpc-2120	338	8	il-22	il-22	ADJ
dpc-2120	338	9	monoclonal	monoclonal	NOUN
dpc-2120	338	10	antibody	antibody	NOUN
dpc-2120	338	11	)	)	PUNCT
dpc-2120	338	12	in	in	ADP
dpc-2120	338	13	adults	adult	NOUN
dpc-2120	338	14	with	with	ADP
dpc-2120	338	15	moderate	moderate	ADJ
dpc-2120	338	16	-	-	PUNCT
dpc-2120	338	17	to	to	ADP
dpc-2120	338	18	-	-	PUNCT
dpc-2120	338	19	severe	severe	ADJ
dpc-2120	338	20	atopic	atopic	NOUN
dpc-2120	338	21	dermatitis	dermatitis	NOUN
dpc-2120	338	22	inadequately	inadequately	ADV
dpc-2120	338	23	controlled	control	VERB
dpc-2120	338	24	by	by	ADP
dpc-2120	338	25	conventional	conventional	ADJ
dpc-2120	338	26	treatments	treatment	NOUN
dpc-2120	338	27	:	:	PUNCT
dpc-2120	338	28	a	a	DET
dpc-2120	338	29	randomized	randomized	ADJ
dpc-2120	338	30	,	,	PUNCT
dpc-2120	338	31	double	double	ADJ
dpc-2120	338	32	-	-	PUNCT
dpc-2120	338	33	blind	blind	ADJ
dpc-2120	338	34	,	,	PUNCT
dpc-2120	338	35	phase	phase	NOUN
dpc-2120	338	36	2a	2a	NUM
dpc-2120	338	37	trial	trial	NOUN
dpc-2120	338	38	.	.	PUNCT
dpc-2120	339	1	j	j	PROPN
dpc-2120	339	2	am	be	AUX
dpc-2120	339	3	acad	acad	PROPN
dpc-2120	339	4	dermatol.2018;(78	dermatol.2018;(78	NOUN
dpc-2120	339	5	)	)	PUNCT
dpc-2120	339	6	5	5	NUM
dpc-2120	339	7	:	:	PUNCT
dpc-2120	339	8	872	872	NUM
dpc-2120	339	9	-	-	PUNCT
dpc-2120	339	10	881.e6	881.e6	NUM
dpc-2120	339	11	.	.	PUNCT
dpc-2120	340	1	doi	doi	NOUN
dpc-2120	340	2	:	:	PUNCT
dpc-2120	340	3	10.1016	10.1016	NUM
dpc-2120	340	4	/	/	SYM
dpc-2120	340	5	j.jaad.2018.01.016	j.jaad.2018.01.016	PROPN
dpc-2120	340	6	.	.	PUNCT
dpc-2120	341	1	pmid	pmid	NOUN
dpc-2120	341	2	:	:	PUNCT
dpc-2120	341	3	29353025	29353025	NUM
dpc-2120	341	4	.	.	PUNCT
dpc-2120	342	1	37	37	NUM
dpc-2120	342	2	.	.	PUNCT
dpc-2120	343	1	koga	koga	PROPN
dpc-2120	343	2	c	c	PROPN
dpc-2120	343	3	,	,	PUNCT
dpc-2120	343	4	kabashima	kabashima	PROPN
dpc-2120	343	5	k	k	PROPN
dpc-2120	343	6	,	,	PUNCT
dpc-2120	343	7	shiraishi	shiraishi	PROPN
dpc-2120	343	8	n	n	CCONJ
dpc-2120	343	9	,	,	PUNCT
dpc-2120	343	10	kobayashi	kobayashi	PROPN
dpc-2120	343	11	m	m	PROPN
dpc-2120	343	12	,	,	PUNCT
dpc-2120	343	13	tokura	tokura	PROPN
dpc-2120	343	14	y.	y.	PROPN
dpc-2120	343	15	possible	possible	ADJ
dpc-2120	343	16	pathogenic	pathogenic	ADJ
dpc-2120	343	17	role	role	NOUN
dpc-2120	343	18	of	of	ADP
dpc-2120	343	19	th17	th17	PROPN
dpc-2120	343	20	cells	cell	NOUN
dpc-2120	343	21	for	for	ADP
dpc-2120	343	22	atopic	atopic	NOUN
dpc-2120	343	23	dermatitis	dermatitis	NOUN
dpc-2120	343	24	.	.	PUNCT
dpc-2120	344	1	j	j	PROPN
dpc-2120	344	2	invest	invest	VERB
dpc-2120	344	3	dermatol	dermatol	NOUN
dpc-2120	344	4	.	.	PUNCT
dpc-2120	345	1	2008;128(11):2625	2008;128(11):2625	NUM
dpc-2120	345	2	-	-	SYM
dpc-2120	345	3	2630	2630	NUM
dpc-2120	345	4	.	.	PUNCT
dpc-2120	346	1	doi	doi	NOUN
dpc-2120	346	2	:	:	PUNCT
dpc-2120	346	3	10.1038/	10.1038/	NUM
dpc-2120	346	4	jid.2008.111	jid.2008.111	NOUN
dpc-2120	346	5	.	.	PUNCT
dpc-2120	347	1	pmid	pmid	NOUN
dpc-2120	347	2	:	:	PUNCT
dpc-2120	347	3	18432274	18432274	NUM
dpc-2120	347	4	.	.	PUNCT